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Chapter 1 
 
 
Introduction 
 
 
1.1 G protein coupled receptors 
G protein coupled receptors (GPCRs) represent one of the most important drug targets for 
pharmacological intervention and play key roles in cellular signaling networks (Hebert and 
Bouvier, 1998). It is estimated that more than 50% of the current therapeutic agents on the 
market are targeted at these receptors (Drews, 2000). The completion of the human genome 
project (International Human Genome Sequencing Consortium, 2004) has enabled the 
identification of more than 800 genes that belong to the GPCR superfamily which accounts 
for about 2% of the human genome (Fredriksson and Schiöth, 2005). The significance of 
GPCRs as drug targets lies in their physiological roles as cell-surface receptors responsible 
for transducing exogenous signals into cellular responses enabling the communication 
between individual cells, tissues or organs (Fang et al., 2003; Wise et al., 2002). 
There are two main requirements for a protein to be classified as a GPCR. The first 
requirement concerns the existence of seven sequence stretches of about 25 to 35 residues 
comprising a high degree of hydrophobicity. These sequences should build seven α-helices 
that span the cell membrane in an anti-clockwise manner when viewed from the extracellular 
side, forming a receptor, or a recognition and connection unit, enabling an extracellular 
ligand to exert a specific effect into the cell (Fredriksson et al., 2003). Following the term 
GPCR, the second main requirement would be the ability of the receptor to interact with a G 
protein. However, phylogenetic analysis uncovered many GPCRs to modulate G protein 
independent pathways (Fredriksson et al., 2003). Therefore, the term seven transmembrane 
(TM) receptors would be more technically correct. Both terms are used by the International 
Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification (NC-
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IUPHAR) (Humphrey and Barnard, 1998; Foord et al., 2005). 
GPCRs are known as extremely versatile receptors for extracellular messengers as diverse 
as biogenic amines, purines and nucleic acid derivatives, lipids, peptides and proteins, 
odorants, pheromones, tastants, ions like calcium and protons, and even photons in the case 
of rhodopsin (Jacoby et al., 2006). GPCRs can roughly be separated into GPCRs responding 
to sensory signals of external origin (chemosensory GPCRs) and GPCRs responding to 
signals produced by endogenous ligands. Based on phylogenetic and ligand-receptor 
relationships the repertoire of human GPCRs is classified into three main 
subclasses/families, A, B, C, or 1, 2, 3, respectively1. The rhodopsin-like class 1 is the largest 
subgroup and contains the opsins, olfactory GPCRs, small-molecules/peptide hormone 
GPCRs, and glycoprotein hormone GPCRs. The binding sites of the endogenous small-
molecule ligands are located within the TM bundle, whereas binding of peptides and 
glycoproteins occurs at the N-terminus, the extracellular loop regions, and the superior parts 
of the TM helices (Kristiansen, 2004). The secretin-like receptor class 2 contains GPCRs for 
peptides such as secretin, calcitonin, and parathyroid hormone. This family is characterized 
by a large N-terminus which is involved in ligand binding. The small glutamate class 3 
comprises the metabotropic glutamate receptor, the γ-aminobutyric acid type B receptor, 
Ca2+-sensing receptors, and pheromone and taste receptors. The ligand binding site of this 
family is located in the very large N-terminal region, which is composed of the so-called 
venus flytrap module that shares sequence similarity with bacterial periplasmic amino acid 
binding proteins (Jacoby et al., 2006). Another separate class comprises the human 
frizzled/smoothened receptors controlling cell development and proliferation mediated by the 
secreted glycoproteins Wnt and hedgehog. 
Up to now, 244 human GPCRs with known ligands were identified, whereas 163 human 
GPCRs have no known ligand and are therefore still orphan receptors (Fredriksson and 
Schiöth, 2006). 
 
1.2 Signal transduction of GPCRs 
Upon extracellular binding of an agonist, GPCRs undergo a conformational change into an 
activated state which specifically interacts with a precoupled or free heterotrimeric G protein, 
consisting of a Gα-subunit and a Gβγ heterodimer, located at the cytosolic side of the 
membrane (Hamm, 1998; Kostenis, 2006; Sprang, 1997).   
When interacting with a GPCR in an active state, the conformation of the G protein α-subunit 
is changed leading to the release of GDP (Figure  1.1). The resulting ternary complex of 
                                                 
1 Both terminologies are synonymously used by the NC-IUPHAR. 
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agonist, GPCR, and G protein is characterized by high agonist affinity and promotes binding 
of GTP to Gα. The binding of GTP to Gα induces a conformational change in this subunit, 
resulting in dissociation of the heterotrimer into Gα-GTP and the Gβγ complex. Different 
subtypes of activated Gα-GTP can selectively stimulate (Gαs) or inhibit (Gαi) adenylyl cyclase 
(AC), activate phospholipase Cβ (Gαq), or interact with guanine nucleotide exchange factors 
(Gα12/13). As a result, the production of second messengers such as cyclic 3’,5’-adenosine 
monophosphate (cAMP), diacylglycerol (DAG), and inositol-1,4,5-triphosphate (IP3) is 
modulated. These second messengers can induce a fast cellular response, such as a 
change in the intracellular ion concentration or the regulation of enzyme activity, or cause a 
long-term biological effect by modulating transcription factors, thereby regulating gene 
expression. The Gβγ subunit is also known to trigger cellular effects, e.g. via interaction with 
phospholipase Cβ, AC or ion channels. The slow intrinsic GTPase activity of the Gα-subunit 
leads to hydrolysis of GTP into GDP and Pi, thus terminating the Gα-induced effector 
activation and allowing the re-association of the subunits for the start of a new cycle. 
 
GPCRagonist
Gsα
GTP
Gsα
GTPγ β
Gsα
GDP
γ β Gsαγ β
γ β
Gsα
GDP
AC
cAMPATP
2
3
6
6
agonist
GDP
GTP
Pi
GPCR
 
 
One ubiquitous feature of signaling through GPCRs is the loss of cellular sensitivity following 
continuous stimulation. Such desensitization processes include phosphorylation of GPCRs 
by G protein coupled receptor kinases (GRK) followed by β-arrestin binding that uncouple the 
receptor at the plasma membrane from the G protein. Subsequent internalization of the 
receptor via clathrin-coated vesicles ultimately leads to sorting of the receptor either back to 
the plasma membrane (receptor recycling) or to lysosomes for degradation. GPCR 
phosphorylation is also mediated by second messenger dependent protein kinases.  
Figure  1.1: Gsα protein activation/deactivation 
cycle after GPCR stimulation by an agonist. 
Adapted from Seifert, 2005. 
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The investigation of the mechanisms of agonist-induced receptor signaling, desensitization, 
internalization, trafficking, and recycling resulted in the discovery of many proteins that 
interact with GPCRs and which are collectively called G protein coupled receptor interacting 
proteins (GIPs) (Bockaert and Pin, 1999; Bockaert et al., 2004). GIPs form large protein 
networks with GPCRs called receptosomes. Investigations on mechanistic principles 
associated with receptosomes and their potential relevance for drug discovery are subject of 
current research (Jacoby et al., 2006). 
 
1.3 Constitutive activity and models of GPCR activation 
Constitutive activity can be defined as the ability of a GPCR to spontaneously (i.e. in the 
absence of an agonist) adopt an active conformation which activates G proteins (Samama et 
al., 1993; Lefkowitz et al., 1993). Until now, constitutive activity is observed in more than 60 
wild-type GPCRs, and a large number of disease-causing GPCR mutations with increased 
constitutive activity has been identified (Seifert and Wenzel-Seifert, 2002).  
The extended ternary complex model (ETC model) (Samama et al., 1993; Lefkowitz et al., 
1993) which is also referred to as the two-state model of receptor activation (Leff, 1995), 
describes the ability of a GPCR to isomerize from an inactive (R) to an active (R*) state of 
which only R* can effectively interact with and activate G proteins. Both states coexist 
according to an allosteric constant L = [R*] / [R] (Figure  1.2 A). The magnitude of L defines  
 
 
 
 
 
 
 
 
 
Figure  1.2: A, Extended ternary complex model of GPCR activation. The equilibrium between R and 
R* is given by the allosteric constant L. Ligands have an affinity (association) constant Ka for R and 
αKa for R*. G proteins have an affinity (association) constant Kg for R* and γKg for AR*. The response 
producing species are the agonist-free and the agonist-occupied complexes R*G and AR*G. B, Cubic 
ternary complex model. The inactive receptor R interacts (precouples) with the G protein to form the 
non-signaling complexes RG and ARG. The constant δ reflects the specific state of the active ligand-
bound receptor/G protein complex.  
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the ease of a spontaneous formation of the R* state, i.e. the degree of constitutive activity. 
Full agonists maximally stabilize the R* state and cause a maximally efficient GDP/GTP 
exchange at a G protein which, in turn, evokes maximum physiological response, called 
efficacy, in the biological system (Kenakin, 2002) (Figure  1.3 A, B). Conversely, full inverse 
agonists maximally stabilize the R state and reduce basal GDP/GTP exchange. Neutral 
antagonists do not alter the equilibrium between R and R* and do not change basal G protein 
activity. Partial agonists and partial inverse agonists have lower efficacies than full agonists 
and full inverse agonists, respectively. 
A more thermodynamically refined model of GPCR activation is established by the cubic 
ternary complex model (CTC model; Figure  1.2 B) (Weiss et al., 1996a, b, c). This model 
allows both the active and inactive receptor species to interact with G proteins. Of all 
theoretically possible receptor states, only the complexes between the activated receptor R*  
 
 
 
 
 
 
 
 
and the G protein, AR*G and R*G, are assumed to give rise to G protein activation and thus 
physiological response.  
To date, there is increasing evidence that GPCRs can adopt more than one active state 
(reviewed in Perez and Karnik, 2005). For example, the concept of agonist-directed 
trafficking of a receptor stimulus refers to the ability of structurally diverse agonists to activate 
different G protein-mediated signaling (Kenakin, 1995). Moreover, Swaminath et al. 
investigated catecholamine-induced β2-adrenoceptor activation by kinetically distinguishable 
A B 
Figure  1.3: The two state model of GPCR activation. A, GPCRs are able to isomerize from an inactive 
state (R) to an active state (R*). Ligands are classified according to their capability of shifting the 
equilibrium to either side of both states. B, differential responses in an effector system upon binding of 
full agonists (■), partial agonists (▲), antagonists (●), partial inverse agonists (♦), and full inverse 
agonists (▼). Adapted from Seifert, 2005. 
Chapter 1: Introduction 6 
active conformational states (Swaminath et al., 2004). GPCRs are thus assumed to adopt 
multiple active conformations with distinct biological activities. 
 
1.4 Histamine and the histamine receptor family 
1.4.1 Historical perspective 
Histamine (HA, Figure  1.5), 2-(1H-imidazol-4-yl)ethylamine, was first synthesized in 1908 
(Windaus and Vogt, 1908). HA was isolated from ergot in 1910 (Barger and Dale, 1910) and 
pharmacologically characterized during the following years (Dale and Laidlaw, 1910, 1911, 
1919). In these early studies, fundamental effects of HA were elaborated, such as stimulation 
of smooth muscles from the gut and respiratory tract, vasodepression, stimulation of cardiac 
contractility, and induction of shock-like syndrome when injected into animals. In 1927, HA 
was isolated from liver and lung, thereby verifying for the first time HA to be an endogenous 
substance (Best et al., 1927). The first in a series of compounds that blocked the action of 
HA on vascular dilation and smooth muscle contraction during an anaphylactic response 
were developed in the 1930s (Fourneau and Bovet, 1933; Bovet and Staub, 1937). 
Subsequently, many other chemicals with similar actions have been identified. Some of 
these compounds (e.g. mepyramine, diphenhydramine) were introduced to clinical use in 
allergic conditions like hay fever. As these classical “antihistamines” were not able to block 
certain effects of HA such as the stimulation of gastric acid secretion, Ash and Schild 
suggested that HA acts via two distinct receptor subtypes (Ash and Schild, 1966). This 
prediction was confirmed when Black and co-workers developed burimamide (Figure  1.4), 
the first compound described to antagonize the HA-stimulated gastric acid secretion and the 
HA-induced relaxation of the electrically stimulated rat uterus (Black et al., 1972). 
Burimamide was shown to be a highly specific, competitive antagonist of the actions of HA 
on non-H1 receptor containing tissues and led to the definition of these receptors as 
histamine H2 receptors. For the treatment of gastric and duodenal ulcer, more potent H2R 
antagonists were chemically derived from burimamide, resulting in the development of 
metiamide (Black et al., 1973) and the first launched H2R antagonist, cimetidine 
(Brimblecombe et al., 1975). Together with the subsequently developed compounds 
ranitidine, famotidine, nizatidine and roxatidine, H2R antagonists became blockbuster drugs 
for the treatment of gastric and duodenal ulcers. In most cases, these compounds contain a 
basically substituted aromatic or heteroaromatic system, connected via a flexible chain to a 
planar structure, which is polar and uncharged at physiological pH. 
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In 1983, the group of Schwartz has shown that HA inhibits its own release from depolarized 
slices of rat cerebral cortex, an action that was proposed to be mediated by a new subtype, 
the histamine H3 receptor (Arrang et al., 1983). This suggestion was confirmed and the 
receptor was characterized in 1987 by the discovery that (R)-α-methylhistamine was a potent 
agonist and that thioperamide was a very selective competitive antagonist (Arrang et al., 
1987). During the 1990s, progress in the field of molecular biology enabled cloning of H1R 
(Yamashita et al., 1991), H2R (Gantz et al., 1991a), and H3R (Lovenberg et al., 1999). A DNA 
sequence with homology to the H3R (35%) was identified, that was cloned and later termed 
H4R (Oda et al., 2000). The existence of the new receptor was confirmed by other 
workgroups (Liu et al., 2001; Morse et al., 2001; Nguyen et al., 2001; Zhu et al., 2001). A 
very recent retrospect about the history of HA and its receptors is given by Parsons and 
Ganellin (Parsons and Ganellin, 2006). 
 
1.4.2 Histamine 
Histamine is one of the most important mediators involved in various physiological and 
pathological conditions, including neurotransmission and numerous brain functions, secretion 
of pituitary hormones, regulation of gastrointestinal and circulatory functions, and inflamma-
tory reactions (Leurs et al., 1995). High concentrations of HA are found in the skin, lung, and 
the gastrointestinal tract. In the hematopoietic system, mast cells and basophils store HA in 
specific granules where it is closely associated with anionic proteoglycans and chondroitin-4-
sulfate. In this form, it can be released in large amounts during degranulation in response to 
various immunological or non-immunological stimuli. Alternatively, HA is liberated upon 
destruction of these cells or by chemical substances (HA liberators). In the stomach, HA is 
Figure  1.4: Structures of H2R antagonists/inverse agonists.
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produced in the enterochromaffin-like cells (ECL) and regulates gastric acid secretion. In the 
central nervous system (CNS), histaminergic neurons are located in the tuberomamillary 
nucleus of the posterior hypothalamus. They are involved in the regulation of brain functions 
such as sleep/wakefulness, emotion, learning, memory, locomotor activity, nociception, food 
intake, etc. (Haas and Panula, 2003). Recently, other cellular sources of HA have been 
discovered (Dy and Schneider, 2004) in which HA is immediately released without prior 
storage. The production of the so-called “neo-synthesized HA” is modulated by cytokines and 
was identified in hematopoietic cells, macrophages, platelets, dendritic cells, and T cells. 
HA is synthesized in the cytosol by decarboxylation of histidine by L-histidine decarboxylase 
(HDC) (EC 4.1.1.22), which requires binding of the cofactor pyridoxal-5-phosphate (Figure 
 1.5). The vesicular monoamine transporter VMAT2 is responsible for the transport of HA 
from the cytosol into the secretory granules (Kazumori et al., 2004). 
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 Figure  1.5: Biosynthesis and metabolism of histamine.
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HA is inactivated by oxidative deamination or methylation to form imidazole-4-acetaldehyde 
and Nτ-methylhistamine. These reactions are catalyzed by diamine oxidase (DAO, EC 
1.4.3.6) and histamine N-methyltransferase (HNMT, EC 2.1.1.8), respectively (Beaven, 
1982). HNMT transfers a methyl group from S-adenosyl-L-methionine to the Nτ of the 
imidazole ring. Imidazole-4-acetaldehyde is oxidized to form imidazole-4-acetic acid. 
Imidazole-4-acetic acid and Nτ-methylhistamine are further metabolized to  
1-ribosylimidazole-4-acetic acid and 1-methylimidazole-4-acetic acid, respectively. At present 
it is not clear if HNMT is translocated to the plasma membrane to metabolize HA or if 
reuptake of HA occurs by means of organic cation transporters (OCT)-2 or -3 (Ogasawara et 
al., 2006). The inactive metabolites are excreted in the urine. 
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HA has two basic centres and fully protonated HA is a dication: the side chain amino group is 
a strong base (pKa2 = 9.40); the imidazole ring is a weak base (pKa1 = 5.80) (Ganellin, 1992). 
Under physiological conditions (pH = 7.4) the monocation predominates and is the form most 
likely to be acting at histamine receptors. The imidazole ring of HA can exist in two 
tautomeric forms (Figure  1.6), with the proton on the N proximal (Nπ-H tautomer) or distal (Nτ-
H tautomer). In aqueous solution about 80% of HA monocation is in the Nτ-H tautomeric form 
(Ganellin, 1973). 
 
1.4.3 Histamine receptors 
Histamine receptors belong to class 1 GPCRs (rhodopsin-like) and are classified in the four 
subtypes H1R, H2R, H3R, and H4R (Foord et al., 2005). The average sequence homology 
between the subtypes is relatively low (20%). H3R and H4R share the highest sequence 
homology of about 40% (58% homology in the TM regions) (Hough, 2001). An overview of 
the most important properties of histamine receptors is given in Table  1.1. 
H1R agonists can be divided into three groups (Figure  1.7): small agonists such as 2-
methylhistamine, 2-(2-thiazolyl)ethanamine, and betahistine derived from HA, agonists with 
aromatic substituents in position 2 of the imidazole ring such as 2-(3-
trifluoromethylphenyl)histamine, and the histaprodifens such as suprahistaprodifen. H1R  
Figure  1.6: Tautomerism of HA in the monocationic form.
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H1R 
Gene localization 3p25 
Amino acids 487 
Agonists 2-methylhistamine, 2-(3-trifluoromethylphenyl)histamine, histaprodifen(s) 
Antagonists/inv. ag. chlorpromazine, chlorpheniramine , mepyramine, cetirizine, astemizole, 
clemastine, terfenadine, loratadine, tripolidine 
Expression airway and vascular smooth muscles, nerve cells, hepatocytes, endothelial 
and epithelial cells, neutrophils, hematopoietic cells 
Signal transduction coupling to Gαq/11, PLC↑, prododuction of DAG and IP3, [Ca2+]↑, PKC↑ 
Actions rhinitis, conjunctivitis, urticaria, asthma, anaphylaxis, bronchoconstriction 
and vascular permeability in the lung, immune response 
H2R  
Gene localization 5 
Amino acids 359 
Agonists 4-methylhistamine, dimaprit, amthamine, impromidine, arpromidine 
Antagonists/inv. ag. cimetidine, raniditine, tiotidine, famotidine, aminopotentidine 
Expression gastric parietal cells, right atrial and ventricular muscle, airway and 
vascular smooth muscles, nerve cells, promyelocytic leukemic cells, 
hematopoietic cells 
Signal transduction coupling to Gαs, AC↑, [cAMP]↑, protein kinases↑, [Ca2+]↑; alternative 
coupling to Gαq/11 
Actions gastric acid secretion, chronotropic and inotropic activity, vascular 
permeability, bronchodilation, hypotension, cell proliferation, differentiation, 
immune response 
H3R  
Gene localization 20 
Amino acids 445 
Agonists (R)-α-methylhistamine, imetit, immepip 
Antagonists/inv. ag. thioperamide, ciproxyfan, clobenpropit, iodoproxyfan, JNJ-5207852 
Expression histaminergic neurons, eosinophils, dendritic cells, monocytes, low 
concentrations in peripheral tissues 
Signal transduction coupling to Gαi/o, AC↓, [cAMP]↓  
Actions pre-synaptic autoreceptor (controlling HA release) and heteroreceptor 
(controlling release of dopamine, serotonine, noradrenaline, GABA, 
acetylcholine) 
H4R  
Gene localization 18q11.2 
Amino acids 390 
Agonists OUP-16, iodophenpropit, imetit 
Antagonists/inv. ag. JNJ-77771202, thioperamide 
Expression hematopoietic and immunocompetent cells, low expression in brain, liver, 
and lung 
Signal transduction coupling to Gαi/o, AC↓, [cAMP]↓, [Ca2+]↑, MAPK↑ 
Actions chemotaxis in mast cells and  eosinophiles, control of IL-16 production by 
CD8+ lymphocytes 
Table  1.1: Overview of human histamine receptors.
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agonists are important experimental tools to analyze H1R function in cellular and organ 
systems (Hill et al., 1997; Seifert et al., 2003). H1R antagonists are commonly divided into 
sedating first-generation (e.g. chlorpheniramine, chlorpromazine) and non-sedating second-
generation (e.g. cetirizine) antagonists. Today, especially the second-generation H1R 
antagonists are of great importance for the treatment of allergic diseases (Hill et al., 1997). In 
our group, for the development of fluorescent H1R ligands the H1R antagonist mepyramine 
was conjugated with several fluorophores such as nitrobenzoxadiazole or carboxyfluorescein 
(Li et al., 2003; Schneider, 2005). 
A detailed characterization of the H2R is given in chapter 1.4.4.  
The H3R is mainly expressed in the CNS and acts as a presynaptic autoreceptor mediating a 
negative feedback on HA synthesis and release from histaminergic neurons. Additionally, 
H3Rs are expressed in several other neurons acting as presynaptic heteroreceptors (Hill et 
al., 1997). Selective H3R agonists such as (R)-α-methylhistamine, imetit, and immepip may 
be useful for the treatment of insomnia or myocardial ischaemic arrhythmias, or as 
antinociceptiva. H3R antagonists can be divided into imidazole-containing (e.g. thioperamide, 
ciproxyfan) and non-imidazole (e.g. JNJ-5207852) antagonists. Generally, the latter group of 
H3R antagonists is characterized by increased selectivity over the H4R, a better susceptibility 
to cross the blood-brain-barrier, and a lower affinity to cytochrome P450. Detailed reviews 
about medicinal chemical and pharmacological aspects of H3R agonists (De Esch and 
Belzar, 2004), imidazole-containing (Stark et al., 2004), and non-imidazole H3R (Cowart et 
al., 2004) antagonists are available. 
H4Rs are predominantly expressed in bone marrow and peripheral hematopoietic cells, 
regulating several events in immune response (e.g. increase in eosinophile chemotaxis, 
increase in IL-16 production). Due to the high homology with the H3R, many H3R ligands also 
bind to the H4R. OUP-16 was the first highly selective H4R agonist (Hashimoto et al., 2003) 
and the indolylpiperazine derivative JNJ-7777120 the first selective H4R antagonist 
(Jablonowski et al., 2003). Ligands targeting the H4R may be useful for the treatment of 
allergic rhinitis, asthma, dermatitis, and autoimmune diseases such as rheumatoid arthritis 
and multiple sclerosis. 
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Figure  1.7: Structures of selected histamine receptor agonists and antagonists/inverse agonists.
Chapter 1: Introduction 13
1.4.4 The histamine H2 receptor 
1.4.4.1 Molecular pharmacological characterization 
To date, H2Rs of the following species have been cloned: canine (Gantz et al., 1991a), 
human (Gantz et al., 1991b), rat (Ruat et al., 1991), guinea pig (Traiffort et al., 1995), and 
mouse (Kobayashi et al., 1996). The nucleotide sequences (genomic DNA) of gorilla, 
chimpanzee, and orang-utan H2R species isoforms were submitted to the 
EMBL/GenBank/DDBJ databases in 2000 by Kitano et al. Genomic Southern Blotting 
identified the human H2R to be located on chromosome 5 (Traiffort et al., 1995). The 
intronless gene encodes for 358 (rat, mouse) or 359 (human, canine, guinea pig, gorilla, 
chimpanzee, orang-utan) amino acids. H2R species isoforms share a considerably high 
sequence identity of more than 80%. 
 
 
0.1 
 
 
Figure  1.8: Phylogenetic tree of class 1 aminergic GPCRs. Black lines correspond to 
receptors with known ligands and red lines to those with unknown ligands (orphan receptors). 
Adapted from Vassilatis et al., 2003. The ruler at the bottom indicates the horizontal distance 
equal to 10% sequence divergence. 
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Phylogenetic analysis of class 1 aminergic GPCRs indicates the histamine receptor family as 
a heterogeneous group (Figure  1.8) (Vassilatis et al., 2003). H3R and H4R cluster together 
representing close relatedness. The H1R is more related to muscarinic acetylcholine 
receptors than to the histamine H3 and H4 subtypes. The H2R is placed in a very distant 
position closest to the serotonin 5-HT4R and the β−adrenergic receptors. 
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The secondary structure of the human H2R as suggested from sequence alignment with 
bovine rhodopsin is shown in Figure  1.9. The receptor is composed of seven TM domains 
that are connected by three extracellular (e1, e2, e3) and three intracellular (i1, i2, i3) loops. 
The N-terminus is located at the extracellular and the C-terminus at the intracellular side of 
the membrane. A disulfide bond that is highly conserved in class 1 GPCRs connects the 
extracellular end of TM3 with e2. The endogenous ligand HA binds to the H2R in a cavity 
between TM3 and TM5 (see chapter 1.4.5.1). As it is observed in all GPCRs, the H2R is 
subjected to post-translational modifications and regulatory mechanisms. Extracellular N-
glycosylation occurs at Asn-4 (N-terminus) and at Asn-162 (e2). It has been shown that N- 
Figure  1.9: Snake representation of the human H2R. Asn-4 and Asn-162 (green) are 
being N-glycosylated, and Cys-305 (yellow) is being palmitoylated. A disulfide bond 
between Cys-91 and Cys-174 is represented by an orange line. Asp-98, Tyr-182, Asp-
186, and Thr-190 that probably interact with HA are colored in blue. 16 amino acids of i3 
and 51 amino acids of the C-terminus are omitted for reasons of clarity. 
Chapter 1: Introduction 15
glycosylation is not required for cell surface localization of the receptor, ligand binding, or 
functional coupling to G proteins (Fukushima et al., 1995). The H2R is palmitoylated at Cys-
305 of the C-terminus which is important for proper membrane targeting of the receptor 
(Fukushima et al., 2001a). Upon agonist exposure, the H2R is internalized in a cAMP-
independent pathway (Smit et al., 1995). Pharmacological characterization of C-terminally 
truncated canine H2Rs revealed Thr-315 to be involved in agonist-induced internalization 
(Fukushima et al., 1997a). Agonist-induced desensitization was first detected by the group of 
Fukushima (Fukushima et al., 1993) and was recently found to be mediated by 
phosphorylation via the G protein receptor kinases GRK2 and GRK3 (Rodriguez-Pena et al., 
2000; Shayo et al., 2001). Although distinct regions of the H2R C-terminus are known to be 
important for GPCR signaling and down-regulation (Smit et al., 1996a), C-terminal truncation 
did not abolish agonist-induced H2R desensitization suggesting that this part is not involved 
in GRK2 and GRK3 mediated desensitization (Rodriguez-Pena et al., 2000). H2R 
dimerization and oligomerization was elucidated by Western Blot analysis in COS7 and Sf9 
cells (Fukushima et al., 1997b). 
Allelic variations of the human H2R gene have been observed (Orange et al., 1996a). The 
impact of an H2R polymorphism with a base exchange of A649 to G, causing a point 
mutation of Asn-217 to Asp, on the incidence of schizophrenia was discussed (Orange et al., 
1996b) but could not be confirmed in recent studies (Ito et al., 2000). However, this H2R gene 
variant displayed low basal activity and resistance to upregulation upon antagonist exposure 
indicating an altered receptor function (Fukushima et al., 2001b). 
Constitutive activity of the H2R was reported first by Smit (Smit et al., 1996b) for the rat 
species isoform leading to a reclassification of the H2R antagonists cimetidine and ranitidine 
to be inverse agonists. Two years later, constitutive activity and structural instability of the 
human H2R were discovered (Alewijnse et al., 1998). Using the technique of fusion proteins 
(Milligan, 2000), it was shown that the magnitude of constitutive activity is similar when the 
human H2R couples to the long and the short splice variants of Gsα (Wenzel-Seifert et al., 
2001). Differences in the constitutive activities of wild-type and mutant H2R species isoforms 
are subject of this work (chapters 7 and 8). 
 
1.4.4.2 H2R distribution, functions, and signaling pathways 
H2Rs are located on the parietal cells of the gastric mucosa and mediate the HA-induced 
increase in gastric acid secretion (Gespach et al., 1982; Soll and Berglindh, 1987). Thus, 
H2R antagonists belong to the most important drugs for the treatment of gastric ulcera (Black 
et al., 1972). At the right atrial and the ventricular muscle of the heart, H2R stimulation leads 
to an increase in the slow inward Ca2+ current (Levi and Aloatti, 1988) thereby causing the 
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positive chronotropic and positive inotropic effects of HA. Accordingly, measuring the change 
in the heart rate of the spontaneously beating guinea pig right atrium upon H2R ligand 
exposure was used as a standard H2R model in organ pharmacology. H2R-mediated smooth 
muscle relaxation has been documented in airway, uterine, and vascular smooth muscles 
(Levi et al., 1982; Jolly and Desmecht, 2003). Moreover, H2Rs are distributed in hippocampal 
pyramidal cells in the brain. The direct effect of H2R stimulation on neuronal membranes is 
usually excitatory or potentiates excitation (Haas and Panula, 2003). HA blocks Ca2+-
dependent K+ conductance, leading to a long-lasting afterhyperpolarization and affecting the 
accommodation of firing (Haas and Konnerth, 1983). Synaptic transmission in the 
hippocampus is potentiated and the firing of several types of neurons is enhanced for many 
hours after exposure to HA or the H2R agonist impromidine (Brown et al., 2001; Selbach et 
al., 1997). Promyelocytic leukemic cells express H2Rs and activation leads to functional 
differentiation to mature granulocytes (Seifert et al., 1992; reviewed in Klinker et al., 1996). 
Thus, H2R agonists are discussed to be useful for the treatment of acute promyelocytic 
leukemia. Finally, there is a complex network in the histaminergic system regulating 
hematopoiesis and immune responses (for recent reviews consider Dy and Schneider, 2004; 
Jutel et al., 2002; Schneider et al., 2002; Akdis and Simons, 2006). This type of regulation is 
particularly relevant in the context of the differentiation of T helper 1 (TH1) and T helper 2 
(TH2) cell differentiation with impact on autoimmunity and tumor immunotherapy. TH1 cells 
show predominant, but not exclusive, expression of H1R, whereas TH2 cells show 
upregulation of H2R (Jutel et al., 2001). The H2R on TH2 cells acts as a negative regulator of 
proliferation as well as IL-4 and IL-13 production.  
The H2R couples to Gsα to activate AC which, in turn, leads to an increase in cAMP 
production (Figure  1.10) (Hill et al., 1997; Del Valle and Gantz, 1997). cAMP activates 
protein kinases, which phosphorylate regulatory proteins, leading to an influx of Ca2+ in 
cardiac myocytes. Alternatively, an increase in intracellular Ca2+ concentration mediated by 
the action of phospholipase C (PLC) has been observed (Del Valle et al., 1992; Wang et al., 
1996). It has been demonstrated in subsequent studies that the H2R is capable of coupling to 
both Gsα and Gαq/11 signaling pathways (Leopoldt et al., 1997; Kühn et al., 1996). 
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1.4.5 Histamine H2 receptor agonists 
1.4.5.1 Interactions of HA and small agonists with the H2R 
The historical model for the agonistic binding site of the H2R was based on a postulated 
activation mechanism (Weinstein et al., 1976). The cationic ammonium group in the HA side 
chain and the Nτ-H group of the imidazole acted as proton donors, whereas the Nπ atom 
acted as a proton acceptor. Participation of the ammonium group in H-bonding with a 
negative charge on the receptor leads to a decrease in positive charge, which was thought to 
induce a tautomeric change in the imidazole ring system from Nτ-H to Nπ-H (in its neutral 
form, HA is mainly found as the Nπ-H tautomer). A consequence of this tautomeric shift was 
the donation of a proton from the receptor to the agonist on one side, while on the other side 
a proton would be donated from the agonist to the receptor. Controversial concepts were 
developed to understand the binding modes of the isothiourea derivative dimaprit (Figure 
 1.11) (Parsons et al., 1977) and the 2-amino-4-methylthiazolyle derivative amthamine 
(Durant et al., 1977; Green et al., 1978; Eriks et al., 1993). 
 
Figure  1.10: H2R-mediated signaling in a cardiac myocyte.
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In the model of Eriks et al., the partially positively charged sulfur atom of amthamine interacts 
with a negatively charged site of the receptor whereas the Nτ atom accepts a proton from a 
proton-donating site of the receptor (Eriks et al., 1993). An analogous binding mode of HA 
requires that the Nπ-H tautomer is the biologically active form (Nederkoorn et al., 1994). This 
model implies that a tautomeric shift is no prerequisite for H2R stimulation and is thus able to 
explain the agonistic activities of all known H2R agonists, including non-tautomeric 
compounds like betahistine and a series of 5-(2-aminoethyl)thiazole derivatives. Recently, 
Giraldo showed that the two mechanistic models of H2R activation by HA (“Weinstein-model” 
vs. “Eriks-model”) are compatible if the amino acid residues which constitute the recognition 
site of the receptor are present in different acid-base conjugate forms (Giraldo, 1999). 
Mutational studies on the H2R indicated an ionic interaction of the protonated amino group of 
HA with Asp-98 in TM3 (Gantz et al., 1992). The second and third site of the three-point 
activation model could principally be formed by the couples Asp-186/Thr-190 (Gantz et al., 
1992) or Tyr-182/Asp-186 (Nederkoorn et al., 1996a, b) in TM5. Molecular mechanics and ab 
initio studies revealed that Tyr-182 and Asp-186 most likely interact with the imidazole ring of 
HA (Figure  1.12). 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
2 Non-selective H2R agonist. 
Figure  1.11: Structures of small H2R agonists.
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Figure  1.12: Interaction of HA in the binding site of the H2R according to 
the model of Nederkoorn (Nederkoorn et al., 1996a). HA is present in the 
Nπ-H tautomeric form. 
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1.4.5.2 Imidazolylpropylguanidines 
Impromidine (IMP) (Durant et al., 1985) was the first highly potent and selective H2R agonist 
(Figure  1.13) (Durant et al., 1978). The compound is about 50-fold more potent than HA in 
increasing the heart rate of the isolated guinea pig right atrium and approaches 100% of HA 
intrinsic activity. IMP is a guanidine derivative with two different imidazolylalkyl substituents. 
The imidazolylpropylguanidine structure acts as weak partial agonist with low potency (pD2 = 
4.65; rel. potency = 0.04; i.a. = 0.3) (Parsons et al., 1975), and the 2-[(5-methyl-1H-imidazol-
4-yl)methylthio]ethyl guanidine moiety is a structural feature of the H2R antagonist cimetidine 
(Figure  1.4) showing no agonistic H2R activity. Thus, the cimetidine-like moiety in IMP is 
assumed to contribute to high potency and affinity whereas the imidazolylpropylguanidine is 
the major determinant of agonistic activity. 
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Figure  1.13: Flow chart of the development of potent and selective H2R agonistic guanidines. H2R 
activities of IMP and ARP were measured at the isolated spontaneously beating guinea pig right 
atrium (data taken from Buschauer, 1989); rel. potency, potency relative to HA = 1; i.a. intrinsic 
activity. 
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About twenty years ago the development of new H2R agonists was encouraged by clinical 
investigations suggesting a therapeutic potential of such compounds. By studying IMP, 
Baumann et al. demonstrated that H2R stimulation could be an effective treatment in patients 
suffering from severe catecholamine-insensitive congestive heart failure (Baumann et al., 
1984). Arpromidine (ARP) and related N-[3-(1H-imidazol-4-yl)propyl]-N’-[3-phenyl-3-(2-
pyridyl)-propyl] guanidines were the most interesting substances of a large series of so-
called ‘cardiohistaminergics’ developed as positive inotropic vasodilators (Buschauer, 1989; 
Buschauer and Baumann, 1991). The ARP-like H2R agonists, in particular the 3,4- and 3,5-
difluorinated analogues, proved to be superior to IMP in potency, hemodynamic profile, and 
side effects when tested in the guinea pig under physiological conditions and in a 
pathophysiological model of severe congestive heart failure (vasopressin-induced acute 
heart failure) (Felix et al., 1991). In ARP, the cimetidine-like moiety of IMP is replaced by the 
pheniramine-like [3-phenyl-3-(2-pyridyl)propyl]guanidine group (Figure  1.7) which is a weak 
H1R antagonist. The hybrid molecule is about 100 times more potent than HA on the guinea 
pig right atrium and exerts an H1R antagonistic profile comparable to that of pheniramine on 
the guinea pig ileum.  
The structure-activity relationships of ARP-type H2R agonists (Figure  1.13, path I) can be 
summarized as follows (Dove et al., 2004): 
 
• The imidazolylpropylguanidine moiety is essential for the H2R agonistic activity. 
• Highest potency is observed in compounds with a three-membered carbon chain 
between the guanidine group and R1/R2. 
• Substituents at the phenyl and pyridyl rings in R2 position are mostly unfavorable for 
H2R agonistic activity, but different aromatics or heteroaromatics such as 2-imidazolyl 
and 2-thiazolyl may replace phenyl and pyridyl. 
• Appropriate substitution at phenyl rings in R1 may increase potency. Highest potency 
in the guinea pig atrium was found in the 3,4-F2, 3,4-Cl2, and 3,5-F2 substituted 
compounds. 
• The aromatic ring systems in R1 and R2 may be replaced by cyclohexyl and methyl 
substituents. 
 
IMP, ARP and related guanidines are strong bases (pKa ~13) and thus nearly quantitatively 
protonated at physiological pH. To yield compounds with improved pharmacokinetic 
properties, particularly oral bioavailability and penetration across the blood-brain-barrier, NG-
acylated imidazolylpropylguanidines were developed (Figure  1.13, path II) (Ghorai, 2005). 
Such agonists may be useful pharmacological tools to gain novel insight into the functions of 
the H2R in the brain. A large series of NG-acylated guanidines with reduced basicity  
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(pKa ~8) was synthesized and pharmacologically characterized (Ghorai, 2005; Xie et al., 
2006a, b). The NG-acylated derivatives contain diverse mono- and diarylalkanoyl, 
heteroarylalkanoyl, and cyclohexylalkanoyl substituents, and most of these compounds 
display potencies and efficacies similar to their non-acylated analogs (Ghorai, 2005). Thus, 
NG-acylation can be considered as a bioisosteric exchange. N1-(3-Cyclohexylbutanoyl)-N2-[3-
(1H-imidazol-4-yl)propyl]guanidine (UR-AK57, Figure  1.14) turned out to be the most potent 
human H2R agonist identified so far (EC50 of 23 nM in a GTPase activity assay at human 
H2R-Gsα fusion protein expressed in Sf9 insect cells) (Xie et al., 2006b). At the human H1R 
this compound did not act as antagonist but rather as a partial agonist. NG-acylated 
guanidines are absorbed from the gastrointestinal tract and are capable of penetrating 
across the blood-brain-barrier as measured by HPLC-MS analysis after administration to 
mice (Keller, personal communication). Very recently, several NG-acylated imidazolylpropyl-
guanidines have been identified as very potent H4R agonists (Ghorai, 2005; Seifert, personal 
communication). 
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An important step towards the development of highly potent and selective H2R agonists was 
achieved by replacing the common imidazole ring of the guanidines by a 2-amino-4-
methylthiazole group (Figure  1.13, path III). As such an exchange did not abolish the H2R 
agonistic activity of small compounds (HA ? amthamine), a corresponding bioisosteric 
replacement was also possible in the case of the bulky guanidines. A series of ARP-related 
compounds with a 3-(4-methyl-2-aminothiazol-5-yl)propyl group displayed remarkably 
increased selectivity over the H3R (Eriks et al., 1991). A similar strategy was successfully 
applied to the series of NG-acylated compounds yielding N-acyl-N’-[3-(2-amino-4-
methylthiazol-5-yl)propyl]guanidines that were similarly potent and efficacious as their 
imidazolyl analogs but devoid of H3R activity (Ghorai, 2005). 
 
Figure  1.14: Structure of the H2R 
agonistic compound UR-AK57. 
Chapter 1: Introduction 22
1.5 References 
Akdis CA and Simons FE (2006) Histamine receptors are hot in immunopharmacology. Eur J 
Pharmacol 533:69-76. 
Alewijnse AE, Smit MJ, Hoffmann M, Verzijl D, Timmerman H and Leurs R (1998) Constitutive activity 
and structural instability of the wild-type human H2 receptor. J Neurochem 71:799-807. 
Arrang JM, Garbarg M and Schwartz JC (1983) Auto-inhibition of brain histamine release mediated by 
a novel class (H3) of histamine receptor. Nature 302:832-837. 
Arrang JM, Garbarg M, Lancelot JC, Lecomte JM, Pollard H, Robba M, Schunack W and Schwartz JC 
(1987) Highly potent and selective ligands for histamine H3-receptors. Nature 327:117-123. 
Ash ASF and Schild HO (1966) Receptors mediating some actions of histamine. Br J Pharmacol 
27:427-439. 
Barger G and Dale HM (1910) The presence in ergot and physiological activity of B-
iminazoylethylamine. J Physiol Paris 40:38-40. 
Baumann G, Permanetter B and Wirtzfeld A (1984) Possible value of H2-receptor agonists for 
treatment of catecholamine-insensitive congestive heart failure. Pharmacol Ther 24:165-177. 
Beaven MA (1982) Factors regulating availability of histamine at tissue receptors, in Pharmacology of 
histamine receptors (Ganellin CR and Parsons EM eds) pp 103-145, Wright PSG, Bristol, 
London, Boston. 
Best CH, Dale HH, Dudley HW and Thorpe WV (1927) The nature of the vasodilator constituents of 
certain tissue extracts. J Physiol 62:397-417. 
Black JW, Duncan WA, Durant CJ, Ganellin CR and Parsons EM (1972) Definition and antagonism of 
histamine H2-receptors. Nature 236:385-390. 
Black JW, Duncan WA, Emmett JC, Ganellin CR, Hesselbo T, Parsons ME and Wyllie JH (1973) 
Metiamide-an orally active histamine H2-receptor antagonist. Agents Actions 3:133-137. 
Bockaert J and Pin JP (1999) Molecular tinkering of G protein-coupled receptors: an evolutionary 
success. EMBO J 18:1723-1729. 
Bockaert J, Dumuis A, Fagni L and Marin P (2004) GPCR-GIP networks: A first step in the discovery 
of new therapeutic drugs? Curr Opin Drug Discovery Dev 7:649-657. 
Bovet D and Staub AM (1937) Action protectrice des éthers phénolique au cours de l'intoxication 
histaminique. C R Soc Biol 124:547-549. 
Brimblecombe RW, Duncan WAM, Durant GJ, Ganellin CR, Parsons EM and Black JW (1975) The 
pharmacology of cimetidine; a new histamine H2-receptor antagonist. Br J Pharmacol 53:435-
436. 
Brown RE, Stevens DR and Haas HL (2001) The physiology of brain histamine. Prog Neurobiol 
63:637-672. 
Buschauer A (1989) Synthesis and in vitro pharmacology of arpromidine and related 
phenyl(pyridylalkyl)guanidines, a potential new class of positive inotropic drugs. J Med Chem 
32:1963-1970. 
Buschauer A and Baumann G (1991) Structure-activity relationships of histamine H2-agonists, a new 
class of positive inotropic drugs. Agents Actions Suppl 33:231-256. 
Cowart M, Altenbach R, Black L, Faghih R, Zhao C and Hancock AA (2004) Medicinal chemistry and 
biological properties of non-imidazole histamine H3 antagonists. Mini Rev Med Chem 4:979-
992. 
Dale HH and Laidlaw PP (1910) The physiological action of beta-iminazolylethylamine. J Physiol 
41:318-344. 
Dale HH and Laidlaw PP (1911) Further observations on the action of beta-iminazolylethylamine. J 
Physiol 43:182-195. 
Chapter 1: Introduction 23
Dale HH and Laidlaw PP (1919) Histamine shock. J Physiol 52:355-390. 
De Esch IJ and Belzar KJ (2004) Histamine H3 receptor agonists. Mini Rev Med Chem 4:955-963. 
Del Valle J and Gantz I (1997) Novel insights into histamine H2 receptor biology. Am J Physiol 
273:G987-996. 
Del Valle J, Wang L, Gantz I and Yamada T (1992) Characterization of H2 histamine receptor: linkage 
to both adenylate cyclase and [Ca2+]i signaling systems. Am J Physiol 263:G967-972. 
Dove S, Elz S, Seifert R and Buschauer A (2004) Structure-activity relationships of histamine H2 
receptor ligands. Mini Rev Med Chem 4:941-954. 
Drews J (2000) Drug discovery: a historical perspective. Science 287:1960-1964. 
Durant GJ, Ganellin CR and Parsons ME (1977) Dimaprit, (S-[3-(N,N-dimethylamino)propyl]-
isothiourea). A highly specific histamine H2-receptor agonist. Part 2. Structure-activity 
considerations. Agents Actions 7:39-43. 
Durant GJ, Duncan WA, Ganellin CR, Parsons ME, Blakemore RC and Rasmussen AC (1978) 
Impromidine (SK&F 92676) is a very potent and specific agonist for histamine H2 receptors. 
Nature 276:403-405. 
Durant GJ, Ganellin CR, Hills DW, Miles PD, Parsons ME, Pepper ES and White GR (1985) The 
histamine H2 receptor agonist impromidine: synthesis and structure-activity considerations. J 
Med Chem 28:1414-1422. 
Dy M and Schneider E (2004) Histamine-cytokine connection in immunity and hematopoiesis. 
Cytokine Growth Factor Rev 15:393-410. 
Eriks JC, Sterk GJ, van der Aar EM, van Acker SA, van der Goot H and Timmerman H (1991) 4- or 5- 
(ω-aminoalkyl) thiazoles and derivatives; new selective H2-receptor agonists. Agents Actions 
Suppl 33:301-314. 
Eriks JC, van der Goot H and Timmerman H (1993) New activation model for the histamine H2 
receptor, explaining the activity of the different classes of histamine H2 receptor agonists. Mol 
Pharmacol 44:886-894. 
Fang Y, Lahiri J and Picard L (2003) G protein-coupled receptor microarrays for drug discovery. Drug 
Discov Today 8:755-761. 
Felix SB, Buschauer A and Baumann G (1991) Therapeutic value of H2-receptor stimulation in 
congestive heart failure. Hemodynamic effects of BU-E-76, BU-E-75 and arpromidine (BU-E-
50) in comparison to impromidine. Agents Actions Suppl 33:257-269. 
Foord SM, Bonner TI, Neubig RR, Rosser EM, Pin JP, Davenport AP, Spedding M and Harmar AJ 
(2005) International Union of Pharmacology. XLVI. G protein-coupled receptor list. Pharmacol 
Rev 57:279-288. 
Fourneau E and Bovet T (1933) Recherches sur l'action sympathicolytique d'un nouveau dérivé du 
dioxane. Arch Int Pharmacodyn 46:179-191. 
Fredriksson R and Schiöth HB (2005) The repertoire of G-protein-coupled receptors in fully sequenced 
genomes. Mol Pharmacol 67:1414-1425. 
Fredriksson R and Schiöth HB (2006) G protein-coupled receptors in the human genome., in Ligand 
design for G protein-coupled receptors (Rognan D ed) pp 1-26, Wiley-VCH, Weinheim. 
Fredriksson R, Lagerström MC, Lundin LG and Schiöth HB (2003) The G-protein-coupled receptors in 
the human genome form five main families. Phylogenetic analysis, paralogon groups, and 
fingerprints. Mol Pharmacol 63:1256-1272. 
Fukushima Y, Oka Y, Katagiri H, Saitoh T, Asano T, Ishihara H, Matsuhashi N, Kodama T, Yazaki Y 
and Sugano K (1993) Desensitization of canine histamine H2 receptor expressed in Chinese 
hamster ovary cells. Biochem Biophys Res Commun 190:1149-1155. 
Fukushima Y, Oka Y, Saitoh T, Katagiri H, Asano T, Matsuhashi N, Takata K, van Breda E, Yazaki Y 
and Sugano K (1995) Structural and functional analysis of the canine histamine H2 receptor by 
site-directed mutagenesis: N-glycosylation is not vital for its action. Biochem J 310 (Pt 2):553-
558. 
Chapter 1: Introduction 24
Fukushima Y, Asano T, Takata K, Funaki M, Ogihara T, Anai M, Tsukuda K, Saitoh T, Katagiri H, 
Aihara M, Matsuhashi N, Oka Y, Yazaki Y and Sugano K (1997a) Role of the C terminus in 
histamine H2 receptor signaling, desensitization, and agonist-induced internalization. J Biol 
Chem 272:19464-19470. 
Fukushima Y, Asano T, Saitoh T, Anai M, Funaki M, Ogihara T, Katagiri H, Matsuhashi N, Yazaki Y 
and Sugano K (1997b) Oligomer formation of histamine H2 receptors expressed in Sf9 and 
COS7 cells. FEBS Lett 409:283-286. 
Fukushima Y, Saitoh T, Anai M, Ogihara T, Inukai K, Funaki M, Sakoda H, Onishi Y, Ono H, Fujishiro 
M, Ishikawa T, Takata K, Nagai R, Omata M and Asano T (2001a) Palmitoylation of the canine 
histamine H2 receptor occurs at Cys(305) and is important for cell surface targeting. Biochim 
Biophys Acta 1539:181-191. 
Fukushima Y, Saitoh T, Anai M, Tsukuda K, Onishi Y, Sakoda H, Inukai K, Ogihara T, Funaki M, Ono 
H, Fujishiro M, Ishikawa T, Nagai R, Omata M and Asano T (2001b) G649, an allelic variant of 
the human H2 receptor with low basal activity, is resistant to upregulation upon antagonist 
exposure. Pharmacogenomics J 1:78-83. 
Ganellin CR (1973) The tautomer ratio of histamine. J Pharm Pharmacol 25:787-792. 
Ganellin CR (1992) Pharmacochemistry of H1 and H2 Receptors, in The histamine receptor (Schwartz 
JC and Haas HL eds) pp 1-56, Wiley-Liss, New York. 
Gantz I, Schaffer M, Del Valle J, Logsdon C, Campbell V, Uhler M and Yamada T (1991a) Molecular 
cloning of a gene encoding the histamine H2 receptor. Proc Natl Acad Sci U S A 88:429-433. 
Gantz I, Munzert G, Tashiro T, Schaffer M, Wang L, Del Valle J and Yamada T (1991b) Molecular 
cloning of the human histamine H2 receptor. Biochem Biophys Res Commun 178:1386-1392. 
Gantz I, Del Valle J, Wang LD, Tashiro T, Munzert G, Guo YJ, Konda Y and Yamada T (1992) 
Molecular basis for the interaction of histamine with the histamine H2 receptor. J Biol Chem 
267:20840-20843. 
Gespach C, Bouhours D, Bouhours JF and Rosselin G (1982) Histamine interaction on surface 
recognition sites of H2-type in parietal and non-parietal cells isolated from the guinea pig 
stomach. FEBS Lett 149:85-90. 
Ghorai P (2005) Arpromidine-related acylguanidines: synthesis and structure-activity relationships of a 
new class of guanidine-type histamine H2 receptor agonists with reduced basicity. Doctoral 
thesis. University of Regensburg, Germany.  
http://www.opus-bayern.de/uni-regensburg/volltexte/2006/561/ 
Giraldo J (1999) A pH-dependent model of the activation mechanism of the histamine H2 receptor. 
Biochem Pharmacol 58:343-353. 
Green JP, Johnson CL and Weinstein H (1978) Histamine as a neurotransmitter., in 
Psychopharmacology, a generation of progress (Lipton MA, Di Mascio A and Killam KF eds) 
pp 319-322, Raven Press, New York. 
Haas HL and Konnerth A (1983) Histamine and noradrenaline decrease calcium-activated potassium 
conductance in hippocampal pyramidal cells. Nature 302:432-434. 
Haas H and Panula P (2003) The role of histamine and the tuberomamillary nucleus in the nervous 
system. Nat Rev Neurosci 4:121-130. 
Hamm HE (1998) The many faces of G protein signaling. J Biol Chem 273:669-672. 
Hashimoto T, Harusawa S, Araki L, Zuiderveld OP, Smit MJ, Imazu T, Takashima S, Yamamoto Y, 
Sakamoto Y, Kurihara T, Leurs R, Bakker RA and Yamatodani A (2003) A selective human 
H4-receptor agonist: (-)-2-cyano-1-methyl-3-[(2R,5R)-5- [1H-imidazol-4(5)-yl]tetrahydrofuran-2-
y] methylguanidine. J Med Chem 46:3162-3165. 
Hebert TE and Bouvier M (1998) Structural and functional aspects of G protein-coupled receptor 
oligomerization. Biochem Cell Biol 76:1-11. 
Hill SJ, Ganellin CR, Timmerman H, Schwartz JC, Shankley NP, Young JM, Schunack W, Levi R and 
Haas HL (1997) International Union of Pharmacology. XIII. Classification of histamine 
receptors. Pharmacol Rev 49:253-278. 
Chapter 1: Introduction 25
Hough LB (2001) Genomics meets histamine receptors: new subtypes, new receptors. Mol Pharmacol 
59:415-419. 
Humphrey PP and Barnard EA (1998) International Union of Pharmacology. XIX. The IUPHAR 
receptor code: a proposal for an alphanumeric classification system. Pharmacol Rev 50:271-
277. 
International Human Genome Sequencing Consortium (2004) Finishing the euchromatic sequence of 
the human genome. Nature 431:931-945. 
Ito C, Morisset S, Krebs MO, Olie JP, Loo H, Poirier MF, Lannfelt L, Schwartz JC and Arrang JM 
(2000) Histamine H2 receptor gene variants: lack of association with schizophrenia. Mol 
Psychiatry 5:159-164. 
Jablonowski JA, Grice CA, Chai W, Dvorak CA, Venable JD, Kwok AK, Ly KS, Wei J, Baker SM, 
Desai PJ, Jiang W, Wilson SJ, Thurmond RL, Karlsson L, Edwards JP, Lovenberg TW and 
Carruthers NI (2003) The first potent and selective non-imidazole human histamine H4 
receptor antagonists. J Med Chem 46:3957-3960. 
Jacoby E, Bouhelal R, Gerspacher M and Seuwen K (2006) The 7 TM G-protein-coupled receptor 
target family. ChemMedChem 1:761-782. 
Jolly S and Desmecht D (2003) Functional identification of epithelial and smooth muscle histamine-
dependent relaxing mechanisms in the bovine trachea, but not in bronchi. Comp Biochem 
Physiol C Toxicol Pharmacol 134:91-100. 
Jutel M, Watanabe T, Klunker S, Akdis M, Thomet OA, Malolepszy J, Zak-Nejmark T, Koga R, 
Kobayashi T, Blaser K and Akdis CA (2001) Histamine regulates T-cell and antibody 
responses by differential expression of H1 and H2 receptors. Nature 413:420-425. 
Jutel M, Watanabe T, Akdis M, Blaser K and Akdis CA (2002) Immune regulation by histamine. Curr 
Opin Immunol 14:735-740. 
Kazumori H, Ishihara S, Rumi MA, Ortega-Cava CF, Kadowaki Y and Kinoshita Y (2004) Transforming 
growth factor alpha directly augments histidine decarboxylase and vesicular monoamine 
transporter 2 production in rat enterochromaffin-like cells. Am J Physiol Gastrointest Liver 
Physiol 286:514. 
Kenakin T (1995) Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends 
Pharmacol Sci 16:232-238. 
Kenakin T (2002) Drug efficacy at G protein-coupled receptors. Annu Rev Pharmacol Toxicol 42:349-
379. 
Klinker JF, Wenzel-Seifert K and Seifert R (1996) G-protein-coupled receptors in HL-60 human 
leukemia cells. Gen Pharmacol 27:33-54. 
Kobayashi T, Inoue I, Jenkins NA, Gilbert DJ, Copeland NG and Watanabe T (1996) Cloning, RNA 
expression, and chromosomal location of a mouse histamine H2 receptor gene. Genomics 
37:390-394. 
Kostenis E (2006) G proteins in drug screening: from analysis of receptor-G protein specificity to 
manipulation of GPCR-mediated signalling pathways. Curr Pharm Des 12:1703-1715. 
Kristiansen K (2004) Molecular mechanisms of ligand binding, signaling, and regulation within the 
superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches 
to receptor structure and function. Pharmacol Ther 103:21-80. 
Kühn B, Schmid A, Harteneck C, Gudermann T and Schultz G (1996) G proteins of the Gq family 
couple the H2 histamine receptor to phospholipase C. Mol Endocrinol 10:1697-1707. 
Leff P (1995) The two-state model of receptor activation. Trends Pharmacol Sci 16:89-97. 
Lefkowitz RJ, Cotecchia S, Samama P and Costa T (1993) Constitutive activity of receptors coupled to 
guanine nucleotide regulatory proteins. Trends Pharmacol Sci 14:303-307. 
Leopoldt D, Harteneck C and Nürnberg B (1997) G proteins endogenously expressed in Sf 9 cells: 
interactions with mammalian histamine receptors. Naunyn Schmiedebergs Arch Pharmacol 
356:216-224. 
Chapter 1: Introduction 26
Leurs R, Smit MJ and Timmerman H (1995) Molecular pharmacological aspects of histamine 
receptors. Pharmacol Ther 66:413-463. 
Levi RC and Alloatti G (1988) Histamine modulates calcium current in guinea pig ventricular myocytes. 
J Pharmacol Exp Ther 246:377-383. 
Levi R, Owen DAA and Trzeciakowski J (1982) Action of histamine on the heart and vasculature., in 
Pharmacology of histamine receptors (Ganellin CR and Parsons EM eds) pp 236-297, Wright, 
Bristol, England. 
Li L, Kracht J, Peng S, Bernhardt G and Buschauer A (2003) Synthesis and pharmacological activity 
of fluorescent histamine H1 receptor antagonists related to mepyramine. Bioorg Med Chem 
Lett 13:1245-1248. 
Liu C, Ma X, Jiang X, Wilson SJ, Hofstra CL, Blevitt J, Pyati J, Li X, Chai W, Carruthers N and 
Lovenberg TW (2001) Cloning and pharmacological characterization of a fourth histamine 
receptor (H4) expressed in bone marrow. Mol Pharmacol 59:420-426. 
Lovenberg TW, Roland BL, Wilson SJ, Jiang X, Pyati J, Huvar A, Jackson MR and Erlander MG 
(1999) Cloning and functional expression of the human histamine H3 receptor. Mol Pharmacol 
55:1101-1107. 
Milligan G (2000) Insights into ligand pharmacology using receptor-G-protein fusion proteins. Trends 
Pharmacol Sci 21:24-28. 
Morse KL, Behan J, Laz TM, West RE, Jr., Greenfeder SA, Anthes JC, Umland S, Wan Y, Hipkin RW, 
Gonsiorek W, Shin N, Gustafson EL, Qiao X, Wang S, Hedrick JA, Greene J, Bayne M and 
Monsma FJ, Jr. (2001) Cloning and characterization of a novel human histamine receptor. J 
Pharmacol Exp Ther 296:1058-1066. 
Nederkoorn PH, Vernooijs P, Donne-Op den Kelder GM, Baerends EJ and Timmerman H (1994) A 
new model for the agonistic binding site on the histamine H2-receptor: the catalytic triad in 
serine proteases as a model for the binding site of histamine H2-receptor agonists. J Mol 
Graph 12:242-256. 
Nederkoorn PH, van Lenthe JH, van der Goot H, Donne-Op den Kelder GM and Timmerman H 
(1996a) The agonistic binding site at the histamine H2 receptor. I. Theoretical investigations of 
histamine binding to an oligopeptide mimicking a part of the fifth transmembrane α-helix. J 
Comput Aided Mol Des 10:461-478. 
Nederkoorn PH, van Gelder EM, Donne-Op den Kelder GM and Timmerman H (1996b) The agonistic 
binding site at the histamine H2 receptor. II. Theoretical investigations of histamine binding to 
receptor models of the seven α-helical transmembrane domain. J Comput Aided Mol Des 
10:479-489. 
Nguyen T, Shapiro DA, George SR, Setola V, Lee DK, Cheng R, Rauser L, Lee SP, Lynch KR, Roth 
BL and O'Dowd BF (2001) Discovery of a novel member of the histamine receptor family. Mol 
Pharmacol 59:427-433. 
Oda T, Morikawa N, Saito Y, Masuho Y and Matsumoto S (2000) Molecular cloning and 
characterization of a novel type of histamine receptor preferentially expressed in leukocytes. J 
Biol Chem 275:36781-36786. 
Ogasawara M, Yamauchi K, Satoh Y, Yamaji R, Inui K, Jonker JW, Schinkel AH and Maeyama K 
(2006) Recent advances in molecular pharmacology of the histamine systems: organic cation 
transporters as a histamine transporter and histamine metabolism. J Pharmacol Sci 101:24-
30. 
Orange PR, Heath PR, Wright SR and Pearson RC (1996a) Allelic variations of the human histamine 
H2 receptor gene. Neuroreport 7:1293-1296. 
Orange PR, Heath PR, Wright SR, Ramchand CN, Kolkeiwicz L and Pearson RC (1996b) Individuals 
with schizophrenia have an increased incidence of the H2R 649G allele for the histamine H2 
receptor gene. Mol Psychiatry 1:466-469. 
Parsons ME and Ganellin CR (2006) Histamine and its receptors. Br J Pharmacol 147 Suppl 1:S127-
135. 
Chapter 1: Introduction 27
Parsons ME, Blakemore RC, Durant GJ, Ganellin CR and Rasmussen AC (1975) Proceedings: 3-
(4(5)-imidazolyl) propylguanidine (SK&F 91486) - a partial agonist at histamine H2-receptors. 
Agents Actions 5:464. 
Parsons ME, Owen DA, Ganellin CR and Durant GJ (1977) Dimaprit -(S-[3-(N,N-dimethylamino)-
prophyl]isothiourea) - a highly specific histamine H2-receptor agonist. Part 1. Pharmacology. 
Agents Actions 7:31-37. 
Perez DM and Karnik SS (2005) Multiple signaling states of G-protein-coupled receptors. Pharmacol 
Rev 57:147-161. 
Rodriguez-Pena MS, Timmerman H and Leurs R (2000) Modulation of histamine H2 receptor 
signalling by G-protein-coupled receptor kinase 2 and 3. Br J Pharmacol 131:1707-1715. 
Ruat M, Traiffort E, Arrang JM, Leurs R and Schwartz JC (1991) Cloning and tissue expression of a 
rat histamine H2-receptor gene. Biochem Biophys Res Commun 179:1470-1478. 
Samama P, Cotecchia S, Costa T and Lefkowitz RJ (1993) A mutation-induced activated state of the 
β2-adrenergic receptor. Extending the ternary complex model. J Biol Chem 268:4625-4636. 
Schneider E (2005) Development of Fluorescence-Based Methods for the Determination of Ligand 
Affinity, Selectivity and Activity at G-Protein Coupled Receptors. Doctoral thesis. University of 
Regensburg, Germany.  
Schneider E, Rolli-Derkinderen M, Arock M and Dy M (2002) Trends in histamine research: new 
functions during immune responses and hematopoiesis. Trends Immunol 23:255-263. 
Seifert R (2005) Constitutive activity of β-adrenoceptors: analysis in membrane systems., in G Protein-
coupled Receptors as Drug Targets. Analysis of Activation and Constitutive Activity (Seifert R 
and Wieland T eds) pp 123-140, Wiley-VCH, Weinheim. 
Seifert R and Wenzel-Seifert K (2002) Constitutive activity of G-protein-coupled receptors: cause of 
disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch 
Pharmacol 366:381-416. 
Seifert R, Hoer A, Schwaner I and Buschauer A (1992) Histamine increases cytosolic Ca2+ in HL-60 
promyelocytes predominantly via H2 receptors with an unique agonist/antagonist profile and 
induces functional differentiation. Mol Pharmacol 42:235-241. 
Seifert R, Wenzel-Seifert K, Bürckstümmer T, Pertz HH, Schunack W, Dove S, Buschauer A and Elz S 
(2003) Multiple differences in agonist and antagonist pharmacology between human and 
guinea pig histamine H1-receptor. J Pharmacol Exp Ther 305:1104-1115. 
Selbach O, Brown RE and Haas HL (1997) Long-term increase of hippocampal excitability by 
histamine and cyclic AMP. Neuropharmacology 36:1539-1548. 
Shayo C, Fernandez N, Legnazzi BL, Monczor F, Mladovan A, Baldi A and Davio C (2001) Histamine 
H2 receptor desensitization: involvement of a select array of G protein-coupled receptor 
kinases. Mol Pharmacol 60:1049-1056. 
Smit MJ, Timmerman H, Alewijnse AE, Punin M, van den Nieuwenhof I, Blauw J, van Minnen J and 
Leurs R (1995) Visualization of agonist-induced internalization of histamine H2 receptors. 
Biochem Biophys Res Commun 214:1138-1145. 
Smit MJ, Timmerman H, Blauw J, Beukers MW, Roovers E, Jacobs EH, Hoffmann M and Leurs R 
(1996a) The C terminal tail of the histamine H2 receptor contains positive and negative signals 
important for signal transduction and receptor down-regulation. J Neurochem 67:1791-1800. 
Smit MJ, Leurs R, Alewijnse AE, Blauw J, Van Nieuw Amerongen GP, Van De Vrede Y, Roovers E 
and Timmerman H (1996b) Inverse agonism of histamine H2 antagonist accounts for 
upregulation of spontaneously active histamine H2 receptors. Proc Natl Acad Sci U S A 
93:6802-6807. 
Soll AH and Berglindh T (1987) Physiology of isolated gastric glands and parietal cells: receptors and 
effectors regulating function., in Physiology of the Gastrointestinal Tract (Johnson LR ed) pp 
883–909, Raven Press, New York. 
Sprang SR (1997) G protein mechanisms: insights from structural analysis. Annu Rev Biochem 
66:639-678. 
Chapter 1: Introduction 28
Stark H, Kathmann M, Schlicker E, Schunack W, Schlegel B and Sippl W (2004) Medicinal chemical 
and pharmacological aspects of imidazole-containing histamine H3 receptor antagonists. Mini 
Rev Med Chem 4:965-977. 
Swaminath G, Xiang Y, Lee TW, Steenhuis J, Parnot C and Kobilka BK (2004) Sequential binding of 
agonists to the β2 adrenoceptor. Kinetic evidence for intermediate conformational states. J Biol 
Chem 279:686-691. 
Traiffort E, Vizuete ML, Tardivel-Lacombe J, Souil E, Schwartz JC and Ruat M (1995) The guinea pig 
histamine H2 receptor: gene cloning, tissue expression and chromosomal localization of its 
human counterpart. Biochem Biophys Res Commun 211:570-577. 
Vassilatis DK, Hohmann JG, Zeng H, Li F, Ranchalis JE, Mortrud MT, Brown A, Rodriguez SS, Weller 
JR, Wright AC, Bergmann JE and Gaitanaris GA (2003) The G protein-coupled receptor 
repertoires of human and mouse. Proc Natl Acad Sci U S A 100:4903-4908. 
Wang L, Gantz I and Del Valle J (1996) Histamine H2 receptor activates adenylate cyclase and PLC 
via separate GTP-dependent pathways. Am J Physiol 271:G613-620. 
Weinstein H, Chou D, Johnson CL, Kang S and Green JP (1976) Tautomerism and the receptor action 
of histamine: a mechanistic model. Mol Pharmacol 12:738-745. 
Weiss JM, Morgan PH, Lutz MW and Kenakin TP (1996a) The Cubic Ternary Complex Receptor-
Occupancy Model I. Model Description. J Theor Biol 178:151-167. 
Weiss JM, Morgan PH, Lutz MW and Kenakin TP (1996b) The Cubic Ternary Complex Receptor-
Occupancy Model II. Understanding Apparent Affinity. J Theor Biol 178:169-182. 
Weiss JM, Morgan PH, Lutz MW and Kenakin TP (1996c) The cubic ternary complex receptor-
occupancy model. III. resurrecting efficacy. J Theor Biol 181:381-397. 
Wenzel-Seifert K, Kelley MT, Buschauer A and Seifert R (2001) Similar apparent constitutive activity 
of human histamine H2-receptor fused to long and short splice variants of Gsα. J Pharmacol 
Exp Ther 299:1013-1020. 
Windaus A and Vogt W (1908) Synthesis of Imidazolylethylamine. Ber Dtsch Ges 40:3691. 
Wise A, Gearing K and Rees S (2002) Target validation of G-protein coupled receptors. Drug Discov 
Today 7:235-246. 
Xie SX, Ghorai P, Ye QZ, Buschauer A and Seifert R (2006a) Probing ligand-specific histamine H1- 
and H2-receptor conformations with NG-acylated Imidazolylpropylguanidines. J Pharmacol Exp 
Ther 317:139-146. 
Xie SX, Kraus A, Ghorai P, Ye QZ, Elz S, Buschauer A and Seifert R (2006b) N1-(3-
cyclohexylbutanoyl)-N2-[3-(1H-imidazol-4-yl)propyl]guanidine (UR-AK57), a potent partial 
agonist for the human histamine H1- and H2-receptors. J Pharmacol Exp Ther 317:1262-1268. 
Yamashita M, Fukui H, Sugama K, Horio Y, Ito S, Mizuguchi H and Wada H (1991) Expression cloning 
of a cDNA encoding the bovine histamine H1 receptor. Proc Natl Acad Sci U S A 88:11515-
11519. 
Zhu Y, Michalovich D, Wu H, Tan KB, Dytko GM, Mannan IJ, Boyce R, Alston J, Tierney LA, Li X, 
Herrity NC, Vawter L, Sarau HM, Ames RS, Davenport CM, Hieble JP, Wilson S, Bergsma DJ 
and Fitzgerald LR (2001) Cloning, expression, and pharmacological characterization of a 
novel human histamine receptor. Mol Pharmacol 59:434-441. 
 
Chapter 2: Scope and Objectives 29
 
 
2  
Chapter 2 
 
 
Scope and Objectives 
 
 
N-[3-(1H-Imidazol-4-yl)propyl]guanidines such as arpromidine are the most potent agonists 
at the H2R known so far and possibly useful as positive inotropic drugs for the treatment of 
severe congestive heart failure, as agents inducing cell differentiation in acute myelogenous 
leukemia, and as anti-inflammatory drugs. Recently, a novel class of less basic NG-acylated 
derivatives with improved pharmacokinetic properties, i.e. oral bioavailability and the 
capability of penetrating across the blood-brain-barrier, was developed. In a membrane 
steady-state GTPase activity assay at fusion proteins of H2R and the short splice variant of 
Gsα, GsαS, guanidines and NG-acylguanidines were considerably more potent and efficacious 
at the guinea pig (gp) than at the human (h) species isoform (Kelley et al., 2001; Xie et al., 
2006a, b). By contrast, histamine and the small H2R agonists dimaprit and amthamine do not 
exhibit species-selectivity. 
The aim of this thesis was to investigate molecular mechanisms underlying distinct functions 
of H2R species isoforms. Deeper insight into species-selective interactions of guanidine-type 
agonists with the human and guinea pig H2R will facilitate the development of novel agonists 
with increased hH2R potency and selectivity. Due to the present lack of GPCR crystal 
structures, investigations must be based on homology models derived from bovine rhodopsin 
(Palczewski et al., 2000). Predictions emerging from computational modelling provided a 
basis for subsequent experimental molecular pharmacological studies. 
Due to the homology of GPCRs in the structurally conserved regions of the seven TM 
domains, the methodology of homology modelling was expected to yield reliable three-
dimensional structural models of hH2R and gpH2R. Conserved intramolecular interactions 
including specific water molecules that were predicted to confer structural stability to the 
transmembrane-spanning domains and to play a role in receptor function had to be analyzed 
according to experimental data. A detailed inspection of the binding pocket was to identify 
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distinct amino acids selectively interacting with guanidine-type agonists. A virtual screening 
approach for appropriate substituents for the variable mono- or diarylalkanoyl groups of NG-
acylated guanidines was expected to result in agonists with increased hH2R potency and 
selectivity. 
Molecular dynamics (MD) simulation is an established computational method to analyze the 
conformational dynamics of membrane proteins. MD simulations of the ligand-free and the 
arpromidine-docked hH2R models are to generate energetically favourable conformations 
representing the transition of the hH2R from an inactive towards an active state, predicted to 
occur on a nanosecond time scale. Since explicit consideration of the protein environment is 
a crucial prerequisite for reliable simulations, the hH2R model was aimed to be embedded in 
a 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylcholine bilayer solvated by water. The 
results from the simulations were expected to help on further refining dynamic models of the 
binding mode of guanidine-type agonists. 
The experimental part of this thesis was aimed at the pharmacological characterization of 
H2R species isoforms of human, guinea pig, rat, and canine. Recombinant proteins were to 
be expressed using a baculovirus/Sf9 insect cells expression system. Measurement of 
steady-state GTPase activity in membranes expressing H2R-GsαS fusion proteins was 
selected as this system was previously shown to be reliable and very sensitive to analyze 
ligand potencies and efficacies. The constitutive activities of the various H2R species 
isoforms had to be quantified with the GTPase assay and supplemented by adenylyl cyclase 
activity assays at membranes expressing fused and non-fused H2Rs. Results from these 
studies had to be analyzed with help of the generated receptor models.  
Mutant hH2R-GsαS fusion proteins with Cys-17 and Ala-271 at the extracellular ends of TM1 
and TM7, respectively, mutated into the corresponding gpH2R residues, Tyr-17 and Asp-271, 
had to be generated and characterized since these residues were predicted to contribute to 
the species-selectivity of guanidine-type agonists (Kelley et al., 2001). The elusive role of the 
second extracellular loop for binding H2R agonists was planned to be analyzed by additional 
site-directed mutagenesis experiments. 
In summary, this thesis was aimed at further characterizing the structure and function of H2R 
species isoforms as well as the ligand-receptor interactions, the structure-activity and 
structure-selectivity relationships of guanidine-type agonists by an interdisciplinary approach 
comprising molecular modelling, in-vitro mutagenesis, and pharmacological assays.  
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3.1 GPCR homology models in pharmacological sciences 
In spite of remarkable advances in the fields of biology and pharmacology of GPCRs, 
progress on the structures of this protein family is rather limited. To date, the only high-
resolution crystal structures of a GPCR are of bovine rhodopsin which was resolved for the 
first time in the year 2000 with 2.80 Å resolution (Palczewski et al., 2000). Meanwhile, four 
additional structures of bovine rhodopsin have been published. Coordinate files of these 
structures can be retrieved from the Brookhaven Protein Data Base (PDB) (Bernstein et al., 
1977) by the identity codes 1F88 (Palczewski et al., 2000), 1HZX (Teller et al., 2001), 1L9H 
(Okada et al., 2002), 1GZM (Li et al., 2004), and 1U19 (Okada et al., 2004). Rhodopsin is 
better suited for structural studies than most other GPCRs because it is possible to obtain 
large quantities of highly enriched protein from bovine retina. Rhodopsin is also a remarkably 
stable GPCR, retaining function under conditions that denature many other GPCRs (Kobilka, 
2007). 
The lack of detailed structural information about GPCRs initiated the quest for three 
dimensional (3D) structural models. Knowledge-based approaches were developed to 
predict 3D structures of proteins that are based on experimental data of 3D structures of 
homologous reference proteins. Class 1 GPCRs (Foord et al., 2005) are homologous with 
rhodopsin (Mirzadegan et al., 2003) and are also referred to the term rhodopsin-like. 
Accordingly, crystal structures of bovine rhodopsin were frequently and successfully used to 
build homology models of class 1 GPCRs. Such models have been shown to provide unique 
insight into molecular mechanisms of GPCR function and activity (Kristiansen, 2004). For 
example, predictions about the specific roles of distinct amino acids for the regulation of 
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GPCR activity can be derived (Figure  3.1). These predictions can subsequently be used as a 
guideline for the construction and characterization of point mutations. Thus there is a tight 
correspondence between suggestions from homology models and the experimental field of 
molecular pharmacology. Furthermore, homology models offer the possibility to study ligand-
receptor interactions at an atomic level that can direct the de novo design of new leads, e.g. 
by application of flexible docking and virtual screening methods (Bissantz et al., 2003). 
 
 
 
 
 
3.2 Sequence alignment 
The first step in homology modelling is the alignment of the amino acid sequence of the 
target protein with that of the template protein. Correspondences between amino acids are 
the basis for transferring the coordinates of the template to the target. Several prediction 
algorithms are available that help to identify structurally conserved hydrophobic 
Sequence alignment 
3D structure generation 
Energy minimization
Model validation
Docking; 
virtual screening  
Molecular dynamics 
simulations 
Discovery of novel 
leads 
Pharmacological 
characterization of point mutants
Structural and functional 
studies of wild-type GPCRs
Analysis of ligand-receptor 
interactions; 3D-QSAR 
Structure revisions 
in silico 
in vitro 
Figure  3.1: Flowchart of steps in homology modelling and possible applications of homology models 
in computational (in silico) and in vitro pharmacological fields of research. 
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(intramembraneous) and less-conserved polar (loop) regions, and may therefore be useful in 
assisting in the sequence alignment.  
Automatic sequence alignment tools are frequently used to search for an optimal similarity of 
sequences. Sequence comparisons are carried out either pairwisely (e.g. ALIGN (Devereux 
et al., 1984)) or as a multi-sequence alignment (e.g. CLUSTAL W (Thompson et al., 1994)). 
Most sequence alignment algorithms more or less try to retrace the evolutionary process 
involved in converting one sequence into another. For this operation homology matrices are 
used that specify the weight for aligning a particular type of amino acid with another. These 
homology matrices make use of the most probable amino acid substitutions according to 
physical, chemical, or statistical properties. In cases of different sequence lengths and 
variations in the locations of conserved regions, gaps are introduced into the alignment. To 
minimize the number of gaps, a gap-penalty function is used. 
 
 
3.3 Construction of 3D structures 
The most important steps in the process of generating 3D structures of GPCRs are 
summarized as follows: 
 
• Construction of structurally conserved regions. In gap-free regions of the sequence 
alignment, the backbone atom coordinates of the target model can be directly retrieved 
from the template structure. For GPCR modelling approaches, structurally conserved 
regions are the TM domains and potentially short loop regions. 
 
• Construction of structurally variable regions. Loop regions and the N-termini and C-
termini of GPCRs display low sequence homology and often contain gaps and deletions. 
A convenient method for constructing such regions is to search for appropriate peptide 
segments in a 3D structure database (loop search). With this approach, homologous loop 
segments can be selected that align with anchor regions and fit into the spatial 
environment of the target model. Alternatively, loops can be generated by de novo 
strategies, e.g. using simulating annealing methods. 
 
• Addition of amino acid side chains and adjustment of side chain conformations and 
protonation states. Generally, identical and homologous amino acids in homologous 
proteins are proposed to adopt similar side chain conformations. Hence, the 
conformations of such residues may be retrieved by adjusting the conformation to that of 
the corresponding residue in the template structure. In cases of non-conserved amino 
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acid exchanges rotamer libraries can assist in the selection of reasonable side chain 
conformations. Rotamer libraries such as the Lovell library (Lovell et al., 2000) 
implemented in Sybyl 7.1 (Tripos, St. Louis, MO) contain a collection of statistically 
favored side chain conformations from which the most frequent one without clashes with 
other residues can be selected. Polar residues are preferably located in loop and terminal 
regions of GPCRs that point into the aqueous medium. Thus, the protonation states of 
these residues can be adjusted according to their pKa values in water. By contrast, polar 
residues in the interior of the TM bundle most often are conserved and undergo distinct 
intramolecular interactions or form H-bonds with structurally important water molecules 
(Okada et al., 2002). The protonation states of these residues must therefore be 
individually adjusted. 
 
• Structural refinement using energy minimization and MD simulations. Energy 
minimization techniques are used to remove strain from the protein structure and to 
transfer it in an energetically relaxed conformation. Energy minimization is based on the 
calculation of the potential energy in a molecular system using force fields. MD 
simulations are used to elaborate the conformational space of macromolecules. The 
principles of both methods are described in more detail in the Appendix 1 (chapter 11). 
 
 
3.4 Validation of homology models 
After GPCR homology models are generated and structurally optimized, validation of the 
resulting models is an essential task to guarantee applicability of the models for the particular 
purposes of the project. The most important parameters to be evaluated are summarized in 
Figure  3.2. 
For an evaluation of the stereochemical quality of a structure model, programs such as 
PROCHECK (Laskowski et al., 1993) and WHATCHECK (Hooft et al., 1996) have been 
developed. A Ramachandran plot is frequently used to check the correctness of the 
backbone φ and ψ torsion angles. A bump check is to detect and remove bad van der Waals 
contacts between adjacent residues and should already be carried out prior to energy 
minimization and MD simulations. An overall estimation of structural differences between the 
backbone structures of the protein model and the template can be obtained by calculating 
the root mean square deviation (RMSD) of all backbone or Cα atoms. When conducting MD  
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simulations, stability of secondary structural elements is an important parameter that can be 
calculated by means of a dssp plot (Kabsch and Sander, 1983). Additionally, the total 
number of intramolecular H-bonds, the radius of gyration, and the solvent-accessible surface 
area give valuable measures of the protein global folding. Finally, distinct interactions 
between adjacent residues and between residues and structurally important water molecules 
that are predicted to be conserved and that may play a functional role in GPCR function 
and/or structural arrangement of the TM domains have to be controlled and eventually 
enforced by application of restraints. 
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Pig Histamine H2 Receptors: Analysis of 
Species-selective Interactions with Guanidine-
type Agonists and Virtual Screening 
 
 
4.1 Introduction 
N-[3-(1H-imidazol-4-yl)propyl]guanidines are the most potent and selective agonists at the 
histamine H2 receptor (H2R) known so far (Dove et al., 2004). Measuring the positive 
chronotropic response on the spontaneously beating guinea pig right atrium served as a 
standard method for the pharmacological characterization of the H2R agonists. Quantitative 
structure-activity relationship (QSAR) approaches were applied to correlate agonist 
potencies (expressed as pD2 values) with structural properties. A Free-Wilson analysis of a 
series of unbranched impromidine-like and branched arpromidine (ARP)-like agonists led to 
first results about favorable and unfavorable arrangements of aromatic rings and substituent 
effects (Franke and Buschauer, 1992). Subsequently, a more powerful Hansch analysis was 
applied to a large series of 141 guanidine-type agonists (Dove and Buschauer, 1998) 
indicating that spatial effects like folding and branching as well as electrostatic interactions of 
heteroatoms like S, O, and N are the main forces for optimal binding of the compounds. 
Particularly, affinity-increasing effects of a branch three methylene units distant from the 
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guanidino group and introduction of a nitrogen atom in one of the two aromatic rings as well 
as an unfavorable influence of substituents at the heteroaryl ring were elucidated. More 
complex steric and electrostatic effects on receptor binding were detected by a 3D-QSAR 
approach submitting the agonists to a comparative molecular field analysis (CoMFA) (Dove 
and Buschauer, 1998, 1999). For this purpose, the 3D structures of 142 compounds were 
aligned based on their common imidazolylpropylguanidine groups. A refined alignment could 
be generated with the weighted field fit method (Dove and Buschauer, 1999). As a result, 
steric and electrostatic field variables contributing to H2R agonism were calculated. With this 
method, distinct effects of the two aromatic rings in N-(imidazolylpropyl)-NG-
(diarylalkyl)guanidines were described. Accordingly, one of the aromatic rings was predicted 
to point into an “upper” binding region where bulk enhances activity. Substitution with 
negatively charged groups in meta and para position of this ring may further increase 
potency. A second “lower” binding region was predicted to be occupied by the other ring 
system where introduction of bulky groups generally decreases potency.  
The results from 3D-QSAR studies were subsequently used to analyze the binding modes of 
guanidine-type agonists in the H2R binding pocket. For this purpose, a homology model of 
the seven transmembrane (TM) domains of the gpH2R was generated using the crystal 
structure of bovine rhodopsin as template (Kelley et al., 2001). In a membrane steady-state 
GTPase activity assay at fusion proteins of H2R and the short splice variant of Gsα, GsαS, the 
guanidines and their NG-acylated derivatives were determined to be considerably more 
potent and efficacious at the guinea pig than at the human H2R-GsαS (Kelley et al., 2001). 
From the generated structure model, the non-conserved residues Asp-271(7.36)1 and 
Tyr-17(1.31) were proposed to selectively interact in the guinea pig species isoform thereby 
stabilizing an active guanidine-bound receptor conformation. This hypothesis was 
subsequently confirmed by site-directed mutagenesis experiments (Kelley et al., 2001). 
In the present study, 3D structure models of the gpH2R and hH2R were generated using the 
crystal structure of bovine rhodopsin as template. In addition to the previous model, the 
N-terminus of the proteins and all extracellular and intracellular loops connecting the TM 
domains were considered. For a further analysis of the binding modes of guanidine-type 
agonists and their NG-acylated derivatives,the extracellular loop regions were expected to be 
in spatial proximity to the agonists and thus to contribute to ligand-receptor interactions. In 
addition, the model of the human receptor was used to perform a virtual screening to develop 
more potent and selective hH2R agonists.  
 
                                                 
1 Residues within TM domains are named according to the Ballesteros/Weinstein nomenclature 
(Ballesteros and Weinstein, 1995). The most conserved residue in each TM is numbered as X.50 
where X is the number of the respective TM domain.  
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4.2 Materials and Methods 
4.2.1 Sequence alignment 
An initial amino acid sequence alignment of bovine rhodopsin with hH2R (Gantz et al., 1991) 
and gpH2R (Traiffort et al., 1995) was generated with CLUSTAL W (Thompson et al., 1994) 
(Figure  4.1). A multi-sequence alignment of a large series of aminergic GPCRs provided by 
the GPCR database (http://www.gpcr.org/7tm) was used as a reference to accomplish 
necessary corrections. Class 1 aminergic GPCRs and rhodopsin share the highest 
conservation within the seven α-helical TM domains (sequence identity of 19.6% and 21.1% 
between bovine rhodopsin and hH2R and gpH2R, respectively). Since a much higher 
conservation exists within structurally conserved regions (Mirzadegan et al., 2003) those 
microdomains were used to refine the alignment. Examples of structurally conserved regions 
are the most conserved residues in each TM domain and highly conserved motifs such as 
the (E/D)RY motif in TM3, the CWxP(F/Y) motif in TM6, the NPxxY(x)5,6F motif in TM7 and 
the short α-helical segment H8 at the C-terminus of the receptor. The final sequence 
alignment was in good agreement with a previous alignment of several GPCRs with bovine 
rhodopsin (Ballesteros et al., 2001a). 
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4.2.2 Generation of 3D structure models of the hH2R and gpH2R 
For the construction of hH2R and gpH2R homology models, three crystal structures of bovine 
rhodopsin (pdb accession numbers 1F88 (Palczewski et al., 2000), 1HZX (Teller et al., 
2001), and 1L9H (Okada et al., 2002)) were used as templates. The sequence of bovine 
rhodopsin was mutated into the corresponding sequences of hH2R and gpH2R at positions 
without gaps and deletions, i.e. TM1 to TM7, extracellular loops e1 and e3, intracellular loop 
i1, N-terminus, and C-terminus up to Phe-303. Since the H2R C-terminus is by 29 residues 
longer than the C-terminus of bovine rhodopsin and since both sequences share a very low 
homology in this part, predictions about the peptide structure following H8 would be highly 
speculative. Therefore, the last 56 C-terminal residues were not considered in the 
construction of the models. The remaining intracellular and extracellular loops (e2, i2, i3) 
were added by the Loop Search tool implemented in Sybyl 7.1 (Tripos, St. Louis, MO). This 
tool searches a binary PDB variant of 3D protein structures for homologous sequences that 
                        N-term                  ______________TM1_____________  i1 
b.Rhod.    1  MNGTEGPNFYVPFSNKTGVVRSPFEAPQYYLAEPWQFSMLAAYMFLLIMLGFPINFLTLYVTVQHKKLRT 
hH2R       1  -------------------MAPNGT.SSFC.DSTACKITITVVLAV..LITVAG.VVVCLAVGLNRR..N 
gpH2R      1  -------------------MAFNGTV.SFCMDFTVYKVTISVILII..LVTVAG.VVVCLAVGLNRR..S 
                                      |         |         |         |         | 
 
              ___________TM2________________  e1  ________________TM3______________ 
b.Rhod.   71  PLNYILLNLAVADLFMVFGGFTTTLYTSLHGYFVFGPTGCNLEGFFATLGGEIALWSLVVLAIERYVVVC 
hH2R      52  LT.CFIVS..IT..LLGLLVLPFSAIYQ.SCKWS..KVF..IYTSLDVMLCTASILN.FMISLD..CA.M 
gpH2R     52  LT.CFIVS...T..LLGLLVLPFSAIYQ.SCKWS.SKVF..IYTSLDVMLCTASILN.FMISLD..CA.T 
                |         |         |                     |         |         |    
 
                 i2      _________TM4___________           e2                  _____ 
b.Rhod.  141  KPMSNFRFGE-NHAIMGVAFTWVMALACAAPPLV-GW-SRYIPE-GMQC--SCGIDYYTPHEETNNESFV 
hH2R     122  D.LRYPVLVTPVRVAISLVLI..ISITLSFLSIHL..N..NETSK.NHTTSK.KVQV--------..VYG 
gpH2R    122  D.LRYPVLITPARVAISLV.I..ISITLSFLSIHL..N..NETSKDNDTIVK.KVQV--------..VYG 
                         |         |         |                                        
 
              _____TM5_____________            i3           ________________TM6_____ 
b.Rhod.  205  IYMFVVHFIIPLIVIFFCYGQLVFTVKEAAAQQQE----SATTQKAEKEVTRMVIIMVIAFLICWLPYAG 
hH2R     184  LVDGL.T.YL..LIMCIT.YR.FKVARDQ.KRINHISSWK.A.IR-.HKA.VTLAAVMG..I...F..FT 
gpH2R    184  LVDGL.T.YL..LIMCIT.FR.FKIAR.Q.RRINHIGSWK.A.IR-.HKA.VTLAAVMG..I...F..FT 
              |         |         |                         |         |         | 
 
              _______   e3   _________TM7_________    ____H8_____                
b.Rhod.  271  VAFYIFTHQGSDFGPIFMTIPAFFAKTSAVYNPVIYIMMNKQFRNCMVTTLCCGKNPLGDDEASTTVSKT 
hH2R     253  AFV.RGLRGDDAINEVLEA.VLWLGYANSAL..IL.AAL.RD..TGYQQLF..RLANRNSHKT.LRSNAS 
gpH2R    253  .FV.RGLKGDDAVNEV.EDVVLWLGYANSAL..IL.AAL.RD..TAYHQLF..RLASHNSH.T.LRLNNS 
                    |               |         |         |         |          
 
              C-term 
b.Rhod.  341  ETSQVAPA-348 
hH2R     323  QL.RTQSREPRQQEEKPLKLQVWSGTEVTAPQGATDR  359 
gpH2R    323  QLNRSQCQEPRWQEDKPLNLQVWSGTEVTAPQGATNR  359 
Figure  4.1: Sequence alignment of bovine rhodopsin with hH2R and gpH2R. Dots in the sequences 
indicate identity with bovine rhodopsin. Amino acids shown with grey shading represent the most 
conserved amino acid in each TM domain. 
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align with the termini before and after the lacking loops. Five buried water molecules 
positioned close to conserved residues were retained from the crystal structure of bovine 
rhodopsin (pdb accession number 1L9H) (Okada et al., 2002). Two water molecules (Wat2a 
and Wat2b) were not implemented in the new H2R models, since these molecules are 
involved in the interaction of the retinal-Schiff base with rhodopsin and interact with specific 
residues in e2 that are not conserved in the H2R. 
 
4.2.3 Structural refinement of the models 
Using a local geometry check (PROTABLE, implemented in Sybyl 7.1), all side chain 
conformations were inspected and, if necessary, corrected to achieve proper chirality and to 
avoid steric hindrance. Generally, the ionic states of basic (Arg, Lys) and acidic (Glu, Asp) 
residues was applied. As an exception, Asp-64(2.50) in TM2 was set to the uncharged form 
to account for the predicted H-bond network (Teller et al., 2001). The receptor model was 
energy-minimized with the Amber 7.0 force field using Amber charges and a dielectric 
constant of 4. In the first minimization steps, the positions of all backbone atoms of the TM 
domains and H8 were fixed. Conserved H-bond and ionic interactions between distinct 
residues (Table  4.2) and between water molecules and residues were enforced by 
application of distance restraints using a force constant of 100 kcal mol-1 Å-2. In that way, the 
backbones of loops and terminal regions as well as amino acid side chains were allowed to 
relax during energy minimization. An initial minimization was performed using the steepest 
descent method followed by a second minimization by the Powell method. During 
subsequent steps, all protein atoms were allowed to move and constraints were successively 
released. In the final minimization, the protein was allowed to relax without constraints down 
to an RMS gradient of less than 0.05 kcal mol-1 Å-1. 
 
4.2.4 Docking of H2R agonists 
Previous 3D-QSAR data obtained by CoMFA (Dove and Buschauer, 1999) and results from 
site-directed mutagenesis (Kelley et al., 2001) were considered on manually docking ARP 
and UR-PG136 (Figure  4.2) into the binding sites of the gpH2R and the hH2R (DOCK, 
implemented in Sybyl 7.1). Attempts of docking the ligands into the ligand-free receptor 
models failed due to steric clashes with the backbone of e2. Thus the conformation of e2 was 
carefully rearranged. Amber 7.0 atom types and Gasteiger-Hückel charges were assigned to 
the agonists. Missing Amber 7.0 parameters were derived by analogy with the Tripos force 
field. The ligand-receptor complexes were energy-minimized with the Amber 7.0 force field 
using Amber charges and a dielectric constant of 4. In the first minimization steps, the 
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positions of all backbone atoms of the TM domains and H8 were fixed. In addition to the 
distance constraints applied on the ligand-free receptor models, a force constant of 100 kcal 
mol-1 Å-2 was applied to enforce an interaction of the imidazolylpropyl moiety of ARP and 
UR-PG136, respectively, with Asp-98(3.32), Tyr-182(5.38), and Asp-186(5.42). An initial 
minimization was performed using the steepest descent method followed by a second 
minimization by the Powell method. During subsequent minimization steps, all protein atoms 
were allowed to move and constraints were successively released until an RMS gradient of 
less than 0.05 kcal mol-1 Å-1 was achieved. 
 
 
 
4.2.5 Preparation of compound databases 
The CStar 2004 (http://www.chemstar.ru; ChemStar, Ltd.), the ambinter 
(http://www.ambinter.com; Ambinter SARL, Paris, France), and the LeadQuest 
(http://leadquest.com; Tripos Inc., St. Louis, MA, USA) 2D libraries of commercially available 
compounds, and the ibscreen (http://www.ibscreen.com; InterBioScreen) 2D chemical library 
for screening programs were pre-processed to remove salts, metals, and isotopes by use of 
the ChemFinder Pro 6.0 software (CambridgeSoft, Cambridge, MA, USA). To generate a 
compound fragment library a molecular weight filter of MW ≤ 250 g mol-1 was applied. To 
eliminate multiple entries, the libraries were subsequently combined to a unified database 
with 26051 records. 2D structures were converted into 3D by use of the CORINA software 
(http://www.mol-net.de; Molecular Networks GmbH, Erlangen, Germany). Here, small 
fragments such as counter-ions in salts and solvent molecules were removed. Existing 
stereoisomers (up to six) were generated. Nitrogen inversion was allowed to consider 
multiple ring conformations. In this way, 6544 isomers were added. The resulting database 
with 32589 entries was prepared with the LUDI module GENFRA (Böhm, 1992, 1993) for 
applicability of the LUDI virtual screening software package (Accelrys Inc., San Diego, USA). 
A link library was generated with link sites at methyl atoms to connect the fragments in the 
database with a reference ligand docked into the hH2R homology model during the LUDI run. 
N
HN HN
H
N
NH
X
N
F
 X 
arpromidine (ARP) CH2 
UR-PG136 CO 
Figure  4.2: Structures of ARP and its 
NG-acylated analogue UR-PG136. 
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4.2.6 Application of the LUDI software for virtual screening 
For virtual screening approaches, the hH2R homology model in complex with UR-PG136 was 
used as starting structure. A link mode was applied to search for small molecule fragments 
using our fragment library (chapter 4.2.5) and a fragment library provided by Accelrys. The 
4-F-phenyl group of docked UR-PG136 was deleted to generate a link-site at the methylene 
group in position 3 of the NG-3-(2-pyridyl)propanoyl chain. In another approach, the 
4-F-phenyl(2-pyridyl)methyl group of UR-PG136 was deleted to generate a link-site at the 
terminal methyl group of the NG-ethanoyl chain. The LUDI routine then linked appropriate 
molecule fragments from the databases to these sites. A sphere of 8 Å radius was defined 
around the link atom in the binding site of the hH2R. The values of the most important LUDI 
parameters were as follows: the maximal RMS distance of the fit between the fragment and 
the interaction site was 0.8 Å, the number of lipophilic and polar interaction sites was set to 
25, and the maximal alignment angle formed by a bond in the fragment and the C-H bond 
that defines the link site in the partially built molecule was 14°. New conformations for the 
library fragments were generated by simultaneously altering two rotatable bonds in a 
molecule. For the remaining parameters default values were applied. 
 
 
4.3 Results 
4.3.1 Characterization of three-dimensional homology models of hH2R and 
gpH2R 
4.3.1.1 Analysis of the stereochemical quality 
The stereochemical qualities of the hH2R and gpH2R homology models (Figure  4.3 A) were 
analyzed using the PROCHECK software (Laskowski et al., 1993). A summary of this 
analysis is listed in Table  4.1. In both models, more than 80% of the backbone φ- and ψ-
angles coincide with the most favoured regions as illustrated in the corresponding 
Ramachandran plots (Figure  4.3 B). All of the analysis parameters shown are within the 
expected limitations and represent a proper stereochemical quality of both receptor models. 
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Parameter hH2R gpH2R 
Residues in most favored regions (A, B, L) 233 (83.5%) 228 (80.8%) 
Residues in additional allowed regions (a, b, l, p) 40 (14.3%) 46 (16.4%) 
Residues in generously allowed regions (~a, ~b, ~l, ~p) 5 (1.8%) 6 (2.1%) 
Residues in disallowed regions 1 (0.4%) 2 (0.7%) 
Bad contacts 0 0 
Main chain bond length within limits (%) 100 100 
Main chain bond angles within limits (%) 87.8 85.8 
Planar groups within limits 96.6 94.7 
Figure  4.3: A, Side view of the secondary structures of the hH2R and gpH2R models. The side chains 
of residues differing in the sequences of both species-isoforms are shown in stick representation; B, 
Ramachandran plots of hH2R (left hand side) and gpH2R (right hand side) models showing the 
distribution of φ- and ψ- torsion angles of amino acids. Glycines are shown as triangles and all 
remaining residues except prolines are shown as squares. Red fields, most favoured regions; yellow 
fields, additional allowed regions; grey fields, generously allowed regions; white fields, disallowed 
regions. A and a, α-helix; B and b, β-strand; L and l, left-hand α-helix; p, allowed ε. 
Table  4.1: PROCHECK analysis of the hH2R and gpH2R homology models.
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4.3.1.2 Conserved intramolecular interactions in rhodopsin and the H2R 
The crystal structure of bovine rhodopsin contains a number of interhelical contacts that are 
assumed to be conserved among class 1 GPCRs (Filipek et al., 2003; Okada et al., 2001; 
Mirzadegan et al., 2003; Palczewski, 2006). Such conserved interactions are predicted to 
confer stability to the TM domains and presumably play a functional role in receptor activity. 
For the generation of the H2R models, some of these interactions were constrained during 
energy minimization. Conserved intramolecular interactions were analyzed by calculating the 
distances between the respective residues in the generated models (Table  4.2). Okada et al. 
proposed conserved interhelical contacts to be mediated by a few water molecules buried in 
the TM bundle (Okada et al., 2002). Therefore, five of these functional water molecules were 
transferred from rhodopsin to the new H2R models. A schematic representation of the 
resulting network of water-mediated H-bonds is shown in Figure  4.4. A cluster of the water 
molecules Wat1a, Wat1b, and Wat1c (names of water molecules match those of 
corresponding water molecules in the crystal structure of bovine rhodopsin (Okada et al., 
2002)) connected residues in TM2 and TM3, TM2 and TM7, and TM6 and TM7. TM6 and 
TM7 were additionally linked via Wat3, and Wat4 was predicted to link TM2 and TM7. 
 
 
 
 
 
 
 
In inactive GPCR conformations, Arg(3.50) of the highly conserved (E/D)RY motif at the 
intracellular end of TM3 was predicted to form ionic interactions with adjacent 
Figure  4.4: Schematic representation of water-mediated H-bonds in hH2R and 
gpH2R. The names of water molecules match those of corresponding water 
molecules in the crystal structure of bovine rhodopsin (Okada et al., 2002). 
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Glu(3.49)/Asp(3.49) and with Glu(6.30) at the intracellular end of TM6 (Ballesteros et al., 
2001b). This network of interactions was proposed to be disrupted upon GPCR activation, 
ultimately leading to an anticlockwise rotation when viewed from the extracellular side and 
outward movement of TM6 (Visiers et al., 2002; Hubbell et al., 2003). H2R mutations of 
Arg-116(3.50) gave rise to a highly instable receptor with increased constitutive activity, 
suggesting that disruption of interactions in the (E/D)RY motif leads to the formation of 
active, but instable receptor conformations (Alewijnse et al., 2000). In the H2R models, ionic 
interactions between Asp-115(3.49), Arg-116(3.50), and Glu-229(6.30) were established. 
Additional ionic interactions were formed between Glu-229(6.30) and the non-conserved 
Arg-228(6.29) as well as between Arg-228(6.29) and Asp-294(7.59) (Figure  4.5 A). 
 
 
 
Domain Residues Typea Min. distance (Å)b 
   hH2R gpH2R 
TM1 N36(1.50) - T32(1.46) h 2.90* 2.91* 
TM1-TM2 N36(1.50) - D64(2.50) h 2.83* 2.84* 
TM1-TM7 N36(1.50) - S281(7.46) h 3.03 2.97 
TM2 I57(2.43) - L60(2.46) vdW 4.83 4.55 
TM2-TM6 I57(2.43) - V239(6.40) vdW 6.80 7.19 
TM2-TM4 S59(2.45) - W143(4.50) h 3.03 3.06 
TM3-TM7 Y94(3.28) - Y278(7.43) h 3.18 3.31 
TM3 L109(3.43) - I112(3.46) vdW 4.70 4.33 
TM3-TM6 L109(3.43) - V239(6.40) vdW 4.16 3.97 
TM3 D115(3.49) - R116(3.50) i 3.04* 3.09* 
TM3-TM6 R116(3.50) - E229(6.30) i 2.91* 2.92* 
TM7-H8 Y288(7.53) - F295(7.60) ar 3.47 3.87 
TM7-H8 A289(7.54) - R296(7.61) h 3.00 3.01 
TM7-H8 A290(7.55) - R296(7.61) h 2.93 3.32 
 
 
 
 
 
TM1 and TM2 strongly interacted via the highly conserved residues Asn-36(1.50) and 
Asp-64(2.50) (Figure  4.5 B). Nδ2-H of Asn-36(1.50) additionally formed H-bonds with the 
backbone oxygens of Thr-32(1.46) and Ser-281(7.46) similar to corresponding interactions in 
bovine rhodopsin (Pardo et al., 2007; Bissantz, 2003). Asp-64(2.50) interacted via Wat1b 
with the backbone-O of Asn-280(7.45) and with the backbone-NH of Asn-284(7.49) thus 
a type of interactions; h, H-bond; i, ionic interaction; vdW, van der Waals interaction; 
ar, aromatic interaction 
b Distance between the nearest heavy atoms of interacting residues 
* Distances between residues were constrained during energy-minimization 
(chapter 4.2.3). 
Table  4.2: Conserved intramolecular interactions in the hH2R and gpH2R models. 
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linking TM2 and TM7. Asn-284(7.49) is a member of the highly conserved NPxxY(x)5,6F motif 
and was previously shown to play a critical role in receptor activation (Govaerts et al., 2001; 
Urizar et al., 2005). In the inactive state, the side chain of this residue is predicted to point 
towards TM6 (Pardo et al., 2007) which is in agreement with the Wat1c-mediated H-bond to 
Val-239(6.40) in the H2R models. Upon receptor activation, Asn-284(7.49) is predicted to 
adopt a different conformation then interacting with Asp-64(2.50) (chapter 5.3.2.3). 
Tyr-288(7.53) and Phe-295(7.60) are also part of the NPxxY(x)5,6F motif and are suggested 
to form an aromatic interaction in the inactive state of rhodopsin. Upon transition to meta 
I/meta II this interaction is proposed to be disrupted (Fritze et al., 2003). In the H2R models 
both residues were in spatial proximity. Additionally, the hydroxyl group of Tyr-288(7.53) 
interacted with the conserved Asn-54(2.40) via Wat4 thus linking the cytoplasmic ends of 
TM2 and TM7. 
The CWxP(F/Y) motif in TM6 is another functionally important microdomain in class 1 
GPCRs. The structure of metarhodopsin I was recently determined by electron 
crystallography (Ruprecht et al., 2004) showing that Trp(6.48) undergoes a conformational 
transition from pointing towards TM7 in the inactive state to pointing towards TM5 in an 
active conformation. The orientation of Trp(6.48) in the inactive state of the H1R was 
predicted to be determined by an interaction with the conserved Asn(7.45) (Jongejan et al., 
2005). In the H2R models, the side chain of Trp-247(6.48) was directed towards TM7 
although a direct interaction with Asn-280(7.45) was not observed (Figure  4.5 C). However, 
since the side chain of Asn-280(7.45) was allowed to rotate around the χ1-angle a 
corresponding interaction would be possible. In agreement with the crystal structure of 
rhodopsin, Wat3 mediated H-bond interactions of Tyr-250(6.51) and Cys-246(6.47) with the 
backbone oxygen of Val-273(7.38). These interactions presumably stabilize the exceptionally 
sharp Pro-kink (triggered by the highly conserved Pro-249(6.50)) of 35° in TM6 (Pardo et al., 
2007). Wat1a mediated an interaction of the carboxylate group of Asp-64(2.50) with the 
backbone-O of Leu-101(3.35). In the H2R models, the hydroxyl group of Ser-105(3.39) 
participated in this H-bond network. Previously it was proposed that Ser(3.39) or Thr(3.39) 
could contribute to a sodium binding site in rhodopsin-like GPCRs (Okada et al., 2002; Neve 
et al., 2001). 
Another network of conserved interhelical interactions in rhodopsin is constituted by 
Asn(2.45), Ser(3.42), Thr(4.49), and Trp(4.50) (Palczewski et al., 2000). In the H2R, the OH 
oxygen of Ser-59(2.45) interacted with the conserved Trp-143(4.50) thus linking TM2 and 
TM4 (Figure  4.5 D). By analogy to H-bond interactions between the conserved Arg(7.61) in 
H8 and the backbone oxygens of Ile(7.54) and Met(7.55) in rhodopsin (Teller et al., 2001), 
Arg-296(7.61) was identified to interact with Ala-289(7.54) and Ala-290(7.55) in the H2R 
models (Table  4.2). Glu(3.28) forms the counterion to the Schiff-base of retinal with 
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Lys(7.43). The corresponding H2R residues, Tyr-94(3.28) and Tyr-278(7.43), interacted via 
their side chain atoms. A large number of hydrophobic interhelical contacts exists in 
rhodopsin, mainly between TM1-TM2, TM2-TM7, TM3-TM4, TM5-TM6, TM6-TM7 (Filipek et 
al., 2003). Met (6.40) was identified to be surrounded by a Leu cluster including Leu(2.43), 
Leu(2.46), Leu(3.43), and Leu(3.46) (Okada et al., 2001). Mutation of Leu(3.43) resulted in 
increased constitutive activity in several GPCRs (Tao et al., 2000; Lu and Hulme, 1999), 
supporting a general function of hydrophobic interactions between these residues in 
maintaining the ground state of GPCRs (Okada et al., 2001). In agreement with these 
studies, the corresponding hydrophobic residues in the H2R models, Val-239(6.40),  
Ile-57(2.43), Leu-60(2.46), Leu-109(3.43), and Ile-112(3.46), were in close proximity to each 
other (Figure  4.5 D). 
 
 
 
 
 
 
Figure  4.5: Conserved interactions in the hH2R. A, interactions of the (E/D)RY motif 
at the intracellular end of TM3; B, interactions of the NPxxY(x)5,6F motif in TM7; C, 
interactions of the CWxP(F/Y) motif in TM6; D, hydrophobic latch between residues 
in TM2, TM3, and TM6, and interaction between Ser-59(2.45) and Trp-143(4.50). 
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Figure  4.6: Conformations of ARP (carbon 
atoms in orange) and UR-PG136 (carbon 
atoms in grey) in the binding pocket of the 
H2R.  
4.3.2 Analysis of the binding modes of imidazolylpropylguanidines and 
NG-acylated derivatives with H2R species isoforms  
4.3.2.1 Similar binding modes of agonists at hH2R and gpH2R 
ARP and its NG-acylated analogue UR-PG136 shared a similar binding mode in the H2R 
models (Figure  4.6), suggesting a common binding mechanism of the two compound 
classes. 
 
 
 
Most amino acids interacting with guanidine-type agonists are identical in hH2R and gpH2R 
species isoforms (Kelley et al., 2001). The complex of ARP in the binding site of the hH2R is 
shown in Figure  4.7. In guanidine-type H2R agonists, the common imidazolylpropylguanidine 
moiety is proposed to mimic binding of HA (Dove et al., 2004). Accordingly, the strongly 
basic guanidino group of the compounds underwent an ionic interaction with the highly 
conserved Asp-98(3.32). The Nπ-H atom of the imidazole ring interacted with the carboxylate 
group of Asp-186(5.42), and the Nτ atom accepted a proton from the hydroxyl group of  
Tyr-182(5.38) in TM5 which is in agreement with the established binding model of HA at the 
H2R (Nederkoorn et al., 1996a, b). Residues of the CWxP(F/Y) motif in TM6 probably 
participate in ligand binding and receptor activation in many class 1 GPCRs (Shi and Javitch, 
2002). In agreement with these studies, Trp-247(6.48) and Tyr-250(6.51) faced the 
imidazolylpropylguanidine moiety of ARP in the H2R model. Asn-293(6.55) in the β2AR 
(Wieland et al., 1996) and Phe-436(6.55) in the H1R (Wieland et al., 1999) have been 
suggested to interact with the β-OH group of epinephrine and with the imidazolylethyl group 
of HA, respectively. The corresponding residue in the H2R, Phe-254(6.55), was in close 
proximity to the imidazolylpropyl moiety of ARP. The pyridyl ring of ARP was predicted to 
point into a “lower” binding region where bulk mainly decreases activity (Dove et al., 2004). In 
the hH2R model, the pyridyl moiety was surrounded by a cluster of aromatic and hydrophobic 
residues in TM2, TM3, and TM7. A conserved Trp(7.40) in TM7 should be involved in ligand-
binding of the β1AR (Wong et al., 1988) and the 5-HT1A receptors (Roth et al., 1997).  
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In the M3 muscarinic acetylcholine receptor (Wess et al., 1991), the dopamine D2 receptor 
(Fu et al., 1996), and the 5-HT2A receptor (Roth et al., 1997), ligands may interact with a 
conserved Tyr(7.43). By analogy, the corresponding residues in the H2R, Trp-275(7.40) and 
Tyr-278(7.43), pointed towards the pyridyl moiety of ARP. In aminergic class 1 GPCRs, 
diverse residues in position 7.39 have shown to belong to the binding sites of ligands (Shi 
and Javitch, 2002). In agreement with these studies, Leu-274(7.39) was in close proximity to 
ARP in the hH2R model. Tyr-78(2.64) and Tyr-94(3.28) at the extracellular ends of TM2 and 
TM3, respectively, surrounded the pyridyl ring of ARP. Residues at corresponding positions 
have previously shown to interact with ligands of aminergic GPCRs (Shi and Javitch, 2002). 
The 4-F-phenyl group of ARP was proposed to point into a second “upper” binding region, 
where bulk may enhance agonist activity (Dove and Buschauer, 1999). Arg-257(6.58) at the 
extracellular end of TM6 was in an appropriate position to serve as H-bond donor for an 
interaction with the 4-F-phenyl group of ARP. Glu-270(7.35) close to the 4-F-phenyl group 
possibly participates in this network of interactions (Kelley et al., 2001; Dove et al., 2004). 
The backbone of e2 folded down between the extracellular ends of the TM domains and 
Figure  4.7: Side view of the hH2R model in complex with ARP. The putative agonist binding site 
and the extracellular components of the hH2R are shown. ARP (carbon atoms in orange) was 
manually docked into the putative binding pocket. Grey ribbon, transmembrane domains TM1-TM7; 
thin grey lines, extracellular loops e1, e2, and e3, and N-terminus (N-term). Amino acid side chains 
in a sphere of 3 Å radius around ARP are displayed.
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formed a lid over the H2R binding pocket (Figure  4.7). The lower part of this loop contains 
Cys-174 forming a disulfide bond with Cys-91(3.25). The side chain of the adjacent Lys-175 
pointed into a cavity close to the imidazolylpropylguanidine moiety of ARP suggesting 
participation of this residue in interaction with the ligand. The ε-amino group of Lys-173 did 
not face ARP although the flexible alkyl chain would allow for an interaction with the 4-F-
phenyl or the pyridyl ring. Ser-165 in e2 also covered the ARP binding pocket and 
furthermore interacted with Glu-270(7.35). 
 
4.3.2.2 Distinct interactions of guanidine-type agonists with hH2R and gpH2R species 
isoforms 
In Figure  4.8, the ARP-bound hH2R and gpH2R models are shown in a superimposed form. 
The positions of backbone atoms and side chain orientations were very similar in both 
receptor models, as RMSD values of 0.86 Å and 1.31 Å were calculated for all Cα-atoms and 
all protein atoms, respectively. In agreement with a previous 3D model of the seven TM 
domains of the gpH2R (Kelley et al., 2001), an interaction between Tyr-17(1.31) and 
Asp-271(7.36) at the extracellular ends of TM1 and TM7, respectively, was selectively 
formed in the gpH2R model. In the model of the human receptor a corresponding interhelical 
interaction was absent due to the presence of Cys-17(1.31) and Ala-271(7.36). The gpH2R 
model further suggested interactions of Asp-271(7.36) with Trp-275(7.40) and with the amino 
group of Lys-173 in e2. Strikingly, this species-selective network of interactions was also 
observed in the ligand-free gpH2R model (not shown), suggesting a ligand-independent 
stabilization of an active gpH2R conformation. To test this hypothesis, an hH2R double 
mutation with Cys-17(1.31)→Tyr-17(1.31) and Ala-271(7.36)→Asp-271(7.36) exchanges 
was generated and pharmacologically characterized (chapter 8). 
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4.3.2.3 Impact of the alkyl chain length on species-selective interactions 
The possibly more open and flexible pocket around Ala-271(7.36) in hH2R may explain the 
inverse impact of the chain length between the guanidino and the phenyl group in the NG-
(phenylalkanoyl)guanidines UR-AK67 and UR-AK22 (Table  4.3) on the activity in the steady-
state GTPase assay at hH2R-GsαS and gpH2R-GsαS fusion proteins. Elongation of the alkyl 
chain in UR-AK67 by one methylene unit reduced the potency at gpH2R-GsαS by ~3-fold, 
while both compounds were similarly potent at hH2R-GsαS. An analogous tendency was 
observed with the NG-[3-phenyl-3-(2-pyridyl)propyl]guanidine moiety in BU-E-42 and the 
homologous NG-[4-phenyl-4-(2-pyridyl)butyl]guanidine portion in BU-E-43. Agonist potency 
was approximately 3-fold decreased at gpH2R-GsαS upon elongation of the alkyl chain but 
slightly increased at hH2R-GsαS. According to previous CoMFA studies (Dove and Buschauer, 
1999), the unbranched alkyl side chain of the guanidines was suggested to interact with the 
“lower” pyridyl binding site close to amino acid position 271. In the model of the hH2R the 
flexible pocket around Ala-271(7.36) and Cys-17(1.31) should allow the accommodation of a 
longer alkyl chain than in the gpH2R where the proposed interaction between Asp-271(7.36) 
and Tyr-17(1.31) limits the accessible receptor volume. In agreement with this hypothesis, at 
Figure  4.8: Top-view from the extracellular side of the superimposed ARP-bound hH2R and gpH2R 
models. The secondary structures of hH2R and gpH2R are shown as grey and blue ribbons, 
respectively. For reasons of clarity, loop regions are not shown. In the hH2R model, residue side
chains and ARP are coloured in grey. In the gpH2R model, residue side chains are coloured in 
orange, and docked ARP is shown in blue. For residues differing in both species isoforms, the 
gpH2R residue name is given first, followed by the corresponding hH2R name (in brackets). 
Chapter 4: Homology Modelling of Histamine H2 Receptors 55
an Ala-271(7.36)→Asp-271(7.36) mutant of the hH2R-GsαS, BU-E-43 was about 4-fold less 
potent than BU-E-42 (BU-E-42: EC50 = 80 ± 10 nM; BU-E-43: EC50 = 280 ± 40 nM) (Kelley et 
al., 2001). 
 
 
 
 
4.3.3 Virtual screening for potent and selective acylguanidine-type hH2R 
agonists 
To guide the synthesis of NG-acylated imidazolylpropylguanidines towards more potent and 
hH2R-selective derivatives, a structure based virtual screening was performed using the 
LUDI program. Since potencies and selectivities of guanidine-type agonists are mainly 
determined by structural variations at the NG-mono- or –diaryl-alkanoyl side chains, the 
purpose of the approach was to identify appropriate substituents for this substructure while 
leaving the N-[3-(1H-imidazol-4-yl)propyl]guanidine moiety unchanged (Figure  4.9). 
LUDI calculations generated 91 hits of which fragments were selected by means of 
synthetical feasibility and chemical stability. Fragments of already known agonists were 
rejected. Finally, nine compounds have been selected for synthesis and pharmacological 
characterization (Table  4.4). Compounds 1-6 represent N-[3-(1H-imidazol-4-yl)propyl]-NG-
(phenylalkanoyl)guanidines with an alkyl branch at position 3 of the phenylalkanoyl chain. In 
the hH2R model, this alkanoyl side chain is flanked by the backbones of e2 and TM7 and the 
side chains of Lys-175 and Glu-270(7.35). In the steady-state GTPase activity assay at 
hH2R-GsαS, the ethyl- (1), isopropyl- (2), and isobutyl- (3) substituted agonists were more 
potent than the unbranched analogue 10 (Table 4.4).  
N
HN HN
H
N
NH
X
Y R1
R2
Cpd. X Y R1 R2 hH2R-GsαS gpH2R-GsαS 
      EC50 (nM) 
UR-AK67 CO (CH2)2 phenyl - 67 ± 9a 21 ± 2a 
UR-AK22 CO (CH2)3 phenyl - 72 ± 23a 56 ± 5a 
BU-E-42 CH2 CH2 phenyl 2-pyridyl 420 ± 70b 70 ± 20b 
BU-E-43 CH2 (CH2)2 phenyl 2-pyridyl 280 ± 70b 190 ± 60b 
a Data were taken from Xie et al., 2006. 
b Data were taken from Kelley et al., 2001. 
Table  4.3: Structures of guanidine-type agonists with variable chain lengths and agonist 
potencies at H2R-GsαS species isoforms derived from the GTPase activity assay. 
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Whereas the three alkyl-branched compounds were similarly potent at the human receptor, 
the efficacy of the bulkiest compound 3 was reduced. At gpH2R-GsαS, the unsubstituted 
compound 10 was about 4-fold more potent than at hH2R-GsαS. The potency differences 
between the species isoforms tended to be reduced in the cases of the 3-alkyl substituted 
derivatives 1-3. In compounds 4, 5, and 6, the alkanoyl spacer between the phenyl ring and 
the guanidine group was successively increased. At both H2R species isoforms 3-methyl 
substitution in compounds 4 and 5 yielded a slight potency increase when compared with the 
corresponding unbranched compounds UR-AK67 and UR-AK22 (Table  4.3), respectively. 
However, with the maximal chain length of five C atoms between the phenyl and the carbonyl 
moieties, the unbranched compound 11 was ~5-fold more potent at hH2R-GsαS than its 
3-methyl branched analogue 6. The potencies of compounds 4, 5, and 6 were only slightly 
increased at the guinea pig compared to the human H2R. Compounds 7 and 8 contain 
primary amine functions which were suggested to interact with the carboxylate group of 
Glu-270(7.35). In addition, the amino group was thought to be an appropriate linker atom for 
fluorescence labelling. Introduction of this function, however, yielded a considerable loss in 
potency at hH2R-GsαS (increased EC50 values of compounds 7 and 8 compared to the EC50 
value of compound 1). Both compounds 7 and 8 were about 8-fold more potent at  
Figure  4.9: Interaction sites inside the binding pocket of the hH2R model generated by LUDI. 
White spheres, lipophilic interaction sites; red, H-bond acceptors; blue, H-bond donors. After 
UR-PG136 was docked into the hH2R binding site, the (4-F-phenyl-2-pyridyl)methyl group was 
deleted to generate a link-site for a virtual screening for appropriate fragments (chapter 4.2.6). 
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 hH2R-GsαS gpH2R-GsαS 
Cpd. N
N
H
N
H
NHR
NH
 
EMaxa EC50 (nM) EMaxa EC50 (nM) 
HA  1.00 990 ± 92 1.00 850 ± 340 
           Rb     
1 
O
 
0.64 ± 0.25 37 ± 29 0.78 ± 0.11 11± 6 
2 
O
 
0.72 33 ± 3 0.72 ± 0.11 30 ± 4 
3 
O
 
0.30 ± 0.06 24 ± 5 0.72 ± 0.11 13 ± 11 
4 
O
 
0.55 ± 0.03 27 ± 7 0.86 ± 0.08 10 ± 2 
5 
O
 
0.49 ± 0.24 50 ± 64 0.59 ± 0.19 23 ± 12 
6 O
 
0.31 ± 0.02 30 ± 23 0.58 ± 0.14 13 ± 4 
7 
O
NH2
 
0.62 ± 0.06 750 ± 420 0.82 ± 0.04 102 ± 65 
8 
O
NH2
 
0.68 ± 0.01 170 ± 81 0.89 ± 0.08 21 ± 8 
9 
O
OH
 
0.82 ± 0.13 47 ± 41 0.97 ± 0.01 4 ± 1 
10c 
O
 
0.84 ± 0.03 100 ± 16 1.05 ± 0.11 23 ± 1 
11 
O
 
0.44 ± 0.22 6 ± 1 0.42 ± 0.10 19 ± 14 
12c 
O
 
0.87 ± 0.01 67 ± 2 1.03 ± 0.06 12 ± 1 
 
Table  4.4: Efficacies (EMax) and potencies of NG-acylated imidazolylpropylguanidines, predicted by 
virtual screening (1-9), and reference compounds (10-12), at hH2R-GsαS and gpH2R-GsαS in the 
GTPase activity assay. Data shown are the means ± S.D. of two experiments performed in duplicates. 
a Efficacy relative to HA ( = 1.00) 
b All compounds were synthesized and pharmacologically characterized by Anja Kraus (Dept. of 
Med./Pharm. Chemistry II, University of Regensburg) and will be part of her doctoral thesis. 
c Data were taken from Xie et al., 2006. 
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gpH2R-GsαS than at hH2R-GsαS. Compounds 1-8 were partial agonists at hH2R-GsαS and 
gpH2R-GsαS with increased efficacies at gpH2R-GsαS compared to hH2R-GsαS. In compound 9, 
a hydroxyl group in m-position of the aromatic ring was suggested to interact with the 
backbone carbonyl group of Lys-173 in e2. At hH2R-GsαS the potency of this compound was 
not increased compared to its non-hydroxylated analogue 12. At gpH2R-GsαS however, this 
compound was ~3-fold more potent than 12 and ~12-fold more potent than at hH2R-GsαS. In 
this series, compound 9 was the only full agonist at gpH2R-GsαS exhibiting only partial 
agonism at the human species isoform. 
Taken together, introduction of ethyl-, isopropyl-, and isobutyl substituents at position 3 of the 
3-phenylpropanoyl chain increased the potencies at hH2R-GsαS vs. gpH2R-GsαS whereas the 
polar substituents in compounds 7-9 strongly enhanced gpH2R-GsαS selectivity. These results 
further support the hypothesis of a network of ionic and/or H-bond interactions of 
Asp-271(7.36) with Tyr-17(1.31), Trp-275(7.40), and Lys-173. A positively charged amino 
group or an H-bond donor may directly or indirectly participate in this network, whereas due 
to a more hydrophobic binding pocket interactions with aliphatic substituents are preferred in 
the case of the hH2R. 
 
 
4.4 Discussion 
Three-dimensional homology models of hH2R and gpH2R were generated using the crystal 
structure of bovine rhodopsin as template. Five water molecules predicted to play a 
functional role for the stabilization of interhelical contacts in class 1 GPCRs (Okada et al., 
2002) were transferred to the receptor models. In the generated models conserved 
intramolecular interactions were formed according to present concepts of GPCR structure 
and function. At the intracellular end of TM6, Glu-229(6.30) formed a network of ionic 
interactions with residues of the conserved (E/D)RY motif in TM3 which is proposed to 
stabilize the inactive state of GPCRs (Bissantz, 2003). Glu-229(6.30) additionally interacted 
with the consecutive residue Arg-228(6.29), and the model further proposed an interaction of 
Arg-228(6.29) with Asp-294(7.59) in H8. Strikingly, many class 1 GPCRs contain a basic 
residue at position 6.29, and a stabilizing role of this residue in the network of ionic 
interactions has been proposed (Ballesteros et al., 2001b). Since Arg-228(6.29) is not 
conserved among all H2R species isoforms (e.g. the canine H2R contains Gly-228(6.29)), the 
selective formation of this network of interactions may be responsible for differences in the 
constitutive activities between H2R species isoforms (chapter 7.4.1). 
The receptor models were used to analyze the binding modes of N-[3-(1H-imidazol-4-
yl)propyl]guanidines and their NG-acylated derivatives. Introduction of an electron-
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withdrawing carbonyl group adjacent to the strongly basic guanidine moiety did not 
significantly change the pharmacological activities of most of these agonists rendering this 
structural modification as a bioisosteric exchange (Ghorai, 2005). In agreement with these 
studies, no specific interaction of the acyl moiety was obvious. Accordingly, the binding 
modes of ARP and its NG-acylated analogue UR-PG136 in the H2R binding pocket were very 
similar. In agreement with a previous 3D model of the TM domains of the gpH2R (Kelley et 
al., 2001), the HA-like imidazolylpropyl group interacted with residues in TM3, TM5, and 
TM6, and the binding site for the variable NG-diarylalkyl or NG-diarylalkanoyl groups was 
formed by amino acids in TM2, TM3, TM6, and TM7. In addition to residues within the TM 
domains, the H2R models suggested amino acids in e2 to contribute to the binding pocket of 
the agonists. Particularly, Lys-173 and Lys-175 in the lower part of this loop are candidates 
to contact ARP. Contribution of residues in e2 to the ligand binding sites was previously 
shown for several aminergic GPCRs (Shi and Javitch, 2004; Kim et al., 1996; Scarselli et al., 
2007). The role of e2 on H2R activity was experimentally investigated by the generation and 
pharmacological characterization of receptor mutants (chapter 9).  
Recently, an ionic interaction between Asp-271(7.36) and Tyr-17(1.31) was proposed to 
stabilize an active conformation of the guanidine-bound gpH2R (Kelley et al., 2001). In 
addition to the formation of this interaction, the present gpH2R model suggested that 
Trp-275(7.40) and Lys-173 participate in this network. Due to the presence of Ala-271(7.36) 
and Cys-17(1.31) in the human species isoform, corresponding interactions were not 
observed in the hH2R model, corroborating the current concept that these two amino acids 
are important determinants for the species-selective activity of guanidine-type H2R agonists. 
A virtual screening for appropriate substituents at the carbonyl group of NG-acylated 
imidazolylpropylguandines was performed to develop more potent and selective agonists for 
the hH2R. Introduction of ethyl-, isopropyl-, and isobutyl substituents at position 3 of the NG-
(3-phenylpropanoyl) group proved to be favorable in terms of enhanced potencies at the 
hH2R, whereas the more hydrophilic NG-[3-(aminoalkyl)-3-phenylpropanoyl)guanidines 
displayed an increased potency at the guinea pig species isoform.  
In summary, 3D structure models of human and guinea pig H2R species isoforms enabled us 
to gain novel insight into the structure and function of the H2R and facilitated the molecular 
analysis of species-selective interactions with guanidine-type agonists. Structure based 
virtual screening was able to predict substituents conferring high potency and selectivity to 
the compounds. The success of the virtual screening approaches was restricted due to few 
limitations of the generated models. First, for LUDI calculations, the hH2R protein was treated 
as a rigid body, disregarding the existence of rotatable bonds. Errors in the preliminary 
adjustment of residue side chain orientations may thus have biased the placement of 
compound fragments in the binding pocket. Second, due to the low sequence homology 
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between the loop regions of class 1 GPCRs it is generally difficult to provide reliable 
predictions about the three-dimensional structure of such loops when using the crystal 
structure of bovine rhodopsin as template. In this context, the course of the e2 backbone is of 
particular relevance due to its proximity to the H2R binding pocket. Finally, the crystal 
structure of bovine rhodopsin in complex with 11-cis retinal represents an inactive receptor 
conformation (Palczewski et al., 2000). It is widely accepted that GPCR activation involves 
large changes in the arrangements of the TM helices. These changes mainly occur within the 
intracellular portions of TM3, TM6, and TM7 (Hubbell et al., 2003) but recent data also 
predict alteration of extracellular parts including the binding pocket (Schwartz et al., 2006). 
Molecular dynamics simulations can thus be useful to study the transitions of the H2R 
towards active guanidine-bound conformations (chapter 5). 
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5.1 Introduction 
Bovine rhodopsin is the only GPCR from which crystal structures are presently available 
(Palczewski et al., 2000; Teller et al., 2001; Okada et al., 2002; Li et al., 2004; Okada et al., 
2004). Despite relatively low sequence homologies with rhodopsin, GPCRs are expected to 
adopt similar general folding characteristics by means of structural mimicry (Ballesteros et 
al., 2001). Accordingly, different amino acids or alternate microdomains may be compatible 
with similar deviations from regular α-helical structure, thereby resulting in related tertiary 
structures. The conformational changes in the transmembrane spanning (TM) domains upon 
receptor activation and the interaction of the intracellular surface with G proteins are 
proposed to be similar among all class 1 GPCRs. The receptor selectivity of agonists and 
antagonists however, is assumed to originate from local variabilities within the TM domains 
and extracellular binding regions of the ligands. The corresponding conservation gradient 
within a GPCR molecule, based on the primary sequences of 270 class 1 GPCRs, indicates 
that the extracellular parts are least conserved, while considerable conservation exists 
toward the cytoplasmic sides (Mirzadegan et al., 2003). At present, the crystal structure of 
bovine rhodopsin is established as a useful template for constructing homology models of 
rhodopsin-like GPCRs (Bissantz et al., 2003; Fanelli and De Benedetti, 2005). However, 
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substantial deviations in the conformations of the GPCR binding sites were predicted to 
require further modifications of the initial template (Ballesteros et al., 2001). 
Recently, Huber et al. suggested that the conformation of rhodopsin in the crystal unit cell 
may be considerably different from the conformations of rhodopsin under physiological 
conditions (Huber et al., 2004). Particularly, the presence of detergent molecules (ß-
nonylglucoside), the crystallization adjuvant heptane-1,2,3-triol, and several heavy atoms 
such as zinc and mercury (Palczewski et al., 2000; Teller et al., 2001; Okada et al., 2002) 
may act as packing constraints. Thus, computational methods describing the dynamic 
behaviour of proteins are necessary to recognize and remove such packing constraints.  
Molecular dynamics (MD) simulation is an established computational methodology to analyze 
the conformational dynamics of membrane proteins. MD simulations can provide information 
about the conformational properties of molecular systems and the way in which the 
conformation changes with time (Leach, 2001). Thus this technique may be useful to gain 
insight into the relationship between structure and biological function (Faraldo-Gomez et al., 
2002; Hansson et al., 2002; Karplus and McCammon, 2002; Gumbart et al., 2005; Ash et al., 
2004). At present, numerous dynamic studies on membrane proteins such as 
transmembrane peptides, fusion proteins, channel and pore proteins, transporters, ion 
pumps, ATP-synthases, and GPCRs, have been performed (for recent reviews consider 
Kandt et al., 2007; Ash et al., 2004; Gumbart et al., 2005). Since the function of membrane 
proteins is influenced by the membrane environment through electrostatic, hydrophobic and 
van der Waals interactions and through the internal pressure of the membrane, explicit 
consideration of the protein environment is a crucial prerequisite for reliable MD studies of 
such proteins (Gumbart et al., 2005). This is supported by experiments suggesting that 
organisms vary the lipid composition of their membranes to modulate protein function (Albert 
et al., 1996; Mitchell et al., 1992). Moreover, specific protein and lipid interactions are related 
to the domain organization of biomembranes in rafts (Simons and Ikonen, 2000; Ostrom and 
Insel, 2004; Simons and Ikonen, 1997). In the case of rhodopsin photoactivation, the 
thermodynamic equilibrium between the meta I and meta II conformations strongly depends 
on the lipid composition of the membrane (Beach et al., 1984), and a native-like lipid mixture 
results in optimal function (Wiedmann et al., 1988). Huber et al. suggested a possible 
microscopic mechanism for lipid effects on rhodopsin activation, based on site-specific 
conformational changes of rhodopsin close to the lipid/protein interfaces (Huber et al., 2004). 
In addition to an explicit consideration of the lipid bilayer, hydration with water and ions are 
needed to mimic a realistic environment of membrane proteins. In particular, when simulating 
under vacuum conditions, polar and charged residues on the protein surface potentially do 
not exhibit extended conformations to account for expected interactions with the hydrophilic 
water shell but rather fold back into the protein surface producing artificial H-bond patterns 
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(Mehler et al., 2002). 
The choice of the lipid model mimicking the bilayer is not a trivial task, since distinct 
properties, e.g. the degree of unsaturation and the lengths of the carbon chains, may 
critically alter the interactions with the protein. In a recent MD simulation of rhodopsin 
embedded in a bilayer containing cholesterol and different lipids comprising poly-unsaturated 
acyl chains it was shown that lipids near the protein preferentially reorient such that their 
unsaturated chains interact with the protein (Pitman et al., 2005).  
In the present study, the human H2R (hH2R) was subjected to MD simulations both in its 
ligand-unoccupied form mimicking the inactive state of the receptor, and in complex with the 
H2R agonist arpromidine (ARP, Figure 4.2). 1-Palmitoyl-2-oleoyl-sn-glycero-3-
phosphatidylcholine (POPC) was used as a lipid model to simulate the membrane 
environment of the hH2R. The system was hydrated by water molecules and counter ions 
were explicitly considered. The purpose of this study was to characterize the structure and 
function of the hH2R and to validate the results on the basis of present concepts of GPCR 
activation mechanisms. Finally, the resulting dynamic hH2R models were used to provide an 
improved model for the binding mode of ARP and related imidazolylpropylguanidines. 
 
 
5.2 Materials and Methods 
5.2.1 Construction of an hH2R-POPC-water system 
A homology model of the ligand-free hH2R (chapter 4.3) was embedded in a 1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphatidylcholine (POPC) (Figure  5.3 A) bilayer. In the first step, the 
software package VEGA ZZ release 2.0.8.60 (Pedretti et al., 2002, 2004; 
http://www.ddl.unimi.it) was used to place the hH2R model into the centre of a triclinic box of 
79 Å x 82 Å x 78 Å dimensions. A bilayer consisting of 81 POPC molecules was then 
constructed around the receptor model. To prepare for an optimal fit of the receptor with the 
lipid molecules, the van der Waals radii of both partners were allowed to overlap by 1.5 Å.  
The software package GROMACS version 3.2 (van der Spoel et al., 2004, 2005; Bekker et 
al., 1993; Berendsen et al., 1995; Lindahl et al., 2001) (Department of Biophysical Chemistry, 
University of Groningen, Nijenborgh 4, 9747 AG Groningen, The Netherlands) was used to 
optimize the hH2R-POPC complex, first with the steepest descent and then with the 
conjugate gradient method. A new triclinic box of 70 Å x 83 Å x 70 Å dimensions was 
generated around the hH2R-POPC system, subsequently solvated with 7345 single-point 
charge (spc) water molecules (command genbox). In the course of this procedure, apart from 
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the upper and lower regions of the box representing the extracellular and intracellular parts of 
the biological system, remaining space at the interface between protein and lipids and at the 
box edges has been filled with water. Accordingly, 634 water molecules in a layer of 18 Å 
thickness in the regions of the lipophilic POPC carbon chains were removed, thus yielding a 
number of 6711 water molecules. After subsequent minimization steps, 10 water molecules 
were exchanged by 10 chloride ions according to the electrostatic potential to achieve a total 
charge of zero of the system (command genion). Finally, five conserved water molecules 
were transferred from the initial hH2R homology model (chapter 4.3.1) to the new system. 
Subsequently, the complete hH2R-POPC-water system was optimized until the maximum 
force was smaller than 100 kJ mol-1 nm-1. The total number of atoms in the system was 
27390. 
 
5.2.2 Docking of ARP into the pre-equilibrated hH2R-POPC-water system 
5.2.2.1 Preparation of the ligand 
With help of the PRODRG software (Schüttelkopf and van Aalten, 2004), a coordinate file of 
ARP in the pdb format was converted into the corresponding GROMACS structure and 
topology file. Atom types and Gasteiger-Hückel charges were assigned to the ligand, 
according to the GROMOS force field parameters. To achieve both appropriate positioning 
and conformation in the binding cavity, the ARP atom coordinates were transferred from the 
initial hH2R-ARP model (chapter 4.2.4) to the new structure file.  
 
5.2.2.2 Preparation of the receptor structure and docking procedure 
For docking ARP, an hH2R-POPC-water system was selected as starting structure consisting 
of the pre-equilibrated POPC bilayer and water shells (chapter 5.3.2). For an optimal fit of the 
ligand in the binding pocket, the torsion angels of Asp-98(3.32), Tyr-182(5.38), Tyr-
250(6.51), Phe-254(6.55), and Trp-275(7.40) were carefully modified. To approach the 
proposed activated state of the hH2R, the total charge of Asp-115(3.49) was set to zero. 18 
water molecules within the binding pocket were removed. Subsequently, all entries in the 
coordinate and topology files of ARP were added to the corresponding files of the hH2R. 
Since the generated ligand-receptor complex comprised a total charge of +2 (considering the 
positive charge of the guanidine group in ARP), two chloride ions were added to achieve an 
overall charge of zero in the system. Finally, the complex of ARP and hH2R in the hydrated 
lipid bilayer was energy-minimized until the maximum force was smaller than 100 kJ mol-1 
nm-1, first with the steepest-descent and then with the conjugate gradient method. 
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5.2.3 Parameters for MD simulations with GROMACS 
A topology file for a POPC molecule and the corresponding lipid parameters (Berger et al., 
1997), containing the interaction parameters between the lipid atoms and the modified 
GROMOS87 force field, have been taken from the group of Prof. Tieleman 
(http://moose.bio.ucalgary.ca; Department of Biological Sciences, 2500 University Drive NW, 
Calgary, AB T2N 1N4, Canada). All MD simulations were thus performed applying the 
GROMOS87 force field. The LINCS algorithm (Hess et al., 1997) was applied to allow for a 
timestep of 2 fs (constraints on all bonds). The cut-off distance for the generation of the 
short-range neighbour list for calculating the van der Waals interactions was set to 1.0 nm. 
The neighbour list was updated every 10 steps of the calculations. Periodic boundary 
conditions were applied in all directions of the simulation box. The Particle Mesh Ewald 
method (Darden et al., 1993; Essmann et al., 1995) was used to calculate the long-range 
electrostatic interactions. The distance for the Lennard Jones cut-off was set to 1.4 nm. The 
Berendsen algorithm (Berendsen et al., 1984) was used to couple the system to an external 
heat bath of 300 K reference temperature with a coupling constant of 0.1 ps. Different 
macroscopic types of ensembles using various methods of pressure coupling were studied 
(chapter 5.3.1). A complete list of run parameters for MD simulations is provided in the 
Appendix 2 (chapter 11). 
 
 
5.3 Results 
5.3.1 Equilibration of the hH2R-POPC-water system 
Prior to performing long-term MD simulations initial runs of MD simulations are generally 
necessary to equilibrate a system until constant physical values, e.g. potential energy, box 
volume, temperature, and pressure, are obtained. Macroscopic ensemble types most 
frequently used for MD simulations are the NVT (canonical) and the NPT (isobaric-
isothermal) ensembles. In both systems, the number of atoms N in the system and the 
temperature T are kept constant. Additionally, in the NVT ensemble the volume V of the 
simulation box is fixed thus allowing the pressure in the system to adapt. Using the NPT 
ensemble, the pressure P in the system is adjusted to a reference value thus allowing the 
simulation box to adapt in its size. To select optimal parameters for MD simulations of the 
hH2R-POPC-water system, both ensemble types were compared.  
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5.3.1.1 NVT ensemble 
By assessing an NVT ensemble, the dimensions of the box remained constant at 70 Å x 83 Å 
x 70 Å during 20 ps of equilibration time. By visual inspection severe disruptions of the 
bilayer structure became apparent (not shown). The hydrophobic lipid chains were 
disordered and space in the region of the lipid bilayer remained free. The density in the box 
was 889 kg m-3 and a pressure of -670 bar was calculated. Due to the low density in the 
starting system setup, adaptation of the box vectors was crucial for appropriate MD 
simulations. Therefore, no further studies were performed using the NVT ensemble. 
 
5.3.1.2 NPT ensemble 
The Berendsen algorithm was applied to coupling the simulation system to an external 
pressure bath. Coordinates and box vectors were scaled every time step using a pressure 
coupling constant of 0.1 ps. 500 ps of equilibration time were applied to the hH2R-POPC-
water system using various types of pressure coupling. In system 1, the pressure was 
coupled isotropically, i.e. all box vectors were scaled similarly. The positions of all hH2R 
heavy atoms were fixed using a force constant of 1000 kJ mol-1 nm-2 to allow for equilibration 
of only the POPC bilayer and water. In system 2, the pressure was coupled anisotropically, 
i.e. all three box vectors were scaled individually. Since there is no coupling between any of 
the directions in anisotropic pressure coupling, deformations of the membrane can occur 
(Kandt et al., 2007). Therefore, special attention was paid to the structure and the size of the 
phospholipid bilayer. Positional restraints were applied on the hH2R heavy atoms during the 
first 400 ps of simulation time. Additionally, within the first 200 ps the positions of POPC 
atoms were fixed in their y dimension perpendicular to the membrane layer and using a force 
constant of 1000 kJ mol-1 nm-2. Thus the bilayer was allowed to move only in the x-z plane 
which should prevent an early reduction of the bilayer size. During the last 100 ps of 
equilibration, the whole system was allowed to move without any restraints. In system 3, 
semi-isotropic pressure coupling was assessed in x- and z-dimensions. Here, the box size 
was allowed to adapt only in x and z directions whereas the y-dimension of the box was 
fixed. Since with this setting the bilayer size was not expected to change, positional restraints 
were applied only on all hH2R heavy atoms (force constant of 1000 kJ mol-1 nm-2). In all three 
systems, isothermal compressibility was set to 4.5 · 10-5 bar-1 corresponding to the 
compressibility of water at 1 atm and a temperature of 300 K. A comparison of the final 
structures of the POPC bilayers in complex with the hH2R models after 500 ps equilibration 
time can be seen in Figure  5.1. 
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5.3.1.3 Analysis of system parameters 
After 500 ps of equilibration, box volumes and densities were approximately similar in the 
three systems (Table  5.1). In system 3 the box y-dimension was highest matching the 
starting value. After releasing the strain on the POPC atom positions, the box y-dimension in 
system 2 was higher compared to system 1. 
Figure  5.1: Structures of hH2R models embedded in a solvated POPC bilayer using different system 
setups. A, NPT ensemble with isotropic pressure coupling (system 1); B, NPT ensemble with semi-
isotropic pressure coupling (system 3); C and D, NPT ensemble with anisotropic pressure coupling in 
all dimensions (system 2). A, B, C, lateral view; D, view from the extracellular side. TM domains are 
shown as grey ribbon. For clarity, water molecules are not shown.
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 Box (Å)a V (nm3)b Density (kg m-3)a 
 x y z   
system 1 66 78 66 345 ± 1 1043 
system 2 65 81 65 345 ± 0 1047 
system 3 65 83 65 346 ± 1 1039 
 
 
Approximately 150 ps of equilibration time were necessary to obtain constant potential 
energies in all systems. In Figure  5.2 A, the time course for the potential energy in system 2 
is shown. Although depending on the restraints applied, in all systems the potential energies 
converged to an approximately similar value of -4.1 · 105 kJ mol-1. After ~50 ps of simulation 
time, the pressures converged to the reference value of 1 bar in all three systems, which is 
shown for system 2 in Figure  5.2 B. 
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5.3.1.4 Structural analysis of the POPC bilayer 
MD simulations should characterize the POPC bilayer system in a state that resembles the 
fluid phase (Lα) naturally occurring at -5 °C to +70 °C (Wiener and White, 1991). In the case 
of rhodopsin, the membrane lipids are entirely in the Lα state at physiological temperature 
(Deese et al., 1981; Miljanich et al., 1985; Ellena et al., 1986). To quantify the dynamics of 
the sn-1 and sn-2 carbon chains of POPC, the deuterium order parameter (SCD), originally 
a values corresponding to the final snapshot after equilibration 
b mean ± S.D. assessed during the last 100 ps of equilibration time 
Figure  5.2: Potential energy (A) and pressure (B) in system 2 during equilibration. 1, release of 
positional restraints on POPC atoms; 2, release of positional restraints on protein heavy atoms. 
Table  5.1: Box dimensions and physical values in the different systems 
after equilibration.  
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obtained from the quadrupolar splittings measured by 2H NMR on phospholipids, was 
calculated. This value is related to the average orientation of the methylen groups and 
provides information about the order within the bilayer which helps in guiding the choice of 
simulation parameters and evaluating MD models. Order parameters are among the most 
accurately determined experimental properties and are readily available from simulations 
(Berendsen and Tieleman, 1998). Preliminary MD studies simulating the Lα phase of a 
hydrated POPC bilayer revealed good agreement of calculated SCD values with experimental 
data (Heller et al., 1993; Huber et al., 2002, 2004). From MD trajectories order parameters 
can be directly calculated as 
 
2
1cos
2
3 2 −= zzS θ       (5.1) 
 
where θz is the angle between the z-axis of the simulation box and the vector from  
Cn-1 to Cn+1. Sx and Sy are defined in the same way. The brackets imply averaging over time 
and molecules. The shape of the palmitoyl chain curve is characterized by a typical plateau 
in the central region of the alkyl chain and by decreasing values for the terminal atoms 
representing an increase in configurational freedom with depth in the bilayer (Seelig and 
Seelig, 1980; Petrache et al., 2001) (Figure  5.3 B). Strikingly, order parameters in system 2 
were in very good agreement with experimental data and were considerably lower in the 
cases of systems 1 and 3. The curve of the unsaturated sn-2 (oleoyl) chain shows a 
significant dip at carbon atoms 9 and 10 representing the cis-double bond (Seelig, 1977; 
Seelig and Seelig, 1980; Huber et al., 2002). Similar SCD values in the three systems were 
observed for the sn-2 chain carbon atoms 2-7 and 14-16, but the characteristic dips 
representing the double bound were less pronounced in system 2 compared to 
approximately similar values in systems 1 and 3.  
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To further analyze the quality of mimicking the Lα phase of the POPC bilayer, RMSD values 
of the POPC atoms were calculated during equilibration. Due to a high degree of disorder of 
the fatty acid chains, RMSD values of at least 20 Å were expected for MD simulations 
(Iadanza et al., 2002). Indeed, after an equilibration time of ~100 ps approximately similar 
RMSD values of 27 Å were determined in all systems. As can be seen in Figure  5.4, RMSD 
values of the POPC molecules were independent from positional restraints applied. 
 
 
A 
sn-1 (16:0) 
sn-2 (18:1ω9) 
B 
Figure  5.3: A, Chemical structure of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylcholine (POPC); 
B, order parameters for carbon atoms in the sn-1 and sn-2 chains of POPC. Data are the means 
calculated from the last 50 ps equilibration time of system 1 (▼), system 2 (▲), and system 3 (●). For 
comparison, experimental data are shown (■) (Seelig, 1977; Seelig and Seelig; 1980). 
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A common feature of membrane proteins is the accumulation of charged amino acids at both 
hydrophilic extensions of the membrane, whereas the protein surfaces at the interface with 
the hydrophobic lipid core mainly consist of hydrophobic residues (hydrophobic belt) (Rees et 
al., 1989; Wallin et al., 1997). In particular, positively charged arginine and lysine residues at 
the extracellular and intracellular sides are predicted to participate in ionic interactions with 
the negatively charged phospholipid head groups (Ballesteros et al., 2001). Thus, in MD 
simulations the protein should be oriented in such a way that its hydrophobic belt is aligned 
with the non-polar lipid tails (Kandt et al., 2007). Rhodopsin-like GPCRs were proposed to be 
in contact with the lipophilic membrane core in a slice of approximately 24 Å thickness 
(Baldwin et al., 1997). Results from neutron diffraction and X-ray diffraction experiments 
revealed a value of 27.1 Å for the thickness of the hydrocarbon core of a pure 
dioleoylphosphatidylcholine bilayer at a temperature of 30 °C (Nagle and Tristam-Nagle, 
2000). To estimate the size of the lipophilic POPC membrane core, the distances between 
the average y-positions of the carbonyl carbon atoms in the upper and lower leaflets of the 
bilayer were calculated for both alkyl chains separately (Table  5.2). In systems 2 and 3, the 
thicknesses of the palmitoyl layers were similar but ~1 Å higher than in system 1. The oleoyl 
chains were of similar lengths in systems 1 and 2 and increased in system 3. Releasing the 
strain on POPC atoms in y-direction (system 2) resulted in a considerable reduction of the 
palmitoyl chain size by 4.3 Å (26.9 ± 0.0 Å when using positional restraints on POPC atoms) 
and that of the oleoyl chain by 1.7 Å (22.3 ± 0.0 Å when using positional restraints on POPC 
atoms). When inspected visually (Figure  5.1), the bilayer in system 1 appeared to be smaller 
than in the other two systems with the extracellular parts of the TM domains being located in 
the water shell. In system 2, arrangement of the phospholipid head groups allowed for 
adequate interactions with the charged residues on the hH2R surface (Figure  5.5). 
Figure  5.4: Trajectory of RMSD values 
of POPC atoms in system 2 during 
equilibration. 1, release of positional 
restraints on POPC atoms; 2, release of 
positional restraints on protein heavy 
atoms. 
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The solvent-accessible surface area (SASA) was calculated for the entire POPC bilayer and 
was used as a measure for the conformational fit between the alkyl chains in the lipophilic 
bilayer core. The lowest values of total and hydrophobic SASA were observed in system 2, 
indicating intensive van der Waals and hydrophobic interactions between adjacent carbon 
chains (Table  5.3). When releasing the strain on the POPC atoms, the hydrophobic SASA 
abruptly decreased (Figure  5.6), coinciding with the reduction in the lipophilic bilayer size. 
Thus, the resulting SASA difference was due to increased van der Waals contacts between 
the chain termini of opposite POPC bilayers. By contrast, the values for the hydrophilic SASA 
evenly increased during the equilibration time and approached the highest value in system 2 
compared to systems 1 and 3, indicating that the polar head groups were most extensively 
solvated by water molecules.  
a Distance between the average y-
positions of the sn-1 and sn-2 carbonyl 
carbon atoms, respectively, in the upper 
and lower leaflets of the POPC bilayer.  
Figure  5.5: Distribution of charged residues (Arg, 
Lys, Glu, Asp; black) on the molecular surface of 
the hH2R model (grey) in system 2 after 
equilibration. Phosphatidylcholine groups of the 
POPC bilayer are shown in blue. 
 d (Å)a 
 sn-1 sn-2 
system 1 21.6 ± 0.2 20.5 ± 0.2 
system 2 22.6 ± 0.2 20.6 ± 0.2 
system 3 22.9 ± 0.2 22.0 ± 0.2 
 
Table  5.2: Analysis of the size of the lipophilic 
POPC bilayer core after equilibration. Values 
shown are the means ± S.D. calculated from 
the last 100 ps of equilibration time. 
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5.3.2 MD simulations of the ligand-free and the ARP-docked hH2R models 
Due to the superior performance in reproducing the dynamic and structural properties of the 
POPC membrane, for the following MD simulations the equilibrated hH2R-POPC-water 
complex from system 2 (NPT ensemble with anisotropic pressure coupling) was used. Both a 
model of the ligand-free hH2R and the hH2R in complex with docked ARP (hH2R-ARP) were 
subjected to total simulation periods of 5.0 ns each. 
In preliminary MD runs, the backbones of TM7 and the extracellular half of TM5 did not 
remain in constant α-helical structures but were disrupted during the first 1.0 ns. To achieve 
stable α-helices within these TM domains, further equilibration steps of 200 ps lengths each 
were executed sequentially applying force constants of 750, 500, and 250 kJ mol-1 nm-2 on all 
protein atom positions, respectively, followed by a final step of 200 ps without application of 
restraints. During subsequent MD simulations, the ligand-free hH2R was allowed to move 
without any restraints. When ARP was docked into the hH2R binding pocket, the helicity of 
the extracellular part of TM5 was broken up within the first 500 ps of unrestrained 
simulations. To prevent this disruption, distance restraints between backbone atoms in the 
critical part of TM5 were applied using a force constant of 1000 kJ mol-1 nm-2. To approach 
the proposed HA-like binding mode of the imidazolylpropylguanidine moiety of ARP and 
related guanidine-type H2R agonists (Dove et al., 2004), additional restraints were applied on 
the distances between the guanidine group of ARP and Asp-98(3.32) (Gantz et al., 1992) 
and between Nπ-H and Nτ of the imidazole group with Asp-186(5.42) and Tyr-182(5.38) 
(Nederkoorn et al., 1996), respectively, using a force constant of 1000 kJ mol-1 nm-2. 
 
Table  5.3: Analysis of the solvent-accessible 
surface area (SASA) of the POPC molecules 
using various system setups. Values shown are 
the means ± S.D. calculated from the last 100 
ps of equilibration time. 
 SASA (nm2) 
 total hydro- phobic 
hydro- 
philic 
system 1 315 ± 3 122 ± 3 157 ± 2 
system 2 296 ± 2 107 ± 2 190 ± 2 
system 3 308 ± 3 123 ± 2 185 ± 2 
Figure  5.6: SASA of POPC molecules during 
equilibration of system 2. 1, release of 
positional restraints on POPC atoms. 
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5.3.2.1 System parameters and POPC bilayer structure 
Similar physical values of potential energy, temperature, and pressure were observed in both 
systems containing hH2R and hH2R-ARP, respectively, during the whole simulation time 
(Table  5.4). Snapshots after 5.0 ns revealed similar densities in both systems, whereas the 
y-dimension of the box was by 4 Å larger in the system of the ligand-free receptor compared 
to hH2R-ARP. 
 
 
 hH2R hH2R-ARP 
Epot (kJ mol-1) -4.10 · 105 ± 560 -4.10 · 105 ± 630 
T (K) 300 ± 1 300 ± 2 
P (bar) 3 ± 150 0 ± 160 
V (nm3) 342 ± 0.4 341 ± 0.4 
Density (kg m-3)a 1052 1054 
Box x, y, z (Å)a 62 x 86 x 65 63 x 82 x 65 
 
 
 
Order parameters of the POPC sn-1 and sn-2 chains were similar in both systems. SCD 
values of the palmitoyl chains corresponded to the values during equilibration phase and 
agreed very well with experimental data. The dip in the graph of the oleoyl chain around 
carbon atoms 9 and 10 representing the cis double bond was considerably more pronounced 
than during the equilibration (Figure  5.7 and Figure  5.3 B). 
Similar RMSD values of 24.1 ± 2.0 Å and 24.7 ± 1.5 Å were calculated for all POPC atoms in 
the systems with hH2R and hH2R-ARP, respectively, during the last 1.0 ns. When simulating 
the ligand-free hH2R, the thickness of the lipophilic bilayer core was 23.1 ± 0.3 Å and 22.9 ± 
0.3 Å, respectively, using the palmitoyl and oleoyl carbonyl carbon atom positions as 
references. With the hH2R-ARP complex, corresponding values of 21.8 Å and 21.7 Å, 
respectively, were measured. 
 
a Values corresponding to the final snapshot after 5.0 ns of simulation time. 
Table  5.4: Physical values and box dimensions in the systems containing hH2R 
and hH2R-ARP, respectively. Data shown are the means ± S.D. from 5.0 ns 
simulation time. 
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5.3.2.2 Arrangement of secondary structure elements 
Global folding of the ligand-free and the ARP-docked hH2R models were analyzed by 
calculating the total number of H-bonds, the radius of gyration (Rgyration), and the total SASA 
of the protein. Docking of ARP into the hH2R binding pocket resulted in the disruption of 12 
intramolecular H-bonds. The values shown in Table  5.5 were very similar in both systems, 
thus representing stable overall protein structures in both hH2R models. 
 
 
 
 
 hH2R hH2R-ARP 
No. of H-bonds 254 ± 8 242 ± 7 
Rgyration (Å) 20.8 ± 0.1 20.8 ± 0.1 
SASAprotein (nm2) 155 ± 2 158 ± 2 
 
 
The stability of secondary structural elements of the protein was calculated throughout the 
whole trajectories by means of dssp-plots (Kabsch and Sander, 1983). Strikingly, the TM 
domains of both hH2R models exhibited constant α-helical patterns during 5.0 ns of MD 
simulations (Figure  5.8 A).  
Two short antiparallel β-strands in the e2 loop (Glu-163 to Ser-165 and Lys-173 to Lys-175, 
Figure  5.7: Order parameters for carbon atoms of POPC sn-1 and sn-2 alkyl chains. Data are 
the means calculated from the last 500 ps of 5.0 ns of MD simulations of the hH2R-ARP 
complex. For comparison, experimental data are shown (■) (Seelig, 1977; Seelig and Seelig, 
1980). 
Table  5.5: Protein global folding in the systems containing the ligand-free and the 
ARP-docked hH2R models. Data shown are the means ± S.D. during 5.0 ns of 
simulation time. 
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respectively) not present in the starting structure emerged during the last 2.5 ns of the 
simulation of the ligand-free hH2R (Figure  5.8 B). By analogy, the crystal structure of bovine 
rhodopsin (Palczewski et al., 2000) contains two β-strands at corresponding positions, i.e. 
between Arg-177 and Glu-181 and between Ser-186 and Asp-190, respectively (Figure  5.8 
C). Intriguingly, analogous β-strands were not observed in the simulated hH2R-ARP complex. 
 
 
 
 
A comparison of RMSD values of backbone atoms in both models during MD simulations is 
shown in Figure  5.9. Within the first 3.0 ns, the RMSD of ligand-free hH2R increased and 
approached a constant value of 1.88 ± 0.06 Å during the last 2.0 ns. By contrast, a constant 
RMSD of 1.20 ± 0.08 Å was observed with hH2R-ARP during 0.5 to 3.0 ns of the simulation. 
The values then increased and approached a similar level as the unoccupied hH2R. Ligand-
receptor interactions and, additionally, the restraints applied on the distances between 
Asp-98(3.32), Tyr-182(5.38), and Asp-186(5.42), respectively, and ARP reduced the 
flexibility of the backbone atoms in the first time period and became less essential during the 
following 2.0 ns. 
Figure  5.8: A, dssp-plot illustrating the dynamics of secondary structure elements of the ligand-free 
hH2R model during the last 1.0 ns of simulation time. Blue, α-helix; red, β-strands; yellow, turn; green, 
bend; white, coil. B, backbone atoms of e2 in the hH2R model after MD simulations. Two short 
antiparallel β-strands are indicated by an orange box. C, backbone atoms of e2 in the crystal structure 
of bovine rhodopsin (Palczewski et al., 2000). Corresponding antiparallel β-strands are indicated by an 
orange box. 
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To identify differences in the flexibilities of entire protein domains, RMSD values of backbone 
atoms were calculated for the TM domains, loops, the N- and the C-terminus (Figure  5.10 A). 
In addition, information about flexibilities of the amino acids was obtained by computing 
average RMSD values for each residue separately (Figure  5.10 B). In both hH2R models, the 
TM domains were the most rigid structures. Large RMSD differences in the N-termini and 
TM1 domains coincide with considerably different spatial displacements as visualized in the 
energy-minimized models of the ligand-free hH2R and the hH2R-ARP complex after 3.0 ns of 
simulations (Figure  5.11). Whereas in the free hH2R the extracellular part of TM1 was shifted 
towards TM7, the intracellular parts of TM1 were similar in both models. The backbone 
positions of TM2 and TM3 were not significantly affected by the ligand as represented by 
only minor differences in the RMSD values. The low RMSD value of TM3 was due to the 
central course of this tilted α-helix within the bundle of TM domains. In the ligand-free hH2R, 
TM4 was shifted in towards the lipid bilayer if compared with hH2R-ARP. The side chain of 
Trp-158 at the N-terminal region of e2 displayed higher flexibility in the hH2R-ARP complex 
than in the free receptor (Figure  5.10 B). This difference was attributed to the close proximity 
of this residue to the side chain of Asn-92(3.26) in the free receptor during the whole 
simulation. In hH2R-ARP, the side chain of Trp-158 turned away from Asn-92(3.26) and 
pointed into the phospholipid bilayer allowing higher conformational flexibility. The large 
RMSD differences between the e2 backbones of hH2R and hH2R-ARP (difference of 1.58 Å) 
Figure  5.9: Trajectory of RMSD values of the backbones of the ligand-free and the ARP-
docked hH2R models after least-square fit of all Cα atoms during 5.0 ns of simulation time. 
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suggested participation of this loop in the binding mode of agonists (chapter 5.3.2.5). Asn-
168, His-169, and Thr-170 formed the turn between the upper and the lower parts of e2 and 
exhibited very high RMSD values (up to 8.9 Å and 6.6 Å in the free and the hH2R-ARP 
models, respectively). These residues were completely solvated by the extracellular water 
shell and thus did not adopt distinct side chain conformations. The extracellular part of TM5 
of the ligand-free receptor was shifted towards TM4, whereas the intracellular end slightly 
pointed out of the TM bundle, relative to the backbone position of TM5 in hH2R-ARP. 
Although the backbones of TM6 and the extracellular parts of TM7 adopted similar positions 
in both hH2R models, the flexibilities of residues in these domains were different. RMSD 
values of Phe-248(6.49), Phe-251(6.52), and Tyr-256(6.57) were considerably higher in the 
ligand-free hH2R (RMSD values of 3.4 Å, 3.8 Å, and 4.1 Å, respectively) than in the hH2R-
ARP complex (RMSD values of 2.3 Å, 1.4 Å, and 0.9 Å, respectively). These residues are 
part of the conserved CWxP(F/Y) motif and pointed into the lipid environment whereas the 
adjacent Trp-247(6.48) and Tyr-250(6.51) belong to the ligand binding pocket. In the case of 
Figure  5.10: Domain- and residue-specific flexibility during the 3.0 to 4.0 ns simulation 
interval. A, Mean RMSD values of the backbone atoms of individual subsequences after 
least-square fit of all Cα atoms. B, Mean RMSD values of all heavy atoms of each residue 
after least-square fit of all Cα atoms. Residues within TM domains are shown as grey 
shading.  
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Tyr-256(6.57) the very large RMSD difference was attributed to an interaction of the hydroxyl 
OH with the carboxyl group of Asp-263 in e3 that was stable during the entire simulation of 
hH2R-ARP (H-bond frequency of 93.4%). In the simulation of the ligand-free hH2R, this 
interaction was broken already at the beginning of the simulation (H-bond frequency of 2.8%) 
leading to random orientations of Tyr-256(6.57) and Asp-263. The terminal residues of e3 
starting from Asn-266 and the first six residues of TM7 were considerably more flexible in the 
 
 
 
 
hH2R-ARP complex as represented by an average RMSD difference of 1.3 Å between the 
two receptors in this region. In the central part of TM7 similar RMSD values were observed in 
both models whereas the intracellular end of TM7, i.e. the sequence from Ile-286(7.51) to 
Asn-292(7.57), was more flexible in the ARP-bound receptor. The positions of the backbones 
of H8 were remarkably different in both receptor models. Residues in this short α-helix were 
solvated by the POPC head groups and water. 
 
5.3.2.3 Analysis of conserved intramolecular interactions 
Interactions between residues predicted to be conserved among aminergic GPCRs (chapter 
4.3.1.2) were analyzed in Table  5.6. Low RMSD values, high H-bond frequencies, and low 
minimum distances between interacting residues were used as measures of the strengths of 
Figure  5.11: Comparison of the energy-minimized backbone structures of ligand-
free hH2R (grey) and ARP-hH2R (colored) after 3.0 ns of MD simulations. A, side 
view; B, TM domains viewed from the extracellular side. Loop regions and the 
termini are not shown for reasons of clarity. 
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interactions. Additional intramolecular interactions analyzed during the simulations are shown 
at the bottom of the list. 
In the ligand-free hH2R a stable ionic interaction was observed between Asp-115(3.49) and 
Arg-116(3.50) of the conserved (E/D)RY motif mimicking the inactive state of the H2R 
(Alewijnse et al., 2000). By protonating Asp-115(3.49) in the hH2R-ARP model according to 
an active state in GPCRs this interaction was inhibited (Figure  5.12 A). In spite of a short 
distance of ~3Å, the proposed ionic interaction between Arg-116(3.50) and Glu-229(6.30) in 
the ligand-free receptor (Bissantz, 2003) did not occur. However, the increased distance 
between both residues and the higher RMSD value of Arg-116(3.50) in the ARP-bound 
receptor indicated release of interhelical constraints within the intracellular ends of TM3 and 
TM6 which is in agreement with current concepts of GPCR activation (Bissantz, 2003). The 
MD simulation of the free hH2R revealed a stable interaction of Arg-228(6.29) with 
Asp-294(7.59). In correlation with the increased flexibility of the TM7 backbone, this 
hypothetic interaction was disrupted in the hH2R-ARP model. The side chains of 
Arg-228(6.29) and Glu-229(6.30) did not interact in both receptor models. 
 
 
 
 
The conserved hydrophobic latch formed by Ile-57(2.43), Leu-60(2.46), Leu-109(3.43), 
Ile-112(3.46), and Val-239(6.40) adopted similar positions in the free and the liganded hH2R 
models. As an exception, the distance between Val-239(6.40) and Ile-57(2.43) was 
increased in the hH2R-ARP complex during MD simulation. An aromatic interaction between 
Tyr-288(7.53) and Phe-295(7.60) of the conserved NPxxY(x)5,6F motif predicted to represent 
the inactive state of bovine rhodopsin and other GPCRs (Fritze et al., 2003) was observed 
during simulation of the free hH2R. After docking of ARP, the RMSD value of Tyr-288(7.53) 
Figure  5.12: Arrangement of conserved residues in the hH2R-ARP complex after 3.0 ns 
of MD simulations (energy-minimized structure). A, intracellular parts of TM2, TM3, TM6, 
and TM7; B, interacting residues in the vicinity of ARP. 
Chapter 5: MD Simulations of the hH2R in a Hydrated POPC Bilayer 85
was increased implicating disruption of this interaction, which is in agreement with the 
concept of a structural rearrangement after activation of bovine rhodopsin (Fritze et al., 
2003). The NPxxY(x)5,6F motif also contains Asn-284(7.49). In the crystal structure of bovine 
rhodopsin and in the initial hH2R models (chapter 4.3.1.2) a water mediated interhelical 
interaction of this residue with the highly conserved Asp-64(2.50) was described. During MD 
simulations of both hH2R models, the H-bonds with this water molecule were lost (see 
chapter 5.3.2.4). Instead, the amide NH2 group of Asn-284(7.49) and the carboxylate of 
Asp-64(2.50) underwent a stable direct interaction in the hH2R-ARP model (Figure  5.12 A) 
but not in the free receptor. Strikingly, this interaction was proposed to be formed during the 
transformation from the inactive to the active state of GPCRs (Bissantz, 2003; Lu et al., 
2002) according to a series of mutational experiments with corresponding residues in the 
gonadotropin-releasing hormone receptor (Zhou et al., 1994), the 5-HT2A receptor (Sealfon et 
al., 1995), the thyrotropin-releasing hormone receptor (Perlman et al., 1997), and the 
tachykinin NK2 receptor (Donnelly et al., 1999). Whereas single point mutations of one of 
these residues disrupted receptor function, double-revertant mutants were able to restore 
functionality. 
Trp-247(6.48) of the highly conserved CWxP(F/Y) motif in TM6 underwent a stable H-bond 
with Asn-280(7.45) in the ligand-free hH2R that was not present in the initial structure and did 
occur considerably less frequently in the hH2R-ARP complex (Figure  5.12 B). These results 
agree with the concept of different orientations of the side chain of Trp-247(6.48) in the 
inactive and the active states of the H1R (Jongejan et al., 2005) and other GPCRs (Pardo et 
al., 2007). Experimental support of a conformational transition of Trp(6.48) was derived from 
the structure of metarhodopsin I by electron crystallography (Ruprecht et al., 2004). 
In the crystal structure of bovine rhodopsin, Glu-113(3.28) forms the counter-ion to the 
protonated Schiff-base of retinal and Lys-296(7.43) (Palczewski et al., 2000). The side 
chains of the corresponding H2R residues Tyr-94(3.28) and Tyr-278(7.43) interacted more 
frequently in hH2R-ARP than in the free receptor. Additionally, a stable H-bond was detected 
between the hydroxyl groups of Tyr-94(3.28) and Ser-75(2.61) in the hH2R-ARP complex but 
not in the free hH2R where instead of that the OH group of Ser-75(2.61) served as donor for 
the hydroxyl oxygen of Tyr-278(7.43). 
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 hH2R hH2R-ARP 
Residues RMSD (Å)a 
H-bond 
(%)b 
Min. distance 
(Å)c 
RMSD 
(Å)a 
H-bond 
(%)b 
Min. 
distance (Å)c 
N36(1.50)-T32(1.46) 1.0; 1.3 68.5 1.97 ± 0.17 1.0; 0.6 36.6 2.08 ± 0.22 
N36(1.50)-D64(2.50) 1.0; 1.1 < 1 3.14 ± 0.29 1.0; 1.4 < 1 2.83 ± 0.47 
N36(1.50)-S281(7.46) 1.0; 1.3 28.7 2.36 ± 0.32 1.0; 1.5 60.2 2.16 ± 0.29 
I57(2.43)-L60(2.46) 1.4; 0.8 vdW 3.12 ± 0.26 1.6; 1.5 vdW 3.15 ± 0.27 
I57(2.43)-V239(6.40) 1.4; 0.9 vdW 5.87 ± 1.02 1.6; 1.2 vdW 8.64 ± 0.89 
S59(2.45)-W143(4.50) 1.0; 1.3 57.2 2.25 ± 0.39 1.1; 1.1 55.6 2.29 ± 0.33 
L60(2.46)-L109(3.43) 0.8; 0.7 vdW 3.91 ± 0.29 1.5; 0.8 vdW 4.32 ± 0.49 
Y94(3.28)-Y278(7.43) 0.8; 1.1 12.6 2.80 ± 0.49 0.8; 1.0 79.6 2.00 ± 0.36 
L109(3.43)-I112(3.46) 0.7; 0.7 vdW 3.11 ± 0.27 0.8; 0.6 vdW 3.16 ± 0.30 
L109(3.43)-V239(6.40) 0.7; 0.9 vdW 4.25 ± 0.45 0.8; 1.2 vdW 3.80 ± 0.27 
D115(3.49)-R116(3.50) 1.2; 1.2 79.4 n.a. 1.3; 2.3 < 1 n.a. 
R116(3.50)-E229(6.30) 1.2; 1.5 < 1 2.97 ± 0.49 2.3; 1.7 < 1 3.56 ± 0.35 
W247(6.48)-N280(7.45) 1.8; 1.3 52.7 2.06 ± 0.22 1.0; 1.8 5.8 2.74 ± 0.45 
Y288(7.53)-F295(7.60) 1.2; 2.1 vdW 3.13 ± 0.56 2.0; 2.3 vdW 2.84 ± 0.32 
A289(7.54)-R296(7.61) 0.8; 2.9 2.6 3.43 ± 1.00 2.1; 3.0 4.2 3.12 ± 0.29 
A290(7.55)-R296(7.61) 0.7; 2.9 3.5 3.68 ± 1.25 2.0; 3.0 1.4 3.80 ± 0.83 
Additional interactions:      
D64(2.50)-N284(7.49) 1.1; 2.3 16.2 3.86 ± 0.93 1.4; 1.4 81.6 2.35 ± 0.78 
S75(2.61)-Y94(3.28) 1.2; 0.8 9.4 1.77 ± 0.19 0.8; 0.8 93.2 1.90 ± 0.26 
S75(2.61)-Y278(7.43) 1.2; 1.1 68.6 1.94 ± 0.43 0.8; 1.0 < 1 2.89 ± 0.44 
R228(6.29)-E229(6.30) 1.3; 1.5 < 1 n.a. 2.3; 1.7 < 1 n.a. 
R228(6.29)-D294(7.59) 1.3; 3.1 77.1 2.42 ± 0.65 2.3; 3.1 9.4 5.19 ± 1.97 
 
 
 
 
 
5.3.2.4  Internal water molecules 
The frequency of H-bonds between residues and five internal water molecules predicted to 
be conserved and structurally important in class 1 GPCRs (Okada et al., 2002) were 
investigated (Table  5.7). Whereas an H-bond of Wat1a with Asp-64(2.50) was stable in both 
models during 5.0 ns, interactions of this water molecule with Ser-105(3.39) and 
Table  5.6: Analysis of important intramolecular interactions in the models of the ligand-free and the 
ARP-docked hH2Rs during 5.0 ns of MD simulations. 
a RMSD mean values of single residues after least-square fit of all Cα-atoms during 3.0 to 4.0 ns of 
simulation time. 
b frequency of the presence of H-bonds between selected residues during 5.0 ns of simulation time. 
vdW, van der Waals interaction 
c mean ± S.D. of the distance between the nearest atoms of selected residues during 5.0 ns of 
simulation time. n.a., not applicable, since both residues are consecutive. 
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Leu-101(3.35) were reduced and lost, respectively. In the case of hH2R-ARP but not the free 
receptor, an additional water molecule interacted with the OH hydrogen of Ser-105(3.39). In 
both systems, interactions of Wat1b with Asn-280(7.45) and Asn-284(7.49) were lost and 
replaced by stable H-bonds with Asn-36(1.50) (H-bond frequencies of 91.4% and 66.6% in 
hH2R and hH2R-ARP, respectively). Interactions of Wat1b with Asp-64(2.50) were stable in 
both models. In the model of the ligand-free hH2R, Wat1c interacted with Asn-284(7.49) and, 
substituting for the absent H-bond with Val-239(6.40), with Asp-64(2.50) (H-bond frequency 
of 94.8%). In the hH2R-ARP model, this water molecule diffused into the water shell. Overall, 
at the interface between TM2, TM3, TM6, and TM7 two additional water molecules not 
present in the starting structure were observed during simulations of the ligand-free hH2R. 
These water molecules were located in the centre of the TM domains nearby the empty 
binding pocket that, by itself, was filled with 18 water molecules. By contrast, in the hH2R-
ARP complex four additional water molecules were located at the intracellular ends of these 
TMs, presumably due to the increased flexibility of TM7. Wat3 strongly interacted with 
Cys-246(6.47), Tyr-250(6.51), and Val-273(7.38) in the free receptor. In hH2R-ARP, the 
corresponding H-bond frequencies were reduced. In both models, Wat4 moved into the 
water shell. 
 
 
Water Residue hH2R hH2R-ARP 
  H-bond (%)a 
Wat1a D64(2.50) 86.8 82.4 
 L101(3.35) 3 < 1 
 S105(3.39) 12.1 29.0 
Wat1b D64(2.50) 83.1 72.0 
 N280(7.45) < 1 < 1 
 N284(7.49) < 1 < 1 
Wat1c V239(6.40) < 1 - 
 N284(7.49) 62.7 - 
Wat3 C246(6.47) 98.3 38.0 
 Y250(6.51) 97.2 41.0 
 V273(7.38) 92.2 49.8 
Wat4 D54(2.40) - - 
 Y288(7.53) - - 
 
 
Table  5.7: Interactions of the hH2R with five internal water 
molecules during 5.0 ns of simulation time. Water molecules are 
named after corresponding water molecules in the crystal structure 
of bovine rhodopsin (pdb entry 1L9H) (Okada et al., 2002). 
a frequency of the presence of H-bonds between selected residues 
during 5.0 ns of simulation time. 
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5.3.2.5 Interactions of ARP with the hH2R binding pocket 
To provide an improved model of the binding mode of ARP and related guanidine-type H2R 
agonists, residues were selected facing ARP most frequently during MD simulations. Every 
time-step of the simulation, residues holding a distance of less than 5 Å from the centre of 
mass of each ARP substructure were collected. Only residues meeting this distance criterion 
in more than 10% of all snapshots registered during 5.0 ns were considered to participate in 
binding ARP (Table  5.8). 
In addition to the enforced interactions of Tyr-182(5.38), Asp-186(5.42), and Asp-98(3.32) 
with the imidazolylpropylguanidine moiety of ARP, also other residues frequently facing ARP 
were identical with the binding residues in the starting homology model (Figure 4.7 in chapter 
4.3.2.1). Most of these residues were less flexible than in the ligand-free receptor, thus 
indicating stable interactions. The increased RMSD values of residues in TM7 were due to 
the high flexibility of this helix backbone (Figure  5.10). Val-176 in e2 and Trp-275(7.40) were 
approximately 4 to 5 Å distant from ARP and achieved the contact criterion with an incidence 
of less than 50%. Additional residues exposed to the binding crevice during the simulation 
that have not been considered in the previous H2R models will be explicitly characterized 
(Figure 5.13). 
The imidazolyl group of ARP was in close proximity to Ser-153(4.60) and Thr-95(3.29), both 
selectively interacting when ARP was bound (frequency of 90% in the ARP-docked hH2R; no 
interaction in the ligand-free hH2R), and Val-99(3.33). By analogy, residues at position 3.29 
may participate in the binding modes of the M1 acetylcholine (Lu and Hulme, 1999) and the 
dopamine D4 receptors (Schetz et al., 2000). Val-115(3.33) was shown to be part of the 
binding crevice of the dopamine D2 receptor (Javitch et al., 1995a). The highly conserved 
Phe-191(5.47) (70% conservation among class 1 GPCRs) (Mirzadegan et al., 2003), one 
helical turn below Asp-186(5.42), was exposed to the binding site during the simulation. 
Phe(5.47) is known to be part of the binding sites of the dopamine D2R (Javitch et al., 1995b) 
and the 5-HT2A receptor (Shapiro et al., 2000). 
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In a previous model of the gpH2R, the basic guanidine group of Arg-257(6.58) was proposed 
to interact with a partially negatively charged substituent at the "upper" phenyl ring of 
diarylalkylguanidines, potentially stabilized by the carboxylate function of Glu-270(7.35) 
(Kelley et al., 2001; Dove et al., 2004). However, during 5.0 ns of simulation a direct 
interaction between Arg-257(6.58) and ARP did not occur. In the ligand-free hH2R model, the 
charged side chains of Arg-257(6.58) and Glu-270(7.35) interacted with an incidence of 39%. 
The positioning of the 4-F-phenyl group of ARP inhibited this interaction. Alternatively, in the 
hH2R-ARP complex Arg-257(6.58) formed H-bonds to the side chain oxygen of Gln-177 (H-
bond frequency of 22%) and the backbone oxygens of Glu-163 (35%) and Lys-175 (79%), all 
of them located in e2. The side chain of Glu-270(7.35) was solvated by a cluster of water 
molecules and adopted greater flexibility as represented by the high RMSD value. Trp-84 in 
e1 was identified to be in close contact with the 2-pyridyl and the 4-F-phenyl moieties of ARP 
during the whole simulation as a much lower RMSD value was calculated for this residue 
Figure  5.13: Side-view into the binding pocket of the hH2R in complex with ARP after 
3.0 ns of MD simulations (energy-minimized structure). Carbon atoms of residues 
forming distinct intramolecular interactions are shown in cyan. Remaining residues 
participating in binding ARP are shown in grey. The backbone of e2 is shown as grey 
ribbon. 
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when the ligand was bound compared to the free receptor. 
Ser-165 and the four consecutive residues Lys-173, Cys-174, Lys-175, and Val-176 in the 
lower leaflet of e2 formed the top of the ARP binding pocket. Whereas in the starting model 
of the hH2R-ARP complex, Lys-175 pointed towards the imidazolylpropylguanidine moiety, 
the amino group of this residue did not face the ligand in the simulated system but interacted 
with the backbone-O of Ser-153(4.60) (frequency of 85%), with the OH group of Thr-95(3.29) 
(21%), and with the side chain O of Asn-92(3.26) (frequency of 2%) or a water molecule. The 
primary amine of Lys-173 interacted with the side chain O of Ser-172 (frequency of 50%) and 
less frequently with the carboxylate group of Glu-270(7.35) (frequency of 24%) and with 
solvent molecules from the surrounding water shell. 
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ARP substructure Residue Contacts (%)a 
Min. dist. 
(Å)b 
hH2R 
RMSD (Å)c 
hH2R-ARP 
RMSD (Å)c 
imidazolyl Y182(5.38) 100 1.9 ± 0.2 2.2 (1.1) 
imidazolyl D186(5.42) 100 2.3 ± 0.3 1.4 (1.1) 
imidazolyl, Im-propyld T95(3.29) 100 3.6 ± 0.2 1.0 0.8 
imidazolyl V99(3.33) 100 3.3 ± 0.2 1.6 0.5 
imidazolyl S153(4.60) 100 2.1 ± 0.3 1.2 1.3 
imidazolyl, 4-F-C6H4 K175(e2) 86 3.2 ± 0.3 1.8 1.2 
imidazolyl V176(e2) 25 4.9 ± 0.4 1.5 0.8 
imidazolyl T190(5.46) 16 3.9 ± 0.4 1.0 1.5 
Im-propyld Y250(6.51) 100 2.9 ± 0.2 2.2 1.8 
guanidine D98(3.32) 100 2.2 ± 0.4 1.7 (0.5) 
guanidine W247(6.48) 100 2.7 ± 0.4 1.8 1.0 
guanidine Y278(7.43) 69 3.6 ± 0.8 1.1 1.0 
guanidine F191(5.47) 25 4.3 ± 1.0 2.0 1.4 
Ar2-propyle, guanidine L274(7.39) 100 3.3 ± 0.2 1.0 0.9 
Ar2-propyle V273(7.38) 33 4.3 ± 0.4 1.4 2.2 
2-pyridyl Y78(2.64) 100 2.9 ± 0.2 0.9 1.3 
2-pyridyl, 4-F-C6H4 E270(7.35) 100 3.2 ± 0.2 1.3 3.0 
2-pyridyl, 4-F-C6H4 K173(e2) 100 3.4 ± 0.2 1.6 1.6 
2-pyridyl, 4-F-C6H4 W84(e1) 98 3.1 ± 0.3 2.4 0.8 
2-pyridyl Y94(3.28) 82 3.6 ± 0.4 0.8 0.8 
2-pyridyl A271(7.36) 55 3.8 ± 0.2 0.9 2.2 
2-pyridyl W275(7.40) 33 4.1 ± 0.5 0.9 1.2 
4-F-C6H4 R257(6.58) 100 2.8 ± 0.3 2.0 0.9 
4-F-C6H4 C174(e2) 88 3.5 ± 0.3 1.2 0.6 
4-F-C6H4 S165(e2) 80 3.7 ± 0.4 3.3 1.7 
 
 
 
 
 
 
 
Table  5.8: Analysis of residues facing ARP most frequently during 5.0 ns of simulation time. 
a Frequency of contacts between substructures of ARP with residues in the hH2R binding pocket. 
Every 10 ps during 5.0 ns simulation time, residues exhibiting a minimum distance of less than 5 Å 
relative to each ARP-substructure were collected. Only residues facing ARP in more than 10% of all 
snapshots were considered.  
b mean ± S.D. of the distance between the nearest atoms of selected residues and ARP during 5.0 ns 
of simulation time. 
c RMSD mean values of residues after least-square fit of all Cα-atoms during 3.0 to 4.0 ns of simulation 
time. Values shown in brackets were biased due to the application of distance restraints (chapter 
5.3.2). 
d propyl group connecting the imidazolyl with the guanidine moiety of ARP 
e propyl group connecting the guanidine with the 4-fluorophenyl group and the pyridin-2-yl moiety of 
ARP. 
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5.4 Discussion 
5.4.1 Setup of the simulation system 
Depending on the methodology of generating a model system containing protein and lipid, 
the starting conditions for equilibration and subsequent MD simulations are considerably 
different and need to be adjusted individually (Kandt et al., 2007). In this study, the POPC 
bilayer was assembled around a pre-defined surface of the hH2R homology model and was 
subsequently solvated by water molecules with explicit consideration of counter ions. Due to 
the low density in this setup, adaptation of the box volume was necessary, rendering the 
NPT ensemble type to be useful for the simulations. This is in agreement with previous MD 
simulations of a hydrated dipalmitoylphosphatidylcholine bilayer showing that application of 
the NPT ensemble allows a system to adjust the box sizes so that the internal virial matches 
the externally applied pressure. Accordingly, with this method only an approximation of the 
initial box size is needed because the system finds its size by itself, based on the force field 
(Tieleman and Berendsen, 1996). By contrast, with the NVT ensemble these volume 
corrections could not take place, leading to severe disruptions of the membrane structure 
mainly in the middle of the bilayer (which is most compressible).  
Generally, in an NPT system the pressure can be coupled isotropically, semi-isotropically, 
and anisotropically. Kandt et al. claimed that application of isotropic pressure coupling is 
inappropriate for membrane simulations, since due to the proportional box scaling in this 
system only very small changes in the size are possible (Kandt et al., 2007). Nevertheless, 
this type of pressure coupling was successfully used for MD simulations of GPCRs 
embedded in hydrated lipid bilayers (Schlegel et al., 2005; Iadanza et al., 2002; Salo et al., 
2004). Semi-isotropic and anisotropic pressure couplings allow surface area fluctuations of 
the bilayer and were recommended for membrane protein simulations (Kandt et al., 2007). 
However, under anisotropic conditions no coupling between any of the directions of pressure 
contributions takes place which can lead to large deformations of the whole simulation 
system.  
For a structural analysis of the POPC bilayer using systems with various types of pressure 
coupling, calculation of the SCD order parameter proved to be the most sensitive parameter. 
Using anisotropic conditions experimental order parameters of POPC carbon atoms in the Lα-
phase were approximated best. A characteristic reduction of the absolute SCD values caused 
by the double bound of the sn-2 chain was more pronounced during 5.0 ns simulation 
compared to the preceding 500 ps of equilibration time which was due to relatively large 
time-scales processes of lipid bilayer dynamics (e.g. lipid diffusion and rotational 
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reorientation) need to occur (Anezo et al., 2003). Adjustment of the proper bilayer size turned 
out to be the most critical parameter when simulating with constant pressure since the 
scaling of the box vectors always caused a reduction of the bilayer thickness. Thus, during 
the simulations, the lipophilic bilayer core was by ~2-3 Å smaller than the proposed value of 
24 Å (Baldwin et al., 1997). However, charged residues at both margins of the hH2R TM 
domains were mainly surrounded by the ionic phosphatidylcholine head groups, reflecting an 
appropriate positioning of the hH2R surface between the complex lipophilic-ionic-water 
interface of the membrane (Kandt et al., 2007). 
 
5.4.2 Application of restraints on protein atoms during MD simulations 
The TM domains of bovine rhodopsin contain several deviations from pure α-helical 
structures that were predicted to be conserved among class 1 GPCRs (Ballesteros et al., 
2001). Studying the dynamics of GPCRs, such helix irregularities can induce severe 
perturbations of secondary structural elements. For example, TM7 of bovine rhodopsin 
exhibits irregular helicity, mainly around Lys-296(7.43) to which retinal is covalently attached 
(Palczewski et al., 2000). According to the concept of structural mimicry it was suggested 
that the structure of TM7 in class 1 GPCRs that lack this interaction is similar to that of 
rhodopsin (Ballesteros et al., 2001). Performing MD simulations of the hH2R, the backbone of 
TM7 was only stable when positional restraints were applied on the protein backbone atoms 
that were successively released during the equilibration. Similarly, TM5 of rhodopsin contains 
an unusual kink around the non-conserved His-211(5.46), presumably due to an interaction 
with Glu-122(3.37). Strikingly, amino acid position 5.46 is located one helical turn below 5.42 
facing the binding site crevice in aminergic GPCRs, and this unusual kink was predicted to 
be necessary to allow for an interaction of residue 5.42 with endogenous ligands (Ballesteros 
et al., 2001). In the simulation of the hH2R, both stability in the secondary structure of TM5 
and stable interactions of Tyr-182(5.38) and Asp-186(5.42) with the imidazolyl group of ARP 
were only achieved when the distances of interacting atoms were restrained. 
 
5.4.3 Characterization of the ligand-free and the ARP-bound hH2R models 
During MD simulations of the ligand-free and the ARP-bound hH2R, the C-terminus of TM7 
and the following short helix H8 were highly flexible and adopted different positions. By 
analogy, great mobility of the rhodopsin C-terminus including H8 was demonstrated by large 
B-factors in the crystal structure (Palczewski et al., 2000) as well as in NMR, spin-labelling, 
and further structural studies (Klein-Seetharamna et al., 2002; Langen et al., 1999; Cai et al., 
1999; Altenbach et al., 2001; Altenbach et al., 1999; reviewed in Klein-Seetharaman, 2002 
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and Hubbell et al., 2003). MD simulations of rhodopsin were able to reproduce these 
observations (Crozier et al., 2003; Huber et al., 2004). In this respect, the high RMSD values 
of the corresponding domains in both hH2R systems agree very well with experimental data. 
Moreover, mutagenesis studies of specific amino acids in rhodopsin have shown the 
involvement of i2, i3, and the C-terminus in binding and activating transducin (Franke et al., 
1990; Franke et al., 1992; Marin et al., 2000; Ernst et al., 2000; Fahmy et al., 2000), and 
Krishna et al. concluded that H8 acts as a membrane-dependent conformational switch 
domain upon photoactivation of rhodopsin (Krishna et al., 2002). Thus it may be possible that 
differential orientations of corresponding domains in the ARP-bound hH2R indeed represent 
an approximation to the active conformation being more susceptible for interacting with a Gs 
protein. Results from our MD simulations clearly coinciding with current concepts of a 
common mechanism of GPCR activation (Bissantz, 2003) are the higher abundance of an H-
bond between Asn-284(7.49) and Asp-64(2.50) and the loss of an aromatic interaction 
between Tyr-288(7.53) and Phe-295(7.60) in the ARP-bound receptor. 
Activation of GPCRs is supposed to include a counterclockwise rotation of TM6 when viewed 
from the extracellular side and an outward movement of the cytoplasmic end of TM6 away 
from TM3 (Visiers et al., 2002; Bissantz, 2003). Upon this movement, the ionic lock between 
Asp(3.49) and Arg(3.50) of the conserved (E/D)RY motif and Glu(6.30) at the intracellular 
ends of TM3 and TM6 is proposed to be disrupted. This process is presumably supported by 
a proton uptake of Asp(3.49) (Ghanouni et al., 2000). During 5.0 ns of MD simulation no such 
large-scale movements of TM6 occurred in the hH2R-ARP model and were actually not 
expected to be observed since receptor activation after binding of a diffusible ligand follows 
rather slow kinetics including discrete intermediate conformational states (Swaminath et al., 
2004). By analogy, meta I to meta II transition of rhodopsin upon photoactivation occurs in a 
millisecond time scale which is longer than usual computer simulations (Palczewski, 2006). 
However, as was shown for a simulation of rhodopsin in a dark-adapted state, MD simulation 
with agonists may simulate early events of activation (Crozier et al., 2003). In this respect, 
our MD simulation of hH2R-ARP starting from the inactive state of the receptor should 
represent perturbations necessary for the transition towards the active conformation. Thus, 
both longer simulation time and application of specific restraints on atoms enforcing the 
expected conformational changes would be required. MD simulations of the liganded hH2R 
however did agree with the concepts of an activated GPCR in that none of the residues 
Asp-115(3.49), Arg-116(3.50), and Glu-229(6.30) underwent directed interactions with other 
residues. The adjacent Arg-228(6.29) interacted with Asp-294(7.59) only in the free hH2R but 
pointed into the intracellular water shell when ARP was present. From these results it is not 
possible to conclude the impact of the non-conserved Arg-228(6.29) on differences in the 
constitutive activities of H2R species isoforms (chapters 4.3.1.2 and 7.4.1). Experimental 
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investigations, e.g. by mutagenesis studies are required. H-bond interactions between 
Trp-247(6.48) of the CWxP(F/Y) motif and Asn-280(7.45) selectively occurring in the ligand-
free hH2R were also consistent with current concepts on receptor activation (Pardo et al., 
2007). 
Five internal water molecules in the crystal structure of bovine rhodopsin were predicted to 
have a functional role in class 1 GPCRs (Okada et al., 2002). In the dynamic models of the 
ligand-free and the ARP-bound hH2R, one and two of these molecules, respectively, 
dissociated into the surrounding water shell whereas the other water molecules stably 
remained at their positions. In return, additional water molecules entered the protein interior, 
depending on the presence of cavities (empty binding pocket of the unliganded hH2R) and 
the flexibility of TM domains and loops at the intracellular side (hH2R-ARP). Influx of water 
from the bulk was observed in previous MD simulations (Huber et al., 2004; Röhrig et al., 
2002). Since these water molecules are in contact with polar residues, the possibility of a 
polar pathway through the rhodopsin protein was discussed (Huber et al., 2004). 
 
5.4.4 Dynamic model of the hH2R binding site for guanidine-type agonists 
ARP is a potent and efficacious H2R agonist at the guinea-pig right atrium (Buschauer, 1989) 
and in a steady-state GTPase activity assay at H2R-GsαS fusion proteins (chapter 7.3.2). In 
this study, ARP was selected as a reference compound to study the binding mode of H2R 
agonistic diarylalkylguanidines at the hH2R. Since the initial models of hH2R and gpH2R 
(chapter 4.3.1) were energy-minimized conformations derived from the crystal structure of 
rhodopsin, these can only be considered as first approximations to H2R conformations that 
exist under physiological conditions. Although these initial models provided striking evidence 
about differences in the interactions of guanidine-type agonists with human and guinea pig 
H2R species isoforms that were confirmed experimentally (Kelley et al., 2001; chapter 8), a 
more realistic model for the H2R agonist binding site was expected to be provided by MD 
simulations. The probability of interactions to occur between distinct residues and pre-
defined ARP-substructures were estimated by calculating the frequencies of close contacts, 
minimum distances between proximal partners, and RMSD values of the residues. 
Apart from residues that were included in the previous model of the hH2R binding pocket, 
eight additional amino acids residing in e1, TM3, TM4, e2, TM5, and TM7 exhibited close 
contacts with ARP. Arg-257(6.58) and Glu-270(7.35) that were suggested to constitute a 
network of electrostatic interactions with a partially negatively charged substituent in p-
position of the upper phenyl ring (Dove et al., 2004) underwent alternative interactions with 
residues in e2 during the simulation. In addition, in the binding pocket networks of H-bond 
interactions between Tyr-94(3.28), Tyr-278(7.43), and Ser-75(2.61) and between 
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Ser-153(4.60) and Thr-95(3.29) were selectively formed in the ARP-bound hH2R model. 
Possibly, these interactions are critical for the shape of the binding pocket and hence for the 
fit of agonists.  
The top of the ARP binding pocket was formed by the backbone of the sequence from 
Lys-173 to Val-176 in the lower leaflet of e2 including Cys-174 that is covalently bound to 
Cys-91(3.25) via a disulfide bond. The side chains of Lys-173 and Lys-175 were in contact 
with adjacent residues in e2, the ends of TM3 and TM7, and with surrounding water 
molecules, and did not directly interact with ARP as was proposed from the previous hH2R 
model. hH2R point mutations of Lys-173 to Ala and Lys-175 to Ala were generated and 
pharmacologically characterized (chapter 9). With these mutants the efficacies and potencies 
of H2R agonists did not significantly differ from the corresponding data of the wild-type hH2R 
further corroborating that both residues do not directly face the H2R binding pocket. 
In the dynamic model of the ligand-free hH2R two short antiparallel β-strands were formed in 
e2 similar to those that were observed in the crystal structure of bovine rhodopsin 
(Palczewski et al., 2000). Possibly these β-strands represent a functional microdomain 
enabled by structural mimicry (Ballesteros et al., 2001), and may also be present in other 
rhodopsin-like GPCRs. However, major differences between both e2 loop structures become 
apparent when comparing RMSD values of e2 from our MD simulation with corresponding 
data of an MD simulation of rhodopsin (Huber et al., 2004). Strikingly, the e2 loop of hH2R 
was much more flexible than that of rhodopsin when compared with the flexibilities of the 
respective TM domains and intracellular segments. The N-terminus of the rhodopsin 
sequence is by 19 amino acids longer than the N-terminus of the H2R sequence and contains 
two β-strands that are in close proximity to e2 in contrast to the spatial arrangement of e2 in 
hH2R that was mainly solvated by water molecules. Since the N-termini and the extracellular 
loops of rhodopsin and other class 1 GPCRs show rather low sequence homology, structure 
and dynamics of the e2 loops may generally be different. 
 
5.4.5 Conclusion 
3D-structure models of the hH2R in an unliganded and an agonist-bound state were studied 
by means of MD simulations with explicit consideration of the membrane and water. 
Boundary conditions were selected and optimized to reliably simulate a POPC bilayer in the 
fluid phase. The simulations with hH2R in complex with ARP did not reproduce large-scale 
movements of entire domains as were predicted to occur during a common GPCR activation 
process. The reason for this limitation is the relatively long time such rigid-body motions need 
to occur. Formation and breakage of distinct interactions dependent on the presence or 
absence of ARP in the hH2R binding pocket were in good agreement with experimental data 
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and previous computational studies. Therefore the ARP-bound hH2R model is proposed to 
represent perturbations, occurring in a nanosecond timescale after binding of agonists, that 
are necessary for the transition towards the active conformation.  
The results of our MD simulations help on further refining dynamic models of the binding 
mode of guanidine-type agonists. They form a basis for pharmacological experiments with 
wild-type and mutant H2R species isoforms to improve our concepts about H2R and GPCR 
function in general on a molecular level. 
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6.1 Materials 
NG-acylated N-[3-(1H-imidazol-4-yl)propyl]guanidines and UR-AK57 were prepared as 
described (Ghorai, 2005; Xie et al., 2006a, b). IMP (Durant et al., 1978) was synthesized as 
described (Durant et al., 1985). ARP and BU-E-43 were synthesized as described 
(Buschauer, 1989). Aminopotentidine and iodoaminopotentidine were prepared as described 
(Hirschfeld et al., 1992). Suprahistaprodifen and 2-benzylhistamine were synthesized as 
described (Elz et al., 2000; Seifert et al., 2003). The structures of compounds were confirmed 
by elemental analysis (C, H, N), 1H NMR, and mass spectrometry. Purity of compounds was 
>98% as determined by high-performance liquid chromatography or capillary electrophoresis. 
The anti-FLAG Ig (M1 monoclonal antibody) was from Sigma (St. Louis, MO). The anti-Gsα Ig 
(C-terminal) was from Santa Cruz Biotechnology (Santa Cruz, CA), and the anti-6His Ig was 
from Clonetech Laboratories (Mountain View, CA). [32P]Pi (8500-9100 Ci/mmol 
orthophosphoric acid), [α-32P]ATP (800 Ci/mmol), and [3H]dihydroalprenolol (85-90 Ci/mmol) 
were from PerkinElmer Life Sciences (Boston, MA). 
All unlabeled nucleotides, glycerol-3-phosphate dehydrogenase, triose phosphate 
isomerase, glyceraldehyde-3-phosphate dehydrogenase, and lactate dehydrogenase were 
from Roche (Indianapolis, IN). 3-Phosphoglycerate kinase, L-α-glycerol phosphate, 
histamine, betahistine, cimetidine, ranitidine, and famotidine were from Sigma. Amthamine 
was from Tocris Cookson (Ballwin, MO). Dimaprit was from RBI (Natick, MA). Burimamide 
and metiamide were from Dr. W. Schunack (Free University of Berlin, Germany). All 
restriction enzymes, T4 DNA ligase, and calf intestinal phosphatase were from New England 
Biolabs (Beverly, MA). Cloned Pfu DNA polymerase was from Stratagene (La Jolla, CA). 
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6.2 Generation of recombinant baculoviruses, cell culture, and 
membrane preparation 
Baculoviruses encoding recombinant proteins were generated in Sf9 cells using the 
BaculoGOLD transfection kit (BD PharMingen, San Diego, CA) according to the 
manufacturer’s instructions. After initial transfection, high-titer virus stocks were generated by 
two sequential virus amplifications. Sf9 cells were cultured in 250-ml disposable Erlenmeyer 
flasks at 28 °C under rotation at 125 rpm in SF 900 II medium (Invitrogen, Carlsbad, CA) 
supplemented with 5% (v/v) fetal calf serum (BioWhittaker, Walkersville, MD) and 0.1 mg/ml 
gentamicin (BioWhittaker). Cells were maintained at a density of 0.5 to 6.0 · 106 cells/ml. For 
infection, cells were sedimented by centrifugation and suspended in fresh medium. Cells 
were seeded at 3.0 · 106 cells/ml and infected with a 1:100 dilution of high-titer baculovirus 
stocks encoding H2Rs, GsαS, or H2R-GsαS proteins. Cells were cultured for 48 h before 
membrane preparation. Sf9 membranes were prepared as described previously (Seifert et 
al., 1998), using 1 mM EDTA, 0.2 mM phenylmethylsulfonyl fluoride, 10 μg/ml benzamidine, 
and 10 μg/ml leupeptin as protease inhibitors. Membranes were suspended in binding buffer 
(12.5 mM MgCl2, 1 mM EDTA, and 75 mM Tris/HCl, pH 7.4) and stored at -80 °C until use. 
 
6.3 SDS-PAGE and immunoblot analysis 
Membrane proteins were separated on SDS polyacrylamide gels containing 12% (w/v) 
acrylamide. Proteins were then transferred onto Immobilon-P transfer membranes (Millipore, 
Bedford, MA). Membranes were reacted with M1 antibody, anti-Gsα Ig, or anti-6His Ig (1:1000 
each). Immunoreactive bands were visualized by enhanced chemoluminescence (Pierce, 
Rockford, IL) using sheep anti-mouse IgG (M1 and anti-6His Ig) and donkey anti-rabbit IgG 
(anti-Gsα Ig), respectively, coupled to peroxidase. 
 
6.4 Steady-state GTPase activity assay 
Membranes were thawed, sedimented, and resuspended in 10 mM Tris/HCl, pH 7.4. Assay 
tubes contained Sf9 membranes expressing H2R-GsαS fusion proteins (10 µg of protein/tube), 
1.0 mM MgCl2, 0.1 mM EDTA, 0.1 mM ATP, 100 nM GTP, 0.1 mM adenylyl 
imidodiphosphate, 5 mM creatine phosphate, 40 µg of creatine kinase, and 0.2% (w/v) 
bovine serum albumin in 50 mM Tris/HCl, pH 7.4, and H2R ligands at various concentrations. 
Reaction mixtures (80 µl) were incubated for 2 min at 25 °C before the addition of 20 µl of  
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[γ-32P]GTP (0.1 µCi/tube). All stock and work dilutions of [γ-32P]GTP were prepared in 20 mM 
Tris/HCl, pH 7.4. Reactions were conducted for 20 min at 25 °C. Preliminary studies under 
basal conditions and with histamine, impromidine, and arpromidine showed that under these 
conditions GTP hydrolysis was linear. Reactions were terminated by the addition of 900 µl of 
slurry consisting of 5% (w/v) activated charcoal and 50 mM NaH2PO4, pH 2.0. Charcoal 
absorbs nucleotides but not Pi. Charcoal-quenched reaction mixtures were centrifuged for 7 
min at room temperature at 15000g. Six hundred microliters of the supernatant fluid of 
reaction mixtures were removed and [32Pi] was determined by liquid scintillation counting. 
Enzyme activities were corrected for spontaneous degradation of [γ-32P]GTP. Spontaneous 
[γ-32P]GTP degradation was determined in tubes containing all of the above described 
components plus a very high concentration of unlabeled GTP (1 mM) that, by competition 
with [γ-32P]GTP, prevents [γ-32P]GTP hydrolysis by enzymatic activities present in Sf9 
membranes. Spontaneous [γ-32P]GTP degradation was <1% of the total amount of 
radioactivity added using 20 mM Tris/HCl, pH 7.4, as solvent for [γ-32P]GTP. The 
experimental conditions chosen ensured that not more than 10% of the total amount of [γ-
32P]GTP added was converted to 32Pi. 
 
6.5 AC activity assay 
AC activity in Sf9 membranes was determined as described previously (Houston et al., 
2002). Briefly, membranes were thawed and sedimented by a 15-min centrifugation at 4 °C 
and 15000g to remove residual endogenous guanine nucleotides as far as possible, and 
were subsequently resuspended in binding buffer. Tubes contained Sf9 membranes 
expressing H2Rs (100 µg of protein/tube), H2Rs coexpressed with mammalian GsαS (50 µg of 
protein/tube), or H2R-GsαS fusion proteins (20 µg of protein/tube), additionally 5 mM MgCl2, 
0.4 mM EDTA, and 30 mM Tris/HCl, pH 7.4. Assay tubes containing membranes and various 
additions in a total volume of 30 µl were incubated for 3 min at 37 °C before starting 
reactions by the addition of 20 µl of reaction mixture containing (final) [α-32P]ATP  
(0.3 µCi/tube) plus 40 µM unlabeled ATP, 2.7 mM mono(cyclohexyl)ammonium 
phosphoenolpyruvate, 0.125 IU of pyruvate kinase, 1 IU of myokinase, and 0.1 mM cAMP. 
Reactions were conducted for 20 min at 37 °C. Reactions were terminated by the addition of 
20 µl of 2.2 N HCl. Denatured protein was sedimented by a 3-min centrifugation at 25 °C and 
15000g. Sixty-five microliters of the supernatant fluid were applied onto disposable columns 
filled with 1.3 g of neutral alumina (Sigma A-1522, super I, WN-6). [32P]cAMP was separated 
from [α-32P]ATP by elution of [32P]cAMP with 4 ml of 0.1 M ammonium acetate, pH 7.0. 
Recovery of [32P]cAMP was ~80%. Blank values were routinely ~0.01% of the total amount 
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of [α-32P]ATP added. [32P]cAMP was determined by liquid scintillation counting. The 
experimental conditions chosen ensured that not more than 1-3% of the total amount of  
[α-32P]ATP added was converted to [32P]cAMP. 
 
6.6 Preparation of [γ-32P]GTP 
[γ-32P]GTP was produced through substrate level phosphorylation of GDP during the 
enzymatic conversion of L-α-glycerol phosphate to 3-phosphoglycerate following a procedure 
described previously (Walseth and Johnson, 1979). The final concentrations of enzymes and 
reagents used were as follows: 43 µg/ml glycerol-3-phosphate dehydrogenase (0.44 IU),  
0.9 µg/ml triose phosphate isomerase (0.27 IU), 34 µg/ml glyceraldehyde-3-phosphate 
dehydrogenase (0.16 IU), 4.3 µg/ml 3-phosphoglycerate kinase (0.12 IU), 21 µg/ml lactate 
dehydrogenase (0.69 IU), 12 mM MgCl2, 27 mM dithiothreitol, 0.8 mM  
L-α-glycerolphosphate, 0.25 mM GDP, 0.5 mM β-NAD+, 1 mM pyruvic acid, and 0.1 mM 
EDTA in 10 mM Tris-HCl, pH 9.0. Immediately before use, a stock solution containing all 
enzymes was sedimented by a 15-min centrifugation at 14000 rpm and a temperature of  
4 °C to remove supernatant ammonium sulfate. Phosphorylation was started by addition of 
1.25 mCi [32P]Pi (orthophosphoric acid) in a total volume of 60 µl and was conducted for  
15 min at 37 °C. The reaction was stopped by placing the reaction mixture on ice and adding 
60 µl of ice-cold EtOH. To monitor conversion of [32P]Pi into [γ-32P]GTP, a pipet tip was 
putted into the reaction mixture to collect a very small amount that was distributed in 1 ml of 
50 mM KH2PO4, pH 2.0. 25 µl of this solution were withdrawn for liquid scintillation counting 
representing the total amount of radioactivity added to the reaction mixture. A spatula full of 
charcoal was then added to the remaining solution. After mixing, [γ-32P]GTP absorbed by 
charcoal was separated from [32P]Pi by a 5-min centrifugation at 14000 rpm. 25 µl of the 
supernatant were used for scintillation counting giving the amount of [32P]Pi in the reaction 
mixture not being converted to [γ-32P]GTP. The experimental conditions ensured that more 
than 99% of [32P]Pi were converted to [γ-32P]GTP. Appropriate aliquots of [γ-32P]GTP were 
stored at -80 °C until use. 
 
6.7 Miscellaneous 
Protein concentrations were determined using the DC protein assay kit (Bio-Rad, Hercules, 
CA). [3H]Dihydroalprenolol saturation binding was performed as described (Seifert et al., 
1998). All analyses of experimental data were performed with the Prism 4 program 
(GraphPad Software, San Diego, CA). KB values were calculated using the Cheng and 
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Prusoff equation (Cheng and Prusoff, 1973). Expression levels of recombinant proteins were 
determined using the BioRad GS-710 Calibrated Imaging Densitometer and the software tool 
Quantity One Version 4.0.3 (Bio-Rad, Hercules, CA). 
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7  
Chapter 7 
 
 
Constitutive Activity and Ligand Selectivity of 
Human, Guinea Pig, Rat, and Canine 
Histamine H2 Receptors 
 
 
7.1 Introduction 
The histamine H2 receptor species isoforms of canine (Gantz et al., 1991a), human (Gantz et 
al., 1991b), rat (Ruat et al., 1991), and guinea pig (Traiffort et al., 1995) had been cloned. 
The four H2R species isoforms are closely related to each other, as is reflected by an overall 
amino acid sequence identity of more than 80%. The highest conservation exists within the 
seven α-helical transmembrane (TM) domains (sequence identity of more than 90%), 
whereas the N-terminal domain together with the extracellular end of TM1 and the C-
terminus are the least conserved regions (Figure  7.1). 
Despite this high degree of structural similarity, N-[3-(1H-imidazol-4-yl)propyl]guanidines 
such as compounds 8-10 (Figure  7.2) differentially activate guinea pig (gpH2R) and human 
(hH2R) H2 receptors. In a membrane steady-state GTPase activity assay using fusion 
proteins of H2R and the short splice variant of Gsα, GsαS, such H2R-selective agonists are 
considerably more potent and efficacious at gpH2R-GsαS than at hH2R-GsαS (Kelley et al., 
2001). By contrast, the small H2R agonists histamine (1, HA), dimaprit (2, DIM), amthamine 
(3, AMT), and betahistine (4, BET) are unselective between these species. Recently, a novel 
class of NG-acylated imidazolylpropylguanidines as represented by compounds 11-16 was 
developed (Ghorai, 2005; Xie et al., 2006a). Generally, by introduction of a carbonyl group 
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adjacent to the guanidine moiety, the species-selectivity of the agonists is preserved (Xie et 
al., 2006a). Comparison of the corresponding agonist efficacies in the GTPase assay and at 
stabilizing the high-affinity ternary complex of the H2R with nucleotide-free Gsα indicate that 
N-[3-(1H-imidazol-4-yl)propyl]guanidines and their NG-acylated analogs stabilize different 
ligand-specific active conformations of hH2R and gpH2R (Kelley et al., 2001; Xie et al., 
2006a). However, it is not known whether these differences also apply for other H2R species 
isoforms. Moreover, H2Rs are known to be constitutively active (Smit et al., 1996a; Alewijnse 
         N-term     ______________TM1_____________  i1  ____________TM2____ 
hH2R   1 MAPNGTASSFCLDSTACKITITVVLAVLILITVAGNVVVCLAVGLNRRLRNLTNCFIVSLAITDLLLGLL 
gpH2R   1 ..F...VP...M.F.VY.V..S.I.II...V...................S..........V........ 
rH2R   1 .E....VH.C....M.L.V..S...TT.....I..........S......S..........A........ 
cH2R   1 .IS...G.......PP.R..VS...T......I.................S................... 
 
 
  ___________  e1  ____________TM3__________________      i2    ___TM4__ 
hH2R  71 VLPFSAIYQLSCKWSFGKVFCNIYTSLDVMLCTASILNLFMISLDRYCAVMDPLRYPVLVTPVRVAISLV 
gpH2R  71 ................S.................................T........I..A....... 
rH2R  71 ...........FT....H................................T................... 
cH2R  71 ......F.....R.....................................T........I......V... 
 
 
  _____TM4_______           e2          ____________TM5___________   
hH2R 141 LIWVISITLSFLSIHLGWNSRNETSKGNHTTSKCKVQVNEVYGLVDGLVTFYLPLLIMCITYYRIFKVAR 
gpH2R 141 F.........................D.D.IV..............................F....I.. 
rH2R 141 F.....................G.RG..D.F-...........................V.......I.. 
cH2R 141 .........................SF...IP.......L................V..........I.. 
 
 
         i3         ______________TM6______________   e3   ______TM7____ 
hH2R 211 DQAKRINHISSWKAATIREHKATVTLAAVMGAFIICWFPYFTAFVYRGLRGDDAINEVLEAIVLWLGYAN 
gpH2R 211 E..R.....G................................V......K....V...F.DV........ 
rH2R 210 E........................................................AV.G......... 
cH2R 211 ......H.MG.......G........................V......K.......AF..V........ 
 
 
  ________                              C-term 
hH2R 281 SALNPILYAALNRDFRTGYQQLFCCRLANRNSHKTSLRSNASQLSRTQSREPRQQEEKPLKLQVWSGTEV 
gpH2R 281 .................A.H........SH...E....L.N...N.S.CQ...W..D...N......... 
rH2R 280 .................A.....H.KF.SH........L.N.L.P.S....G.W...............L 
cH2R 281 .........T.......A.....R..P.SH.AQE......S...A.N.....MR................ 
 
 
 
hH2R  351 TAPQGATDR  359 
gpH2R 351 .......N.  359 
rH2R 350 .H...NPI.  358 
cH2R 351 ...R.....  359 
Figure  7.1: Comparison of the amino acid sequences of hH2R, gpH2R, rH2R, and cH2R. Dots in the 
sequences of gpH2R, rH2R, and cH2R indicate identity with hH2R. Amino acids shown in white with 
black shading represent the interaction sites of HA with the H2R (Gantz et al., 1992; Nederkoorn et al., 
1996). The most conserved residues in each TM domain are indicated in grey shading. Amino acids 
shown in regular font in the sequences of gpH2R, rH2R, and cH2R represent conservative exchanges. 
Amino acids shown in bold in the sequences of gpH2R, rH2R, and cH2R represent nonconservative 
exchanges. 
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et al., 1998), but the degree to which constitutive activity varies among several species 
isoforms remains elusive. To generate an expanded pharmacological profile of H2R species 
isoforms, we compare human, guinea pig, rat (r), and canine (c) H2Rs. 
Sf9 cell membranes expressing H2R-GsαS fusion proteins were used to measure steady-state 
GTPase activity. For this purpose, we studied several classes of H2R ligands (Figure  7.2). 
HA (1) and related small H2R agonists DIM (2), AMT (3), and BET (4) similarly interact with 
the binding site of H2R. The amino group of HA forms an ionic interaction with Asp-98(3.32) 
in TM3 and the imidazolyl ring presumably interacts with Tyr-182(5.38) and Asp-186(5.42) in 
TM5 (Figure  7.1). The guanidine-type H2R agonists impromidine (8, IMP), arpromidine (9, 
ARP), and BU-E-43 (10), as well as the NG-acylated derivatives 11-16 share a common N-[3-
(1H-imidazol-4-yl)propyl]guanidine moiety that mimics binding of HA and thus is crucial for 
agonistic activity (Dove et al., 2004). The 2-(5-methylimidazol-4-ylmethylthio)ethyl moiety of 
IMP and the 3-(4-fluorophenyl)-3-(2-pyridyl)propyl group of ARP are supposed to interact 
with a pocket formed by multiple residues in TM2, TM3, TM6, and TM7 (chapters 4 and 5; 
Kelley et al., 2001). 
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Figure  7.2: Structures of H2R agonists, partial agonists, and antagonists. 1-4, small H2R agonists; 5
and 6, H1R agonists with partial agonism at the H2R; 8-10, guanidine-type H2R agonists; 11-16, NG-
acylated N-[3-(1H-imidazol-4-yl)propyl]guanidines with agonistic H2R activity; 7 and 17-22, H2R 
antagonists. 
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The variable side chains of the ARP derivatives 10-16 consist of diverse mono- or diarylalkyl 
groups with different chain lengths between the aromatic ring system and the guanidine 
group. In compound 16 (Xie et al., 2006b), the aryl ring is replaced by a cyclohexyl moiety. 
Compound 13 is the pure (R)-enantiomer (eutomer). 2-Benzylhistamine (5) and 
suprahistaprodifen (6) represent H1R agonists with partial H2R agonism (Seifert et al., 2003). 
Burimamide (7) and metiamide (22) are neutral H2R antagonists, whereas cimetidine (17, 
CIM), ranitidine (18, RAN), famotidine (19, FAM), aminopotentidine (20, APT), and 
iodoaminopotentidine (21, IAPT) act as inverse agonists (Hill et al., 1997; Dove et al., 2004). 
Previous studies showed that the determination of adenylyl cyclase (AC) activity in Sf9 cell 
membranes is a very sensitive system to elucidate differences in the constitutive activities of 
GPCRs (Seifert et al., 1998b). Therefore, we also assessed AC activity in membranes 
expressing non-fused H2Rs (coupling to endogenous Gsα-like G proteins), in membranes 
coexpressing H2R and mammalian GsαS, and in membranes expressing H2R-GsαS fusion 
proteins. 
 
 
7.2 Materials and Methods 
7.2.1 Materials 
The cDNA for the rH2R was kindly provided by Dr. R. Leurs (Leiden/Amsterdam Center for 
Drug Research, Department of Medicinal Chemistry, Vrije Universiteit Amsterdam, 
Amsterdam, The Netherlands) (Ruat et al., 1991). The cDNA for the cH2R was kindly 
provided by Dr. I. Gantz (University of Michigan, Medical School and Ann Arbor VA Medical 
Center, Ann Arbor, MI) (Gantz et al., 1991a). The generation of the baculoviruses encoding 
hH2R, gpH2R, hH2R-GsαS, and gpH2R-GsαS was described previously (Kelley et al., 2001; 
Houston et al., 2002). The baculoviruses encoding GsαS were kindly provided by Drs. R. 
Sunahara and A. G. Gilman (Department of Pharmacology, University of Southwestern 
Medical Center, Dallas, TX, USA). The generation of pGEM-3Z-SF-β1AR-GsαS and pVL1392-
SF-β1AR-GsαS was described previously (Wenzel-Seifert et al., 2002). A description of the 
preparation of all remaining materials is given in chapter 6.1. 
 
7.2.2 Construction of the cDNAs for rH2R and rH2R-GsαS 
The cDNAs encoding for the proteins were generated by sequential overlap-extension PCRs. 
With pGEM-3Z-SF-gpH2R-GsαS as template, PCR 1A was used to amplify a DNA fragment 
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consisting of the cleavable signal peptide from influenza hemagglutinin (S), the FLAG 
epitope (F) recognized by the M1 monoclonal antibody, and the start codon of the rH2R. The 
sense primer annealed with 18 bp of pGEM-3Z prior to the 5’-end of SF. The antisense 
primer annealed with 15 bp of the 3’-end of SF and with ATG. In PCR 1B, the cDNA 
encoding the rH2R followed by a hexahistidine tag in 3’-position was generated. The 
hexahistidine tag was included to allow future purification and to provide additional protection 
against proteolysis (Seifert et al., 1998a). The sense primer consisted of 15 bp of the 3’-end 
of SF and the first 22 bp of the 5’-end of the rH2R. The antisense primer consisted of 18 bp of 
the C-terminus of the rH2R, the hexahistidine tag, the stop codon, and an Xba I site. The 
cDNA for the rH2R was extracted from pcDNA-rH2R after restriction digestion with Hind III 
and Bgl II and was used as template. In PCR 2, the products of PCR 1A and PCR 1B 
annealed in the region encoding SF and ATG. Here, the sense primer of PCR 1A and the 
antisense primer of PCR 1B were used. In that way, a fragment encoding SF, the rH2R, the 
hexahistidine tag, the stop codon, and an Xba I site was obtained. This fragment was 
digested with Sac I and Xba I and cloned into pGEM-3Z-SF-hH2R digested with Sac I and 
Xba I to yield pGEM-3Z-SF-rH2R. pGEM-3Z-SF-rH2R was digested with Sac I and Xba I and 
cloned into the baculovirus transfer vector pVL1392-SF-hH2R digested with Sac I and Xba I. 
With pGEM-3Z-SF-rH2R as template, the sense primer of PCR 1A, and an antisense primer 
encoding six histidines, in PCR 3A a fragment encoding SF, the cDNA for the rH2R, and the 
hexahistidine tag was generated. In PCR 3B, a fragment encoding the hexahistidine tag, the 
cDNA of GsαS, the stop codon, and an Xba I site was generated. Here, the sense primer 
annealed with the hexahistidine tag and the start codon of GsαS, and the antisense primer 
annealed with the cDNA encoding the 5 C-terminal amino acids of GsαS, the stop codon, and 
an Xba I site. pGEM-3Z-SF-gpH2R-GsαS was used as template. In PCR 4, the products of 
PCRs 3A and 3B annealed in the hexahistidine region, and the sense primer of PCR 1A and 
the antisense primer of PCR 3B were used. In that way, the complete cDNA for the rH2R-
GsαS fusion protein, consisting of SF, the cDNA for the rH2R, the hexahistidine tag, and the 
cDNA of GsαS was amplified. The product of PCR 4 was digested with Sac I and Bgl II and 
cloned into pGEM-3Z-SF-β1AR-GsαS digested with Sac I and Bgl II. Additionally, the PCR 4 
product was digested with Sac I and Bgl II and directly cloned into pVL1392-SF-β1AR-GsαS 
that was digested with Sac I and Bgl II and treated with calf intestinal phosphatase to yield 
the baculovirus transfer vector pVL1392-SF-rH2R-GsαS. 
 
7.2.3 Construction of the cDNAs for cH2R and cH2R-GsαS 
The strategy for the generation of the cDNAs for the epitope-tagged cH2R and cH2R-GsαS 
was analogous to the strategy for the generation of the cDNAs for rH2R and rH2R-GsαS. With 
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pGEM-3Z-SF-gpH2R-GsαS as template, in PCR 1A the SF region and the start codon of the 
cH2R were amplified. The sense primer annealed with 18 bp of pGEM-3Z prior to the 5’-end 
of SF, and the antisense primer annealed with 15 bp of the 3’-end of SF and with ATG. In 
PCR 1B, the cDNA encoding the sequence for the cH2R followed by the hexahistidine tag in 
3’-position was generated. The sense primer consisted of 15 bp of the 3’-end of SF and the 
first 21 bp of the 5’-end of cH2R. The antisense primer consisted of 18 bp of the C-terminus 
of the cH2R, the hexahistidine tag, the stop codon, and an Xba I site. The cDNA for the cH2R 
was extracted from CMVneo-cH2R after digestion with Bgl II and was used as template. In 
PCR 2, the products of PCR 1A and PCR 1B annealed in the region encoding SF and ATG. 
Here, the sense primer of PCR 1A and the antisense primer of PCR 1B were used. In that 
way, a fragment encoding SF, the cH2R, the hexahistidine tag, the stop codon, and an Xba I 
site was obtained. This fragment was digested with Sac I and Xba I and cloned into pGEM-
3Z-SF-hH2R digested with Sac I and Xba I to yield pGEM-3Z-SF-cH2R. pGEM-3Z-SF-cH2R 
was digested with Sac I and Xba I and cloned into the baculovirus transfer vector pVL1392-
SF-hH2R digested with Sac I and Xba I. PCR 3 was used to generate a fragment encoding 
the C-terminus of the cH2R, the hexahistidine tag, and GsαS. The sense primer encoded the 
last 10 amino acids of the C-terminus of the cH2R, the hexahistidine tag, and the start codon 
of GsαS, and the antisense primer encoded the 5 C-terminal amino acids of GsαS, the stop 
codon, and an Xba I site. Here, pGEM-3Z-SF-hH2R-GsαS was used as template. This 
fragment was digested with Xho I and Xba I and cloned into pGEM-3Z-SF-cH2R digested 
with Xho I and Xba I to yield pGEM-3Z-SF-cH2R-GsαS. pGEM-3Z-SF-cH2R-GsαS  was digested 
with Sac I and Bgl II and cloned into pVL1392-SF-β1AR-GsαS  that was digested with Sac I 
and Bgl II and treated with calf intestinal phosphatase, to yield the baculovirus transfer vector 
pVL1392-SF-cH2R-GsαS . 
 
7.2.4 Generation of recombinant baculoviruses, cell culture, and membrane 
preparation 
A description is given in chapter 6.2. 
 
7.2.5 SDS-PAGE and immunoblot analysis 
A description is given in chapter 6.3. 
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7.2.6 Steady-state GTPase activity assay 
A description is given in chapter 6.4. 
 
7.2.7 AC activity assay 
A description is given in chapter 6.5. 
 
 
7.3 Results 
7.3.1 Immunological detection of recombinant proteins in Sf9 cell membranes 
The predicted molecular mass of the H2R is ~33 kDa (Gantz et al., 1991a, b; Fukushima et 
al., 1997). H2R species isoforms presumably exhibit similar glycosylation patterns, since the 
putative N-glycosylation sites for the H2R, Asn-4 and Asn-162, are fully conserved within their 
sequences (Figure 7.1) (Fukushima et al., 1995). However, only rH2R and hH2R migrated as 
the expected bands for monomeric GPCRs (Figure  7.3 A, B). Both bands occurred as 
doublets, representing different glycosylation forms (Houston et al., 2002). Additional bands 
were detected at ~70 kDa, presumably representing receptor dimers. A similar pattern of 
immunoreactive bands was previously observed for the hH2R (Houston et al., 2002). In 
contrast, both cH2R and gpH2R displayed strong doublet bands at ~60 kDa that coincide with 
the expected bands of differentially glycosylated H2R dimers, whereas the bands for 
monomers were absent. Additional bands were detected at ~150 kDa and above 250 kDa, 
possibly corresponding to H2R tetramers and higher oligomers, respectively. Dimerization 
and oligomerization of the cH2R has been described previously (Fukushima et al., 1997), but 
in those experiments, also receptor monomers were detected. Hence, gpH2R and cH2R 
possibly migrated atypically in SDS-PAGE, i.e. the bands at ~60 kDa and ~150 kDa could 
correspond to monomers and dimers, respectively, and not to dimers and tetramers. With the 
anti-6His Ig, in membranes expressing cH2R an additional doublet band at ~23 kDa was 
detected, and in rH2R- and hH2R membranes a ~27 kDa band was present. However, no 
such bands were detected in gpH2R membranes. The ~23-27 kDa bands may represent 
differentially and atypically migrating H2R monomers not recognized by the M1 antibody 
because of a lack of epitope exposure. By analogy to formyl peptide receptors (Wenzel-
Seifert and Seifert, 2003), differences in the C-termini of H2R species isoforms may 
constitute the molecular basis for the species-selective migration pattern. Thus, H2R species  
Chapter 7: Analysis of H2R species isoforms 116
 
 
 
isoforms were well expressed in Sf9 membranes, but due to their widely different migration, it 
was impossible to precisely assess their expression levels using β2AR-membranes calibrated 
with [3H]dihydroalprenolol saturation binding as standard (Kelley et al., 2001). 
H2R-GsαS fusion proteins of canine, rat, guinea pig, and human occurred as strong bands at 
~80 kDa (Figure  7.3 C). Since GsαS has an apparent molecular mass of ~45 kDa (Graziano et 
al., 1989), these bands correspond to H2R-GsαS monomers. Weaker bands were detected at 
~110 kDa, most probably representing differently glycosylated fusion proteins. With all 
species additional bands at ~250 kDa were detected, presumably representing H2R-GsαS 
dimers or oligomers. cH2R-GsαS was expressed at ~5 pmol mg-1, rH2R-GsαS at ~4 pmol mg-1,  
gpH2R-GsαS at ~1 pmol mg-1, and hH2R-GsαS at ~3 pmol mg-1 using β2AR-membranes as 
standard. To account for the decreased expression level of gpH2R-GsαS, in this case the 
amount of protein applied to the gel was adjusted to 40 µg. 
Figure  7.3: Immunological detection and analysis of the expression of recombinant proteins in Sf9 
cells. In each lane, 10 µg of membrane protein was loaded onto the gel, unless otherwise indicated 
below membranes. Exceptionally, 40 µg of a membrane expressing gpH2R-GsαS were loaded onto the 
gels in panels C and D. Numbers on the left of membranes designate masses of marker proteins in 
kDa. In A and C, 1, 2, 5, and 10 µg of protein of Sf9 membranes expressing the β2AR at 7.5 pmol mg-1
(as determined by [3H]DHA saturation binding) were used as standard to assess the expression levels 
of H2R species isoforms. In D, membranes expressing H2R-GsαS fusion proteins and membranes 
coexpressing H2R species and mammalian GsαS were loaded onto the gel. 
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Probing membranes expressing H2R-GsαS species with the anti-Gsα Ig yielded ~80 kDa and 
~250 kDa bands (Figure  7.3 D) which are consistent with those bands observed with the anti-
FLAG Ig. Additional bands appeared at ~45 kDa, representing atypically migrating or partially 
degraded fusion proteins. In all membranes coexpressing H2R species and GsαS, the 
expected bands for GsαS monomers were detected at ~45 kDa. The expression levels of GsαS 
in membranes coexpressing H2R and GsαS were estimated using the ~80 kDa peak 
intensities of H2R-GsαS species as standard and were ~2 pmol mg-1 in membranes 
coexpressing cH2R and GsαS, ~2 pmol mg-1 in membranes coexpressing rH2R and GsαS, ~1 
pmol mg-1 in membranes coexpressing gpH2R and GsαS, and ~1 pmol mg-1 in membranes 
coexpressing hH2R and GsαS. 
 
7.3.2 Efficacies and potencies of agonists at H2R-GsαS species isoforms 
derived from the GTPase assay 
Efficacies and potencies of compounds 1-16 and 22 at H2R-GsαS fusion proteins of human, 
guinea pig, rat, and canine are summarized in Table  7.1. The small H2R agonists acted as 
full (1-3) or as nearly full (4) agonists at the four receptors with approximately similar 
efficacies. HA (1) and DIM (2) were equipotent at human, guinea pig, and rat H2R-GsαS, but 
showed lower EC50 values at cH2R-GsαS. AMT (3) was slightly more potent at cH2R-GsαS than 
at hH2R-GsαS and gpH2R-GsαS. At rH2R-GsαS, the potency of AMT (3) was further decreased. 
BET (4) acted with increased potencies at gpH2R-GsαS and cH2R-GsαS, compared to hH2R-
GsαS and rH2R-GsαS. In agreement with previous studies (Kelley et al., 2001; Xie et al., 2006a, 
b), N-[3-(1H-imidazol-4-yl)propyl]guanidines (8-10) and their NG-acylated analogs (11-16) 
were more potent and more efficacious at gpH2R-GsαS than at hH2R-GsαS. At gpH2R-GsαS, 
UR-PG222A (13) was more efficacious than HA (1). At hH2R-GsαS and rH2R-GsαS the 
compounds exhibited similar efficacies and potencies. Only UR-PG214 (11) was slightly 
more potent at rH2R-GsαS than at hH2R-GsαS. Apart from ARP (9) and its NG-acylated analog 
UR-PG136 (15) that acted with similar efficacies at cH2R-GsαS and hH2R-GsαS, compounds 8-
16 were more efficacious at cH2R-GsαS than at hH2R-GsαS. Compounds 8-16 were also more 
potent at cH2R-GsαS than at hH2R-GsαS. An exception of this rule was UR-PG123 (14) that 
exhibited the largest efficacy increase (~4-fold) but was somewhat less potent at cH2R-GsαS 
than at hH2R-GsαS. In summary, small H2R agonists 1-4 acted with similar efficacies at all 
H2R-GsαS species isoforms investigated, but were more potent at cH2R-GsαS compared to 
hH2R-GsαS, gpH2R-GsαS, and rH2R-GsαS. Guanidines and NG-acylated guanidines 8-16 acted 
with increased efficacies and potencies at gpH2R-GsαS and cH2R-GsαS compared to hH2R-
GsαS, whereas no selectivity was observed between rH2R-GsαS and hH2R-GsαS. 
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 hH2R-GsαS gpH2R-GsαS rH2R-GsαS cH2R-GsαS 
Cpd. EMaxa EC50 (nM) EMaxa EC50 (nM) EMaxa EC50 (nM) EMaxa EC50 (nM) 
1 1.00 990 ± 92 
 
1.00 850 ± 340 1.00 1200 ± 16 1.00 290 ± 50++ 
2 0.85 ± 
0.02 
910 ± 430 0.94 ± 
0.06* 
740 ± 360 0.89 ± 
0.03 
1100 ± 92 0.90 ± 
0.04 
480 ± 82 
3 0.91 ± 
0.02 
190 ± 50 1.04 ± 
0.01** 
190 ± 42 0.91 ± 
0.03 
360 ± 
100+ 
0.82 ± 
0.03** 
110 ± 66 
4 0.81 ± 
0.07 
44000 ± 
8900 
0.72 ± 
0.02 
28000 ± 
4400+ 
0.71 ± 
0.03 
47000 ± 
9100 
0.78 ± 
0.08 
27000 ± 
6900+ 
5 0.45 ± 
0.05 
13000 ± 
1000 
0.26 ± 
0.01** 
6800 ± 
1900++ 
0.43 ± 
0.01 
13000 ± 
1000 
0.68 ± 
0.02** 
13000 ± 
1200 
6 0.54 ± 
0.08 
240 ± 41 0.43 ± 
0.02* 
310 ± 62 0.43 ± 
0.02* 
400 ± 81+ 0.77 ± 
0.03** 
260 ± 18 
7 0.16 ± 
0.01 
14000 ± 
12000 
0.17 ± 
0.02 
12000 ± 
3600 
0.18 ± 
0.02 
15000 ± 
2100 
0.40 ± 
0.01** 
11000 ± 
210 
8 0.82 ± 
0.02 
160 ± 42 0.96 ± 
0.06 
18 ± 9++ 0.99 ± 
0.06* 
110 ± 9 0.99 ± 
0.10* 
41 ± 18++ 
9 0.84 ± 
0.03 
72 ± 9 0.94 ± 
0.05* 
7 ± 1++ 0.80 ± 
0.03 
90 ± 7++ 0.84 ± 
0.07 
10 ± 1++ 
10 0.71 ± 
0.11 
130 ± 13 0.87 ± 
0.05 
43 ± 10++ 0.70 ± 
0.04 
140 ± 22 0.88 ± 
0.05* 
46 ± 6++ 
11 0.91 ± 
0.08 
130 ± 45 0.94 ± 
0.05 
25 ± 10++ 1.03 ± 
0.06 
84 ± 8 1.00 ± 
0.06 
28 ± 8++ 
12 0.80 ± 
0.04 
120 ± 45 0.94 ± 
0.05* 
14 ± 4++ 0.82 ± 
0.06 
96 ± 12 0.99 ± 
0.05** 
40 ± 10++ 
13 0.90 ± 
0.04 
18 ± 6 1.18 ± 
0.08** 
5 ± 1++ 0.93 ± 
0.01 
13 ± 1 0.98 ± 
0.03 
3 ± 2++ 
14 0.14 ± 
0.03 
250 ± 13 0.40 ± 
0.02** 
220 ± 22 0.15 ± 
0.02 
250 ± 48 0.59 ± 
0.02** 
340 ± 33+ 
15 0.82 ± 
0.05 
100 ± 9 1.02 ± 
0.11* 
29 ± 10++ 0.73 ± 
0.02 
100 ± 16 0.86 ± 
0.08 
52 ± 4++ 
16 0.86 ± 
0.05 
15 ± 4 0.97 ± 
0.18 
14 ± 6 0.73 ± 
0.02 
14 ± 1 0.92 ± 
0.03 
5 ± 3+ 
22 -0.08 ± 
0.01 
1400 ± 
900 
-0.06 ± 
0.01 
750 ± 460 -0.04 ± 
0.01** 
670 ± 510 0.06 ± 
0.01** 
21000 ± 
2200++ 
 
 
Table  7.1: Agonist efficacies (EMax) and potencies at H2R-GsαS species isoforms in the GTPase assay. 
GTPase activity in Sf9 membranes was determined as described in chapter 6.4. Data shown are the 
means ± S.D. of three to five experiments performed in duplicate. Efficacies and potencies, 
respectively, of ligands at hH2R-GsαS were compared with the corresponding parameters at gpH2R-
GsαS, rH2R-GsαS, and cH2R-GsαS, respectively, using one-way ANOVA. 
a Efficacy relative to HA ( = 1.00) 
* comparison with the efficacy at hH2R-GsαS; * p < 0.05; ** p < 0.01 
+ comparison with the EC50 value at hH2R-GsαS; + p < 0.05; ++ p < 0.01 
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Compounds 5 and 6 are representatives of H1R agonists with partial H2R agonism (Seifert et 
al., 2003). Both compounds were less efficacious at gpH2R-GsαS than at hH2R-GsαS and 
similarly efficacious at rH2R-GsαS and hH2R-GsαS (Table  7.1). In the GTPase assay at H2R-
GsαS fusion proteins, burimamide (7) was a weak partial agonist with similar efficacies at 
human, guinea pig, and rat species. Strikingly, compounds 5, 6, and 7 acted with significantly 
increased efficacies at cH2R-GsαS compared to hH2R-GsαS. Apart from 2-benzylhistamine (5) 
with ~2-fold increased potency at gpH2R-GsαS, the potencies of 5-7 did not significantly differ 
between the species investigated. Taken together, partial H2R agonists were considerably 
more efficacious at cH2R-GsαS than at human, guinea pig, and rat H2R-GsαS.  
 
7.3.3 Potencies and inverse agonist efficacies of antagonists at H2R-GsαS 
species isoforms derived from the GTPase assay 
KB values and inverse agonist efficacies of the H2R antagonists CIM (17), RAN (18), FAM 
(19), APT (20), and IAPT (21) are listed in Table  7.2. The compounds decreased GTPase 
activities below basal values and thus acted as inverse agonists at all four species. At hH2R-
GsαS and gpH2R-GsαS compounds 17-21 decreased the basal GTPase signal (0%) by ~10% if 
the maximum stimulatory effect of 100 µM HA was set to 100%. At rH2R-GsαS the inverse 
agonist efficacies of 17-21 were somewhat smaller. At cH2R-GsαS all compounds except CIM 
(17) showed a significantly higher reduction of the basal GTPase activity by ~20%. The KB 
values of 17-21 were similar at hH2R-GsαS and gpH2R-GsαS. At rH2R-GsαS, 17-19 were less 
potent, and 20 and 21 were similarly potent compared to hH2R-GsαS. By contrast, all 
compounds except FAM (19) were less potent at cH2R-GsαS than at hH2R-GsαS. Taken 
together, most of the H2R antagonists studied displayed increased inverse agonist efficacies 
and decreased potencies at cH2R-GsαS compared to hH2R-GsαS. 
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 hH2R-GsαS gpH2R-GsαS rH2R-GsαS cH2R-GsαS 
Cpd. KB (nM) Inv. Eff. KB (nM) Inv. Eff. KB (nM) Inv. Eff. KB (nM) Inv. Eff. 
17 1700 ± 
430 
-0.08 ± 
0.01 
1300 ± 
270 
-0.09 ± 
0.02 
2800 ± 
340* 
-0.06 ± 
0.01 
7500 ± 
400** 
-0.07 ± 
0.02 
18 840 ± 94 -0.09 ± 
0.01 
1000 ± 
170 
-0.08 ± 
0.01 
2100 ± 
410** 
-0.06 ± 
0.01++ 
1500 ± 
160* 
-0.18 ± 
0.01++ 
19 48 ± 10 -0.10 ± 
0.02 
38 ± 3 -0.10 ± 
0.01 
91 ± 7** -0.07 ± 
0.01+ 
59 ± 1 -0.22 ± 
0.01++ 
20 180 ± 12 -0.09 ± 
0.01 
260 ± 43* -0.09 ± 
0.01 
170 ± 27 -0.06 ± 
0.01+ 
620 ± 
49** 
-0.20 ± 
0.01++ 
21 35 ± 7 -0.10 ± 
0.01 
26 ± 4 -0.10 ± 
0.01 
32 ± 8 -0.07 ± 
0.01++ 
83 ± 21** -0.22 ± 
0.01++ 
 
 
 
7.3.4 Constitutive activities of hH2R-GsαS, gpH2R-GsαS, rH2R-GsαS, and  
cH2R-GsαS in the GTPase assay 
As was reported for a constitutively activated mutant of the β2AR (Samama et al., 1993), the 
following major hallmarks distinguish constitutively active GPCRs from not (quiescent) or less 
constitutively active GPCRs. First, the efficacies of partial agonists are increased at the more 
constitutively active receptor. To uncover differences in the constitutive activities among 
H2R-GsαS species, efficacies of partial and full agonists 1-16 and inverse agonist efficacies of 
antagonists 17-21 were compared at hH2R-GsαS with gpH2R-GsαS, rH2R-GsαS, and cH2R-GsαS, 
respectively (Figure  7.4 A, C, E). Second, constitutively active receptors exhibit an increased 
affinity for agonists but not antagonists, with the extent of affinity increase being correlated 
with the efficacy of the ligand (Lefkowitz et al., 1993). Essentially, the potencies in the 
GTPase assay represent apparent affinities and can be therefore related, as logEC50 
differences between hH2R-GsαS and the other H2R species isoforms, to the corresponding 
Table  7.2: Potencies and inverse agonist efficacies of antagonists at H2R-GsαS species isoforms in the 
GTPase assay. Reaction mixtures contained Sf9 membranes expressing fusion proteins, 1 µM HA as 
agonist and antagonists at concentrations from 1 nM to 100 µM as appropriate to generate saturated 
competition curves. To determine the inverse agonist efficacies (Inv. Eff.), the effects of antagonists at 
fixed concentrations (10 µM of 18-21; 100 µM of 17) on basal GTPase activity were assessed and 
referred to the stimulatory effect of 100 µM HA (= 1.00). Data shown are the means ± S.D. of three 
experiments performed in duplicates. KB values and inverse agonist efficacies, respectively, of 
antagonists at hH2R-GsαS were compared with the corresponding parameters at gpH2R-GsαS, rH2R-
GsαS, and cH2R-GsαS, respectively, using one-way ANOVA. 
* comparison with the KB value at hH2R-GsαS; * p < 0.05; ** p < 0.01 
+ comparison with Inv. Eff. at hH2R-GsαS; + p < 0.05; ++ p < 0.01 
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efficacies at hH2R-GsαS (Figure  7.4 B, D, F). Finally, at receptors with increased constitutive 
activity inverse agonists have an elevated inhibitory effect on GTP hydrolysis (Seifert et al., 
1998b). 
Similar inverse agonist efficacies of antagonists 17-21 and the absence of selectivity in the 
efficacies of partial agonists 5-7 and 14 indicate equal magnitudes of constitutive activities for 
gpH2R-GsαS and hH2R-GsαS (Figure  7.4 A). As Figure  7.4 B illustrates, a poor but significant 
correlation (r2 = 0.27, p = 0.016) was observed between the log (potency ratio) of these 
species and the efficacies of compounds 1-21 at hH2R-GsαS. However, this correlation was 
determined by ligand-specific interactions, namely the high potencies of guanidines (8-10) 
and NG-acylguanidines (11-16) at gpH2R-GsαS (Kelley et al., 2001; Xie et al., 2006a, b), and 
disappeared if only compounds 1-7 and 17-21 were considered (r2 = 0.04, p = 0.527). The 
efficacies of compounds 1-21 at rH2R-GsαS and hH2R-GsαS were almost identical (Figure  7.4 
C). Moreover, no correlation between the log (potency ratio) and the efficacies at hH2R-GsαS 
was evident (r2 = 0.16, p = 0.077) (Figure  7.4 D). Thus, in the steady-state GTPase assay, 
rH2R-GsαS and hH2R-GsαS exhibited similar levels of constitutive activities. By contrast,  
cH2R-GsαS showed the hallmarks of a GPCR with increased constitutive activity compared to 
hH2R-GsαS. Specifically, partial agonists 5-7 and 14 were considerably more efficacious at 
cH2R-GsαS and the inverse agonist efficacies of antagonists 18-21 were increased compared 
to hH2R-GsαS (Figure  7.4 E). A highly significant correlation between the log (potency ratio) 
and the efficacies of compounds 1-21 at hH2R-GsαS was determined (r2 = 0.77, p < 0.0001, 
Figure  7.4 F). It is noteworthy that this correlation was independent of distinct interactions of 
guanidines and NG-acylguanidines with cH2R-GsαS as omitting compounds 8-16 did not 
change the fit (r2 = 0.75, p = 0.0003). 
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Figure  7.4: Efficacies and potencies of ligands 1-21 at hH2R-GsαS in pairwise comparison with gpH2R-
GsαS, rH2R-GsαS, and cH2R-GsαS, respectively, as determined in the steady-state GTPase assay. A, C, 
E, relation between the efficacies of compounds 1-21 at hH2R-GsαS vs. gpH2R-GsαS (A), rH2R-GsαS (C), 
and cH2R-GsαS (E), respectively. The dashed line has a slope of 1.0 and represents a theoretical curve 
of identical efficacies in both systems. B, D, F, relation between log (potency ratio) of compounds 1-21
at gpH2R-GsαS (B), rH2R-GsαS (D), and cH2R-GsαS (F), respectively, and the corresponding efficacies at 
hH2R-GsαS. The potency ratio is the ratio of EC50 values of full and partial agonists (1-16) at hH2R-GsαS
and at gpH2R-GsαS, rH2R-GsαS, and cH2R-GsαS, respectively. Accordingly, the potency ratio of 
antagonists (17-21) is the ratio of the corresponding KB values at hH2R-GsαS and at gpH2R-GsαS, rH2R-
GsαS, and cH2R-GsαS, respectively. The vertical dashed line intersects the abscissa at 0.0 and 
represents a theoretical curve of identical potencies in both systems. 
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7.3.5 Ambiguous response of metiamide in the GTPase assay 
At hH2R-GsαS, metiamide (22) decreased the basal GTPase signal by 8 ± 1% and thus acted 
as weak inverse agonist (Table  7.1; Figure  7.5). At gpH2R-GsαS and rH2R-GsαS, metiamide 
inhibited the basal GTPase signals by 6 ± 1% and 4 ± 1%, respectively, and was ~2-fold 
more potent than at hH2R-GsαS. Intriguingly, at cH2R-GsαS metiamide did not act as an inverse 
agonist but rather as a very weak partial agonist (efficacy of 6 ± 1%). This is in marked 
contrast to the results of antagonists 18-21 reducing the basal GTPase signal at cH2R-GsαS 
(increased constitutive activity) more effectively than at the other less constitutively active 
species. Furthermore, the potency of 22 was lowered by approximately 15-fold compared to 
hH2R-GsαS and not increased as would have been expected for a partial agonist (Samama et 
al., 1993). Attempts to detect changes in AC activity upon stimulation with metiamide in 
membranes coexpressing cH2R and GsαS failed due to the much lower sensitivity of this 
system compared to the GTPase activity assay using fusion proteins (data not shown). 
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Figure  7.5: Effects of metiamide on GTPase activity in membranes expressing H2R-GsαS species
isoforms. Data are expressed as percentage change in GTPase activity induced by metiamide 
compared to the GTPase activity stimulated by HA (100 µM). Data shown are the means ± S.E.M. of 
three independent experiments performed in duplicates. The significance of the deviation from zero 
was calculated for each mean value using the t-test; * p < 0.05; ** p < 0.01; *** p < 0.001. 
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7.3.6 Regulation of AC activities in membranes expressing fused and non-
fused H2R species isoforms 
AC activity was measured in Sf9 cell membranes expressing H2Rs (coupling to endogenous 
Gsα-like G proteins), in membranes coexpressing H2R and mammalian GsαS, and in 
membranes expressing H2R-GsαS fusion proteins. Basal AC activities were similar in 
membranes expressing hH2R, gpH2R, and rH2R (Table  7.3) and ~2-fold higher in the case of 
the cH2R. GTP (10 µM) by itself increased AC activities at all four H2R species by ~2-fold 
above the basal level. HA (1) further increased, and IAPT (21) inhibited this GTP-dependent 
signal increase, indicative for constitutive activity of all four H2R species isoforms in Sf9 
membranes (Figure  7.6 A-D). These observations are in agreement with previous studies at 
the β2AR (Seifert et al., 1998a). The stimulatory effects of GTP, as determined by relating the 
effects of GTP (10 µM) to the effects of HA (100 µM) plus GTP (10 µM), were largest at cH2R 
and rH2R, compared to hH2R and gpH2R. Both the high basal AC activity and the strong 
stimulation with GTP indicate an elevated level of constitutive activity in membranes 
expressing the cH2R relative to membranes expressing hH2R, gpH2R, and rH2R. Notably, the 
constitutive activity of rH2R seemed to be slightly increased compared to hH2R and gpH2R. 
The GPCR/G protein stoichiometry affects the magnitude of response (Kenakin, 2001). In 
H2R membranes coexpressing mammalian GsαS, 5- to 18-fold increased basal levels of AC 
activity were measured relative to membranes expressing H2R alone (Table  7.3). Basal AC 
activities were ~6-fold higher at cH2R plus GsαS and ~2-fold higher at rH2R plus GsαS, 
respectively, compared to hH2R plus GsαS. With gpH2R plus GsαS, the basal AC activity was 
somewhat lower than with hH2R plus GsαS. As was observed in membranes expressing H2R 
alone, the highest stimulatory effects of GTP in the coexpression system were observed with 
cH2R and rH2R compared to gpH2R and hH2R. The inverse agonist IAPT (10 µM) decreased 
the GTP-dependent increases of AC activity at all species isoforms (Figure  7.6 E-H), but 
even strongly reduced basal AC activities at the lowest concentrations of added GTP. These 
effects were probably due to traces of GDP being converted to GTP by the action of 
nucleoside diphosphate kinase, and were most prominent in membranes expressing cH2R 
plus GsαS (~69% reduction below basal) and rH2R plus GsαS (~59% reduction), compared to 
hH2R plus GsαS (~29% reduction) and gpH2R plus GsαS (~23% reduction). Taken together, 
among H2R species isoforms coexpressed with GsαS, cH2R was the most constitutively active 
GPCR. 
Due to the efficient coupling of the signaling partners in GPCR-Gsα fusion proteins (Seifert et 
al., 1999), in membranes expressing H2R-GsαS, strongly elevated basal AC activities were 
measured, compared to membranes expressing non-fused H2Rs coexpressing GsαS (Table 
7.3).
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 Basal GTP 10 µM GTP 10 µM +  HA 100 µM Rel. GTP Effect 
Construct AC activity (pmol mg-1 min-1) % 
hH2R 0.3 ± 0.0 0.6 ± 0.1 3.4 ± 0.2 10 
gpH2R 0.3 ± 0.1 0.5 ± 0.0 2.6 ± 0.2 9 
rH2R 0.4 ± 0.0 0.8 ± 0.1 3.1 ± 0.2 15 
cH2R 0.7 ± 0.1 1.5 ± 0.2 4.3 ± 0.7 22 
     
hH2R + GsαS 2.3 ± 0.4 6.3 ± 0.8 11.8 ± 0.5 42 
gpH2R + GsαS 1.5 ± 0.3 4.4 ± 0.5 10.8 ± 1.5 31 
rH2R + GsαS 4.9 ± 0.4 11.1 ± 1.3 16.1 ± 0.7 55 
cH2R + GsαS 12.8 ± 1.9 24.7 ± 4.1 31.1 ± 3.7 65 
     
hH2R-GsαS 12.1 ± 2.1 24.3 ± 4.8 28.7 ± 5.3 73 
gpH2R-GsαS 13.4 ± 3.1 25.0 ± 0.6 28.5 ± 2.2 77 
rH2R-GsαS 30.5 ± 2.6 43.5 ± 1.7 44.4 ± 3.0 94 
cH2R-GsαS 26.3 ± 3.6 41.9 ± 5.3 40.9 ± 5.2 107 
 
 
In agreement with the results obtained for membranes expressing non-fused H2Rs, among 
the four species isoforms, cH2R-GsαS and rH2R-GsαS exhibited the highest basal AC activities. 
As shown in Figure  7.6 K-L, GTP increased AC activity in those membranes so effectively 
that HA could not produce a further increase, reflecting exhaustion of the limiting pool of AC 
molecules (Seifert et al., 1998a). At hH2R-GsαS and gpH2R-GsαS, GTP induced only smaller 
increases, allowing HA to further enhance AC activity. By contrast, in the absence of added 
GTP, HA (100 µM) yielded a reduction of basal AC activities at all four species (Figure  7.6 I-
L). Very similar effects were observed previously for the β2AR-GsαS fusion protein (Seifert et 
al., 1998b) and are due to dissociation of GDP from GsαS following agonist binding to the 
receptor without subsequent binding of GTP. Since Gsα-GDP is more effective in activating AC 
than nucleotide-free Gsα, AC activity was reduced below basal. Due to much less efficient 
coupling in membranes coexpressing receptors and GsαS (Seifert et al., 1998a; Houston et 
Table  7.3: AC activities in Sf9 membranes expressing H2R species isoforms without or with GsαS, and 
in Sf9 membranes expressing H2R-GsαS fusion proteins. Basal AC activities and the effects of GTP 
and HA on AC activity were assessed. Reaction mixtures contained Sf9 membranes expressing 20 to 
100 µg protein/tube as appropriate and distilled water (basal), GTP (10 µM), or GTP (10 µM) and HA
(100 µM). Data shown are the means ± S.D. of three to four experiments performed in triplicates. To 
calculate the stimulatory effect of GTP (Rel. GTP Effect), the effect of GTP (10 µM) was referred to the 
effect of GTP (10 µM) plus HA (100 µM). 
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al., 2002; Gille and Seifert, 2003), in this case HA did not reduce basal AC activity (Figure 
7.6 E-H). Similar differences in the coupling efficiencies between fusion proteins and non-
fused expression systems were observed in terms of ternary complex formation, guanosine 
5’-O-(3-thio)triphosphate binding, GTP hydrolysis, and AC activation in the presence of GTP 
(Gille and Seifert, 2003; Seifert et al., 1998a; Wenzel-Seifert et al., 2002). Thus, in mem-
branes expressing H2R-GsαS fusion proteins the apparent constitutive activities were consi-
derably higher than in membranes expressing non-fused H2Rs. In the case of cH2R-GsαS and 
rH2R-GsαS, saturation of AC molecules became manifest upon agonist (HA) stimulation. 
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Figure  7.6: Regulation of AC activities in Sf9 membranes expressing H2R species isoforms (A-D), H2R 
species isoforms plus GsαS (E-H), or H2R-GsαS fusion proteins (I-L). Reaction mixtures contained Sf9 
membranes expressing the proteins indicated on top of each panel and GTP at concentrations 
indicated at the abscissa. Reaction mixtures additionally contained H2O (■), HA (100 µM) (▲), or IAPT 
(10 µM) (▼). Data shown are the means ± S.E.M. of one representative experiment performed in 
duplicates. The statistical analysis of AC activities is provided in Table  7.3.  
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7.4 Discussion 
7.4.1 Increased constitutive activity of the cH2R compared to hH2R, gpH2R, 
and rH2R 
The use of GPCR-Gsα fusion protein in combination with the determination of GTPase activity 
in Sf9 cell membranes was previously shown to be an appropriate system to quantify 
constitutive activity (Seifert et al., 1998b; Seifert and Wenzel-Seifert, 2002). This system fixes 
GPCR/G protein coupling and stays at a proximal level, thus avoiding potential bias caused 
by more downstream effects, such as effector activation or changes in gene expression. 
Moreover, due to the defined 1:1 stoichiometry of receptor and Gsα in fusion proteins, ligand 
potencies and efficacies in the steady-state GTPase assay are independent of the 
expression levels, allowing for the comparison of various membrane preparations with 
different expression levels (Seifert et al., 1999; Milligan, 2000).  
We comprehensively characterized the human, guinea pig, rat, and canine H2R species 
isoforms in steady-state GTPase assays in Sf9 cell membranes expressing H2R-GsαS fusion 
proteins. Structurally diverse H2R full and partial agonists and antagonists unmasked 
considerable differences in the constitutive activities of the receptors. Specifically, cH2R-GsαS 
but neither rH2R-GsαS nor gpH2R-GsαS displayed the hallmarks of increased constitutive 
activity compared with hH2R-GsαS (Samama et al., 1993; Lefkowitz et al., 1993); (i) increased 
efficacies of partial agonists, (ii) increased potencies of agonists with the extent of potency 
increase being correlated with the efficacy, and (iii) increased inverse agonist efficacies and 
decreased potencies of antagonists.  
The determination of AC activity in Sf9 cell membranes is an alternative and sensitive 
method to investigate constitutive activity of GPCRs (Seifert et al., 1998a). With respect to 
AC, differences in the basal activity and in the magnitudes of signal increases upon 
stimulation with GTP are indicators for various levels of constitutive activity. In the AC activity 
assay with membranes expressing non-fused H2R species isoforms either without or together 
with mammalian GsαS, both effects were most pronounced for canine relative to human, 
guinea pig, and rat, corroborating the outstanding role of cH2R in terms of constitutive 
activity. 
However, our analysis of AC activity in membranes expressing H2R species isoforms also 
illustrates the limitations of this system. Most importantly, the low concentration levels of AC 
molecules constrain the maximal signal output, thereby yielding large stimulatory effects of 
GTP and large inhibitory effects of inverse agonists on AC activity. In contrast, the 
stimulatory effects of the agonist HA are small if at all detectable. Additionally, in the case of 
the rH2R, basal AC activities and the increases of AC activity upon stimulation with GTP were 
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moderately higher compared to the hH2R, whereas in the GTPase activity assay rH2R-GsαS 
and hH2R-GsαS showed similar constitutive activities. The accumulation of rH2R in Sf9 cell 
membrane microdomains rich in AC molecules could be an explanation for the observed 
effects (Ostrom and Insel, 2004). 
It is now widely accepted that GPCR activation involves disruption of an ionic lock between 
Asp(3.49) and Arg(3.50) of the highly conserved (E/D)RY motif in TM3 and Glu(6.30) in the 
cytoplasmatic extension of TM6 (Ballesteros et al., 2001; Visiers et al., 2002; Shapiro et al., 
2002). The effects of mutations in the DRY motif on constitutive activity and structural 
instability of the rat H2R were shown previously (Alewijnse et al., 2000). Asp-115(3.49),  
Arg-116(3.50), and Glu-228/229(6.30) are conserved among all H2R species isoforms. 
However, preceding Glu-229(6.30) in hH2R and gpH2R and the corresponding Glu-228(6.30) 
in rH2R, human, guinea pig, and rat H2Rs exhibit an arginine(6.29), compared to a 
glycine(6.29) in cH2R. Strikingly, many class 1 GPCRs contain a basic amino acid at the 
corresponding position, and accordingly, a stabilizing role of this residue in the network of 
ionic interactions was proposed (Ballesteros et al., 2001). According to a dynamic model of 
the hH2R (chapters 4.3.1.2 and 5.3.2.3), the lack of this additional constraint in cH2R could 
facilitate the transition from the inactive to an active state, thus resulting in the observed 
enhancement in constitutive activity. 
Other differences in amino acid sequences could contribute to the differences in constitutive 
activity as well. Specifically, in G649, an allelic variant of the hH2R, Asn-217 in i3 is replaced 
by Asp-217. This mutant displays low basal activity and is resistant to upregulation upon 
antagonist exposure (Fukushima et al., 2001). Intriguingly, Asn-217 is conserved within 
hH2R, gpH2R and rH2R but replaced by a histidine in cH2R. Moreover, major variations in the 
sequences of H2R species isoforms occur in the C-terminal domain. Since the C-terminus of 
H2R is important for Gs protein activation (Smit et al., 1996b), the observed variations in the 
constitutive activities may alternatively or additionally be due to differences in this domain. In 
fact, an influence of the C-terminus on the constitutive activities of various GPCRs was 
described previously (Prezeau et al., 1996; Wenzel-Seifert and Seifert, 2003). 
 
7.4.2 Ligand-specific interactions at H2R species isoforms 
In the GTPase activity assay, N-[3-(1H-imidazol-4-yl)propyl]guanidines and their NG-acylated 
analogs were more potent and more efficacious at gpH2R-GsαS than at hH2R-GsαS which is in 
agreement with previous studies (Kelley et al., 2001; Xie et al., 2006a). Since both species 
isoforms exhibit similar constitutive activities, our present data further support the concept of 
distinct interactions as a rationale for this species-selectivity. As was predicted by molecular 
modelling studies and subsequently verified by site-directed mutagenesis, the species-
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selectivity of guanidine-type agonists is based on two distinct amino acids, Tyr-17(1.31) in 
TM1 and Asp-271(7.36) in TM7 in the gpH2R, presumably interacting via a charge assisted 
H-bond and thereby stabilizing an active agonist-bound conformation (Kelley et al., 2001). In 
the hH2R (Cys-17(1.31), Ala-271(7.36)) and the rH2R (Leu-17(1.31), Gly-270(7.36)) this 
interaction is impossible. Consistently, the guanidine-type agonists were similarly efficacious 
and potent at rH2R-GsαS and hH2R-GsαS. Both cH2R and hH2R contain Cys-17(1.31) and  
Ala-271(7.36) and the differences in potencies and efficacies of the compounds between 
cH2R-GsαS and hH2R-GsαS were not specific to the guanidines. Thus, these differences can be 
explained by the increased constitutive activity of cH2R-GsαS rather than by distinct 
ligand/GPCR interactions. 
Recently, certain NG-acylated guanidines have shown to be more efficacious than HA at 
gpH2R-GsαS in the GTPase assay (Xie et al., 2006b), similar to the observations made with 
UR-PG222A (13) in the present study. These effects can be attributed to the concept of 
ligand-specific gpH2R conformations as well, i.e. these compounds stabilize active gpH2R 
conformations that lead to more efficient interactions with GsαS than achieved with the 
endogenous ligand HA. By analogy, at the β2AR labeled with a fluorescent probe, the 
synthetic ligand isoproterenol induced a stronger change in fluorescence intensity than the 
endogenous ligand norepinephrine (Swaminath et al., 2004). 
A further example of ligand-specific interactions at H2R species isoforms is given by 
metiamide, acting as a weak partial agonist with low potency at cH2R-GsαS in the GTPase 
assay compared to being an inverse agonist with increased potency at human, guinea pig, 
and rat H2R-GsαS. Moreover, in contrast to increased inverse agonist efficacies of antagonists 
18-21 at cH2R-GsαS relative to hH2R-GsαS, gpH2R-GsαS, and rH2R-GsαS, the inverse agonist 
efficacies of cimetidine (17), a cyanoguanidine analog of metiamide, were similar at all four 
species whereas its potency was significantly decreased at cH2R-GsαS. Presumably because 
of the common 2[(5-methylimidazol-4-yl)methylthio]ethyl moiety, both metiamide and 
cimetidine stabilize distinct conformations in cH2R relative to the other species isoforms, thus 
leading to an altered interaction with GsαS, which, in the extreme case of metiamide, causes 
weak partial agonism rather than increased inverse agonism. 
 
7.4.3 Conclusion 
In the present study we demonstrate that the cH2R exhibits increased constitutive activity 
compared to hH2R, gpH2R, and rH2R. Species-specific differences in constitutive activity 
were previously reported for the cholecystokinin-B/gastrin receptor that, like the H2R, 
stimulates gastric H+ production (Kopin et al., 2000). Thus, differences in constitutive 
activities of GPCRs regulating H+ production may reflect species-specific requirements for 
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“basal” and peak H+ secretion in the stomach. For example, following stimulation with HA, 
gastric acid secretion rates in dogs exceed those of the human (Kararli, 1995). Moreover, by 
studying the H2R antagonist metiamide, further evidence for ligand-specific conformations of 
H2R species isoforms was obtained. The present study validates the notion that quantitative 
comparison of species isoforms of GPCRs provides unique insight into the molecular 
mechanisms of GPCR activation and ligand/GPCR interactions. 
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Point Mutations of Cys-17 and Ala-271 in the 
Human Histamine H2 Receptor 
 
 
8.1 Introduction 
The histamine H2 receptor (H2R) is a biogenic amine receptor that belongs to the class 1 of 
the family of GPCRs. Following stimulation by histamine (HA, 1, Figure  8.1) the H2R couples 
to Gs proteins to activate adenylyl cyclase (AC). H2Rs mediate regulation of gastric acid 
secretion in parietal cells, cardiac contractility, and myeloid cell differentiation (Del Valle and 
Gantz, 1997). 
N-[3-(1H-Imidazol-4-yl)propyl]guanidines are the most potent agonists at the H2R known so 
far (up to 400 times more active than HA at the guinea pig right atrium) and possibly useful 
as positive inotropic drugs for the treatment of severe congestive heart failure, as agents 
inducing cell differentiation in acute myelogenous leukemia, and as anti-inflammatory drugs 
(Dove et al., 2004). Guanidines are less potent and efficient agonists at the H2R of human 
neutrophils than at the H2R of the guinea pig right atrium (Burde et al., 1989, 1990). In a 
membrane steady-state GTPase activity assay with fusion proteins of H2R and the short 
splice variant of Gsα, GsαS, these compounds are considerably more potent and efficacious at 
gpH2R-GsαS than at hH2R-GsαS (Kelley et al., 2001). Recently, a novel class of NG-acylated 
imidazolylpropylguanidines was developed (Ghorai, 2005). The introduction of an electron-
withdrawing carbonyl group adjacent to the guanidine moiety reduces the basicity of the 
compounds (pKa ca. 8). This structural modification does not change the species-selectivity 
between hH2R-GsαS and gpH2R-GsαS (Xie et al., 2006a).  
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By contrast, HA and the small H2R agonists dimaprit (2, DIM) and amthamine (3, AMT) do 
not exhibit species-selectivity.  
A three-dimensional homology model of the gpH2R suggested that the nonconserved  
Asp-271(7.36) in transmembrane domain (TM) 7 confers high potency to the guanidines 
which was subsequently confirmed by an Ala-271(7.36)→Asp-271(7.36) mutation in  
hH2R-GsαS (hH2R-A271D-GsαS) (Kelley et al., 2001). However, the efficacies of guanidines at 
this mutant and at hH2R/gpH2R chimeras were lower than at gpH2R, demonstrating that 
guanidine efficacy depends on additional or other interactions. As a rationale, an interhelical 
H-bond between Tyr-17(1.31) in TM1 and Asp-271(7.36) was predicted from the model, 
stabilizing an active guanidine-bound conformation only in gpH2R but not in hH2R (containing 
Cys-17(1.31) and Ala-271(7.36)) (Kelley et al., 2001). 
To test this hypothesis, we generated an hH2R-GsαS mutant with a Cys-17(1.31)→ 
Tyr-17(1.31) exchange and a double mutant with Cys-17(1.31)→Tyr-17(1.31) and  
Figure  8.1: Structures of H2R agonists and inverse agonists. 1-3, small H2R agonists; 4, H1R agonist 
with partial agonism at the H2R; 5-7, guanidine-type H2R agonists; 8-12, NG-acylated N-[3-(1H-
imidazol-4-yl)propyl]guanidines with agonistic H2R activity; 13, (R)-N-[3-(2-amino-4-methylthiazol-5-
yl)propyl]-N’-(3-phenylbutanoyl)guanidine, an H2R agonist; and 14-18, H2R inverse agonists. 
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Ala-271(7.36)→Asp-271(7.36) exchanges in the sequence of hH2R. Sf9 cell membranes 
expressing mutant and wild-type H2R-GsαS were used to measure steady-state GTPase 
activity as this system was previously shown to be reliable and very sensitive to analyze 
ligand potencies and efficacies (Seifert et al., 1999; Milligan, 2000). Due to the defined 1:1 
stoichiometry of receptor and Gsα in fusion proteins, ligand potencies and efficacies in the 
steady-state GTPase assay are independent of the expression levels, allowing for the 
comparison of various membrane preparations with different expression levels. We also 
assessed AC activity in Sf9 membranes as a sensitive readout to compare distinct levels of 
constitutive activity of mutant and wild-type H2R-GsαS fusion proteins. Figure  8.1 shows the 
structures of H2R agonists examined in the present study. Impromidine (IMP, 5), arpromidine 
(ARP, 6), and BU-E-43 (7) are representatives of N-[3-(1H-imidazol-4-yl)propyl]guanidines. 
Their NG-acylated derivatives contain diverse diarylpropanoyl (9, 11), 3-(hetero)arylbutanoyl 
(8, 10), and 3-(cyclohexylbutanoyl) (12) groups. Compound 13 contains a 2-amino-4-
methylthiazol-5-yl group and exhibits enhanced selectivity relative to the H3R (Ghorai, 2005). 
Compounds 10 and 13 are the pure (R)-enantiomers. In addition, the inverse agonists 
cimetidine (CIM, 14), ranitidine (RAN, 15), famotidine (FAM, 16), aminopotentidine (APT, 17), 
and iodoaminopotentidine (IAPT, 18) were studied (Hill et al., 1997; Dove et al., 2004). 
 
 
8.2 Materials and Methods 
8.2.1 Materials 
The generation of pGEM-3Z-SF-hH2R-GsαS, pGEM-3Z-SF-hH2R-A271D-GsαS, and pVL1392-
SF-hH2R-GsαS was described previously (Kelley et al., 2001). The generation of the 
baculoviruses encoding hH2R-GsαS and gpH2R-GsαS was described previously (Kelley et al., 
2001; Houston et al., 2002). A description of the preparation of all remaining materials is 
given in chapter 6.1. 
 
8.2.2 Construction of the cDNA for hH2R-C17Y-GsαS 
The Cys-17(1.31)→Tyr-17(1.31) exchange in hH2R was generated by sequential overlap-
extension PCRs. With pGEM-3Z-SF-hH2R-GsαS as template, PCR 1A was used to amplify a 
DNA fragment consisting of the cleavable signal peptide from influenza hemagglutinin (S), 
the FLAG epitope (F) recognized by the M1 monoclonal antibody, and the N-terminal portion 
of the hH2R. The sense primer annealed with 18 bp of pGEM-3Z prior to the 5’-end of SF. 
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The antisense primer encoded the sequence GATCTTATATGCGGTAGAGTCTAGAC-
AAAAGGAAGAGGCTG to generate the Cys-17(1.31)→Tyr-17(1.31) exchange and a new 
Xba I site (TCTAGA). In PCR 1B, the DNA sequence of the hH2R, a hexahistidine tag, and 
the entire sequence of GsαS was amplified using pGEM-3Z-SF-hH2R-GsαS as template. The 
sense primer encoded the sequence CTTTTGTCTAGACTCTACCGCATATAAGAT-
CACCATCACCG to generate the Cys-17(1.31)→Tyr-17(1.31) exchange and the new Xba I 
site. The antisense primer annealed with the cDNA encoding the 5 C-terminal amino acids of 
GsαS, the stop codon, and an Xba I site. In PCR 2, the products of PCR 1A and 1B annealed 
in the region encoding the newly created Cys-17(1.31)→Tyr-17(1.31) exchange and the new 
Xba I site. Here, the sense primer of PCR 1A and the antisense primer of PCR 1B were 
used. In that way, the complete cDNA for the hH2R-C17Y-GsαS fusion protein was amplified. 
The product of PCR 2 was digested with Sac I and Kpn I and cloned into pGEM-3Z-SF-
hH2R-GsαS digested with Sac I and Kpn I. pGEM-3Z-SF-hH2R-C17Y-GsαS was digested with 
Sac I and EcoN I and cloned into the baculovirus transfer vector pVL1392-SF-hH2R-GsαS 
digested with Sac I and EcoN I. PCR-generated DNA sequences were confirmed by 
extensive restriction enzyme analysis and enzymatic sequencing. 
 
8.2.3 Construction of the cDNA for hH2R-C17Y-A271D-GsαS 
To generate the DNA for fusion proteins with two amino acid exchanges Cys-17(1.31)→ 
Tyr-17(1.31) and Ala-271(7.36)→Asp-271(7.36), pGEM-3Z-SF-hH2R-A271D-GsαS was 
digested with Kpn I and Bgl II and cloned into pGEM-3Z-SF-hH2R-C17Y-GsαS digested with 
Kpn I and Bgl II. pGEM-3Z-SF-hH2R-C17Y-A271D-GsαS was digested with Nco I and Bgl II 
and cloned into the baculovirus transfer vector pVL1392-SF-hH2R-GsαS digested with Nco I 
and Bgl II. 
 
8.2.4 Reverse transcription 
mRNA was extracted from Sf9 cells expressing recombinant proteins using the RNeasy Kit 
(Qiagen, Hilden, Germany). Corresponding cDNA was generated by reverse transcription 
using MMLV reverse transcriptase (Invitrogen, Carlsbad, CA). In a subsequent PCR a sense 
primer annealing with 29 bp of the 5’-end of hH2R and an antisense primer annealing with 15 
bp of the 3’-end of GsαS were used to generate double-stranded DNA of the full-length fusion 
proteins. 
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8.2.5 Generation of recombinant baculoviruses, cell culture, and membrane 
preparation 
A description is given in chapter 6.2. 
 
8.2.6 SDS-PAGE and immunoblot analysis 
A description is given in chapter 6.3. 
 
8.2.7 Steady-state GTPase activity assay 
A description is given in chapter 6.4. 
 
8.2.8 AC activity assay 
A description is given in chapter 6.5. 
 
8.3 Results 
8.3.1 Immunological detection of recombinant proteins in Sf9 cell membranes 
In Sf9 cells hH2R-C17Y-GsαS and hH2R-C17Y-A271D-GsαS were well expressed (Figure  8.2 
A, B). Monomeric non-fused H2R expressed in Sf9 cells migrates as a ~33 kDa band in SDS-
PAGE (Fukushima et al., 1997; Houston et al., 2002), and the apparent molecular mass of 
GsαS is ~45 kDa (Graziano et al., 1989). SDS-PAGE analysis of membranes expressing 
hH2R-C17Y-A271D-GsαS yielded intense bands at ~80 kDa, recognized by both the anti-
FLAG and the anti-6His antibodies, that coincide with the expected apparent molecular 
masses of H2R-GsαS monomers (Kelley et al., 2001; Houston et al., 2002). Both bands 
appeared somewhat diffuse, representing different glycosylation forms of the proteins. With 
the anti-6His antibody, an additional doublet band was detected at ~45 kDa not recognized 
by the anti-FLAG antibody which is presumably due to a lack of epitope exposure. By 
contrast, SDS-PAGE of membranes expressing hH2R-C17Y-GsαS yielded strong and diffuse 
bands at ~40 kDa and lacked the expected bands at ~80 kDa. These bands could either 
represent atypically migrating glycosylated forms of H2R-GsαS monomers or degraded 
proteins. Since the anti-FLAG Ig recognizes the N-terminus and the anti-6His Ig the C-
terminus of the H2R, it can be concluded that for either case the complete amino acid 
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sequence of hH2R-C17Y was expressed. Additional diffuse bands at ~110 kDa may 
correspond to GPCR dimers or higher oligomers and were also observed in wild-type hH2R-
GsαS fusion proteins (Kelley et al., 2001). Comparison with the peak intensities of calibrated 
Sf9 membranes expressing the β2AR at 7.5 pmol mg-1 (as determined by 
[3H]dihydroalprenolol saturation binding) revealed approximately similar expression levels of 
~2 pmol mg-1 for hH2R-C17Y-GsαS and hH2R-C17Y-A271D-GsαS. 
 
 
 
 
 
 
 
 
8.3.2 Analysis of the mRNA in Sf9 membranes expressing hH2R-C17Y-GsαS 
and hH2R-C17Y-A271D-GsαS 
Reverse transcriptase PCR of isolated mRNA and subsequent amplification of the 
corresponding cDNA yielded DNA sequences that displayed the expected bands of 2240 bp 
for the full-length fusion proteins of both receptor mutants after separation in agarose gel 
electrophoresis (Figure  8.3 A, lane 2 and 4). Restriction digestion with EcoR V and Xba I 
yielded the specific fragments of 1341 bp and 862 bp for hH2R-C17Y-GsαS (Figure  8.3 A, B; 
lane 1) and 1341 bp and 780 bp for hH2R-C17Y-A271D-GsαS (Figure  8.3 A, B; lane 3), 
verifying the existence of the desired point mutations. The 1341 bp bands in lanes 1 and 3 
migrated slightly differently in the two gels for unknown reason. In lane 3, the expected band 
at 82 bp was not detectable. 
Figure  8.2: Immunological detection of recombinant proteins in Sf9 cells. Sf9 membranes expressing 
various proteins were prepared, separated by SDS-PAGE on gels containing 12% (w/v) acrylamide, 
transferred onto Immobilon P membranes, and probed with the respective Ig indicated on top of each 
panel. In each lane, 10 µg of membrane protein was loaded onto the gel. Numbers on the left of 
membranes designate masses of marker proteins in kDa. 
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8.3.3 Efficacies and potencies of agonists at hH2R-GsαS, gpH2R-GsαS, 
hH2R-C17Y-GsαS, and hH2R-C17Y-A271D-GsαS 
The basal GTPase activity of the hH2R-GsαS amounted to 0.66 ± 0.09 pmol mg-1 min-1 (n = 
10). Compared to it, the data were similar in membranes expressing gpH2R-GsαS (0.69 ± 0.19 
pmol mg-1 min-1; n = 8), and hH2R-C17Y-GsαS (0.78 ± 0.10 pmol mg-1 min-1; n = 9), 
respectively, but significantly increased at hH2R-C17Y-A271D-GsαS (1.67 ± 0.38 pmol mg-1 
min-1; n = 9; p < 0.01). At the fusion proteins of both wild-type receptors and at hH2R-C17Y-
A271D-GsαS, stimulation with 100 µM HA yielded GTPase activities 400 to 600% of the basal 
levels. By contrast, at hH2R-C17Y-GsαS maximum HA GTPase activities amounted to just 
140% of the basal signal, thereby yielding lower signal-to-noise ratios for the analysis of 
agonists (Figure  8.4). 
Figure  8.3: Analysis of the mRNA in Sf9 cells expressing hH2R-C17Y-GsαS (lanes 1 and 2) and hH2R-
C17Y-A271D-GsαS (lanes 3 and 4). Lanes 1 and 3, digestion with EcoR V and Xba I; lanes 2 and 4, 
undigested DNA fragment. The DNA fragments were separated on gels containing 1% (A) or 2% (B) 
agarose. M, DNA marker. 
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Efficacies and potencies of compounds 1-13 are summarized in Table  8.1. The efficacies of 
the small agonists DIM (2) and AMT (3) were similar at hH2R-GsαS and hH2R-C17Y-GsαS, and 
slightly increased at gpH2R-GsαS and hH2R-C17Y-A271D-GsαS. HA (1) was ~3-fold more 
potent at hH2R-C17Y-GsαS and hH2R-C17Y-A271D-GsαS than at hH2R-GsαS and gpH2R-GsαS 
(Figure  8.4). The potencies of 2 and 3 were similar at hH2R-C17Y-GsαS and the wild-type 
receptors but were increased at hH2R-C17Y-A271D-GsαS. The H1R-selective agonist 
suprahistaprodifen (4) (Seifert et al., 2003) acted as a partial agonist with similar efficacies 
and potencies at hH2R-GsαS, gpH2R-GsαS, and hH2R-C17Y-A271D-GsαS and with increased 
efficacy and potency at hH2R-C17Y-GsαS. 
In agreement with previous studies (Kelley et al., 2001, Xie et al., 2006a, b), N-[3-(1H-
imidazol-4-yl)propyl]guanidines 5-7 and most of their NG-acylated derivatives 8-13 were more 
efficacious and more potent at gpH2R-GsαS than at hH2R-GsαS. Except for IMP (5) being more 
efficacious at hH2R-C17Y-A271D-GsαS, the efficacies of 5-7 were not significantly changed at 
both receptor mutants if compared with wild-type hH2R-GsαS. The differences in the efficacies 
of the NG-acylated imidazolylpropylguanidines (8-13) between hH2R-C17Y-GsαS and hH2R-
GsαS were not significant. 
Figure  8.4: Concentration-dependent increase of GTPase activity by HA in membranes expressing
hH2R-GsαS (■), gpH2R-GsαS (▼), hH2R-C17Y-GsαS (●), and hH2R-C17Y-A271D-GsαS (▲). GTPase 
activity in Sf9 membranes was determined as described in chapter 6.4. Reaction mixtures contained 
membranes (10 µg of protein/tube) expressing fusion proteins and HA at concentrations indicated on 
the abscissa. Data shown are the means ± S.E.M. of three independent experiments performed in 
duplicates. Data were analyzed by nonlinear regression and were best fitted to sigmoidal 
concentration/response curves. 
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 hH2R-GsαS gpH2R-GsαS hH2R-C17Y-GsαS 
hH2R-C17Y-A271D-
GsαS 
Cpd. EMaxa EC50 (nM) EMaxa EC50 (nM) EMaxa EC50 (nM) EMaxa EC50 (nM) 
1 1.00 990 ± 92 1.00 850 ± 340 1.00 260 ± 
110+++ 
1.00 320 ± 9+++ 
2 0.85 ± 
0.02 
910 ± 430 0.94 ± 
0.06* 
740 ± 360 0.92 ± 
0.14 
670 ± 420 0.98 ± 
0.01*** 
370 ± 36+ 
3 0.91 ± 
0.02 
190 ± 50 1.04 ± 
0.01** 
190 ± 42 0.86 ± 
0.19 
120 ± 20 0.97 ± 
0.01** 
65 ± 6+ 
4 0.54 ± 
0.08 
240 ± 41 0.43 ± 
0.02 
310 ± 62 0.79 ± 
0.12* 
120 ± 52+ 0.61 ± 
0.02 
320 ± 11+ 
5 0.82 ± 
0.02 
160 ± 40 0.96 ± 
0.06* 
18 ± 9++ 0.73 ± 
0.16 
43 ± 9++ 0.95 ± 
0.02** 
37 ± 5+ 
6 0.84 ± 
0.03 
72 ± 9 0.94 ± 
0.05* 
7 ± 1+++ 0.78 ± 
0.15 
68 ± 26 0.87 ± 
0.02 
39 ± 4++ 
7 0.71 ± 
0.11 
130 ± 13 0.87 ± 
0.05 
43 ± 10+++ 0.52 ± 
0.16 
30 ± 22++ 0.73 ± 
0.01 
150 ± 6+ 
8 0.91 ± 
0.08 
130 ± 45 0.94 ± 
0.05 
25 ± 10++ 1.14 ± 
0.30 
57 ± 33+ 0.92 ± 
0.09 
44 ± 13+ 
9 0.80 ± 
0.04 
120 ± 45 0.94 ± 
0.05* 
14 ± 4++ 0.72 ± 
0.17 
68 ± 35 0.83 ± 
0.04 
46 ± 21 
10 0.90 ± 
0.04 
18 ± 6 1.18 ± 
0.08** 
5 ± 1+ 1.11 ± 
0.22 
9 ± 3+ 1.01 ± 
0.04** 
13 ± 5 
11 0.82 ± 
0.05 
100 ± 9 1.02 ± 
0.11* 
29 ± 10+++ 0.62 ± 
0.18 
200 ± 33++ 0.92 ± 
0.04* 
66 ± 5++ 
12 0.86 ± 
0.05 
15 ± 4 0.97 ± 
0.18 
14 ± 6 0.83 ± 
0.16 
27 ± 9 0.78 ± 
0.03 
21 ± 10 
13 0.55 ± 
0.06 
49 ± 9 0.82 ± 
0.02*** 
12 ± ++ 0.58 ± 
0.25 
74 ± 118 0.68 ± 
0.06 
29 ± 16 
 
 
 
 
Whereas mutation into Tyr-17(1.31) did not change the potency of ARP, the NG-acylated 
analog 11 was less potent at hH2R-C17Y-GsαS than at hH2R-GsαS. By contrast, 11 but not 
ARP was more efficacious and both were more potent at hH2R-C17Y-A271D-GsαS than at 
wild-type hH2R-GsαS. Compounds 8 and 9 share a 2-thiazolyl moiety and were more potent at 
both receptor mutants compared to hH2R-GsαS although for compound 9 the difference was 
a Efficacy relative to HA ( = 1.00) 
* comparison with the efficacy at hH2R-GsαS; * p < 0.05; ** p < 0.01; *** p < 0.001 
+ comparison with the EC50 value at hH2R-GsαS; + p < 0.05; ++ p < 0.01; +++ p < 0.001 
Table  8.1: Agonist efficacies (EMax) and potencies at hH2R-GsαS, gpH2R-GsαS, hH2R-C17Y-GsαS, and 
hH2R-C17Y-A271D-GsαS in the GTPase assay. GTPase activity in Sf9 membranes was determined as 
described in chapter 6.4. Data shown are the means ± S.D. of three to six experiments performed in 
duplicates or triplicates. Efficacies and potencies, respectively, of ligands at hH2R-GsαS were compared 
with the corresponding parameters at gpH2R-GsαS, hH2R-C17Y-GsαS, and hH2R-C17Y-A271D-GsαS, 
respectively, using the t-test. 
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not significant. When the 2-thiazolyl group was replaced by a cyclohexyl group (12) the 
selectivity for the mutants was lost. Compound 10 was more potent at hH2R-C17Y-GsαS than 
at hH2R-GsαS. Taken together, the small H2R agonists 1-3 were considerably more potent at 
hH2R-C17Y-A271D-GsαS than at the wild-type human and guinea pig H2R-GsαS. Some 
guanidines and NG-acylated guanidines displayed enhanced potencies at the mutant 
receptor compared to hH2R-GsαS. However, these compounds were all less potent at hH2R-
C17Y-A271D-GsαS than at gpH2R-GsαS, and the efficacies varied between the corresponding 
values at both wild-type receptors. 
 
8.3.4 Potencies and inverse agonist efficacies of antagonists at hH2R-GsαS, 
gpH2R-GsαS, hH2R-C17Y-GsαS, and hH2R-C17Y-A271D-GsαS 
At wild-type and mutant H2R-GsαS, CIM (14), RAN (15), FAM (16), APT (17), and IAPT (18) 
decreased GTPase activities below basal and thus acted as inverse agonists (Table  8.2). All 
compounds exhibited similar inverse agonist efficacies at hH2R-C17Y-GsαS and at both wild-
type receptors. By contrast, at hH2R-C17Y-A271D-GsαS inverse agonist efficacies of 14-18 
were significantly increased. Because inverse agonists stabilize an inactive receptor 
conformation (Milligan et al., 1995), the differences in inverse agonist efficacies reflect an 
increased level of constitutive activity of hH2R-C17Y-A271D-GsαS relative to wild-type 
receptors. The magnitudes of constitutive activity measured critically depend on the relative 
stoichiometry of GPCR and G-protein in the system (Kenakin, 2001). Physical tethering of 
H2R with GsαS in the fusion proteins used provides a fixed 1:1 stoichiometry of both partners, 
allowing for a direct comparison of the efficacies in an expression-independent manner 
(Milligan, 2000). 16 and 18 were slightly more potent at hH2R-C17Y-A271D-GsαS than at the 
wild-type receptors, whereas no significant differences in the KB values were observed for 14, 
15, and 17. By comparison, 15-18 were more potent at hH2R-C17Y-GsαS than at hH2R-GsαS 
and gpH2R-GsαS. 
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 hH2R-GsαS gpH2R-GsαS hH2R-C17Y-GsαS 
hH2R-C17Y-
A271D-GsαS 
Cpd. KB (nM) Inv. Eff. KB (nM) Inv. Eff. KB (nM) Inv. Eff. KB (nM) Inv. Eff. 
14 1700 ±  
430 
-0.08 ±  
0.01 
1300 ±  
270 
-0.09 ±  
0.02 
2000 ±  
1900 
-0.08 ±  
0.13 
1400 ±  
19 
-0.25 ±  
0.04++ 
15 840 ±  
94 
-0.09 ±  
0.01 
1000 ±  
170 
-0.08 ±  
0.01 
140 ±  
73*** 
-0.09 ±  
0.08 
1000 ±  
64 
-0.21 ±  
0.05++ 
16 48 ±  
10 
-0.10 ±  
0.02 
38 ±  
3 
-0.10 ±  
0.01 
22 ±  
1** 
-0.12 ±  
0.09 
29 ±  
2* 
-0.27 ±  
0.06++ 
17 180 ±  
12 
-0.09 ±  
0.01 
260 ±  
43* 
-0.09 ±  
0.01 
65 ±  
61* 
-0.10 ±  
0.08 
200 ±  
31 
-0.26 ±  
0.05++ 
18 35 ±  
7 
-0.10 ±  
0.01 
26 ±  
4 
-0.10 ±  
0.01 
7 ±  
3** 
-0.11 ±  
0.04 
12 ±  
2** 
-0.27 ±  
0.05+++ 
 
 
 
8.3.5 Regulation of AC activities in membranes expressing hH2R-GsαS,  
gpH2R-GsαS, hH2R-C17Y-GsαS, and hH2R-C17Y-A271D-GsαS 
AC activities were measured in Sf9 membranes expressing hH2R-C17Y-GsαS and hH2R-
C17Y-A271D-GsαS, and they were compared with results at wild-type human and guinea pig 
H2R-GsαS (Table  8.3). hH2R-GsαS and gpH2R-GsαS were similarly expressed in Sf9 cells (at ~3 
and 1 pmol mg-1, respectively) and produced similar basal AC activities. By contrast, basal 
AC activities were increased ~3-fold at hH2R-C17Y-A271D-GsαS. At both mutant and both 
wild-type receptors, GTP (10 µM) by itself increased AC activities above the basal level 
(Figure  8.5), indicating constitutive activity of these receptors (Seifert et al., 1998a, b; Gille 
and Seifert, 2003). Accordingly, at all four H2Rs, the inverse agonist IAPT (18) reduced this 
GTP-dependent AC activity. At hH2R-GsαS and gpH2R-GsαS, AC activity increases by 10 µM 
GTP achieved 73% and 77%, respectively, of the signal increases by  
* comparison with the KB value at hH2R-GsαS; * p < 0.05; ** p < 0.01; *** p < 0.001 
+ comparison with Inv. Eff. at hH2R-GsαS; + p < 0.05; ++ p < 0.01; +++ p < 0.001 
Table  8.2: Potencies and inverse agonist efficacies of antagonists at hH2R-GsαS, gpH2R-GsαS, hH2R-
C17Y-GsαS, and hH2R-C17Y-A271D-GsαS in the GTPase assay. Reaction mixtures contained Sf9 
membranes expressing fusion proteins, 1 µM HA as agonist and antagonists at concentrations from 
1 nM to 1 mM as appropriate to generate saturated competition curves. To determine the inverse 
agonist efficacies (Inv. Eff.), the effects of antagonists at fixed concentrations (10 µM of cpds. 15 to 18; 
100 µM of cpd. 14) on basal GTPase activity were assessed and referred to the stimulatory effect of 
100 µM HA (= 1.00). Data shown are the means ± S.D. of three experiments performed in duplicates. 
KB values and inverse agonist efficacies, respectively, of antagonists at hH2R-GsαS were compared 
with the corresponding parameters at gpH2R-GsαS, hH2R-C17Y-GsαS, and hH2R-C17Y-A271D-GsαS, 
respectively, using the t-test. 
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Basal GTP (10 µM) GTP (10 µM) + 
HA (100 µM) 
Rel. GTP  
Effect 
Construct AC activity (pmol mg-1 min-1) % 
hH2R-GsαS 12.1 ± 2.1 24.3 ± 4.8 28.7 ± 5.3 73 
gpH2R-GsαS 13.4 ± 3.1 25.0 ± 0.6 28.5 ± 2.2 77 
hH2R-C17Y-GsαS 0.8 ± 0.2 2.4 ± 0.4 7.0 ± 0.8 26 
hH2R-C17Y-A271D-GsαS 42.5 ± 2.2 66.9 ± 4.2 66.4 ± 3.3 100 
 
 
10 µM GTP plus 100 µM HA. Strikingly, at hH2R-C17Y-A271D-GsαS, HA did not further 
enhance the GTP effect. Both higher basal AC activity and a strong stimulation by GTP 
caused exhaustion of the limiting pool of AC molecules in Sf9 cells and reflect an increased 
level of constitutive activity of hH2R-C17Y-A271D-GsαS, compared to the wild-type fusion 
proteins. Similar reduced agonist-responsiveness due to high constitutive activity was shown 
for other aminergic GPCRs, e.g. β2AR-Gsα fusion proteins (Seifert et al., 1998a) and mutants 
of the 5-HT4 receptor (Claeysen et al., 1999). At hH2R-C17Y-GsαS much lower basal AC 
activities and a much smaller stimulatory effect of GTP were determined. In this case, GTP 
on its own caused only 26% of the effect with HA addition.  
At hH2R-GsαS, gpH2R-GsαS, and hH2R-C17Y-A271D-GsαS, HA (100 µM) reduced the basal AC 
activities in the absence of added GTP (Figure  8.5 A-C). Similar effects were observed at 
β2AR-GsαS fusion proteins (Seifert et al., 1998b) and are due to dissociation of GDP from GsαS 
following agonist binding to the receptor without subsequent binding of GTP. Gsα-GDP is more 
effective in activating AC than nucleotide-free Gsα, and therefore AC activities were 
decreased. 
 
Table  8.3: AC activities in Sf9 membranes expressing hH2R-GsαS, gpH2R-GsαS, hH2R-C17Y-GsαS, and 
hH2R-C17Y-A271D-GsαS. Reaction mixtures contained Sf9 membranes (20 µg protein/tube) 
expressing fusion proteins and distilled water (basal), GTP (10 µM), or GTP (10 µM) plus HA 
(100 µM). Data shown are the means ± S.D. of three experiments performed in triplicates. To calculate 
the stimulatory effect of GTP (Rel. GTP Effect), the effect of GTP (10 µM) was referred to the effect of 
GTP (10 µM) plus HA (100 µM). 
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8.4 Discussion 
8.4.1 Impaired coupling in membranes expressing hH2R-C17Y-GsαS 
In Sf9 cells expressing hH2R-C17Y-GsαS the increases of GTPase activity upon agonist 
stimulation were much lower than in the wild-type H2R-GsαS species. Moreover, the basal AC 
activities and the stimulatory effects of GTP on AC activity were largely reduced and were 
similar to the values typical for Sf9 membranes expressing non-fused H2R species (Houston 
et al., 2002). However, in the GTPase assay potencies and efficacies of agonists and inverse 
Figure  8.5: Regulation of AC activities in Sf9 membranes expressing hH2R-GsαS (A), gpH2R-GsαS (B), 
hH2R-C17Y-A271D-GsαS (C), and hH2R-C17Y-GsαS (D). Reaction mixtures contained Sf9 membranes 
expressing the proteins indicated on top of each panel and GTP at concentrations indicated at the 
abscissa. Reaction mixtures additionally contained H2O (■), HA (100 µM) (▲), or IAPT (10 µM) (▼). 
Data shown are the means ± S.E.M. of one representative experiment performed in triplicates. The 
statistical analysis of AC activities is provided in Table  8.3. Please note the different scale of the 
ordinate in D. 
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agonists were similar or even increased, compared to hH2R-GsαS and gpH2R-GsαS, indicating 
functionality of hH2R-C17Y. This is corroborated by substantial stimulatory effects of HA and 
inhibitory effects of IAPT on the GTP-dependent AC activity increases. Strikingly, the anti-
FLAG and the anti-6His antibodies recognized similarly migrating diffuse proteins in SDS-
PAGE which verifies the existence of the full-length amino acid sequence of hH2R-C17Y. It 
can therefore be concluded that in membranes expressing hH2R-C17Y-GsαS the coupling of 
hH2R-C17Y to GsαS was much less efficient than is characteristic for GPCR-Gsα fusion 
proteins (Gille and Seifert, 2003; Seifert et al., 1999). As a rationale, GsαS could be incorrectly 
expressed or degraded in Sf9 cells. Instead, hH2R-C17Y possibly coupled to endogenous 
Gsα-like G-proteins with much lower efficiency.  
However, several findings argue against degradation or proteolysis of GsαS in hH2R-C17Y-
GsαS. First, basal GTPase activities were not reduced relative to hH2R-GsαS and gpH2R-GsαS 
as would have been expected for membranes expressing non-fused H2Rs without or with 
recombinant GsαS, according to studies with Sf9 membranes expressing non-fused β2ARs or 
β2AR-Gsα fusion proteins (Seifert et al., 1998a). Second, although being lower than at 
H2R-GsαS, GTPase activity increases with the mutant fusion protein upon agonist stimulation 
were ~2-fold higher than in membranes expressing non-fused hH2R (Houston et al., 2002). 
Third, the immunoreactive bands observed at ~40 kDa did not coincide with the expected 
bands for monomeric H2Rs at ~33 kDa (Fukushima et al., 1997), and additional bands at 
~110 kDa may correspond to H2R-GsαS dimers or oligomers (Kelley et al., 2001). Notably, the 
use of GPCR-Gsα fusion proteins expressed in Sf9 cells is a well established pharmacological 
method and proteolysis has not been observed so far (Milligan, 2000; Seifert and Wenzel-
Seifert, 2002).  
Considering that only a fraction of mutant receptors may be fused with GsαS or a deficiency of 
functional G proteins in Sf9 cells, the potencies (apparent affinities) of agonists and inverse 
agonists may increase (receptor reserve). This could explain the mostly higher potencies of 
agonists and inverse agonists at hH2R-C17Y-GsαS relative to wild-type hH2R-GsαS, since the 
large distance between Tyr-17(1.31) and the putative binding site of the gpH2R renders a 
direct interaction with ligands unlikely. 
 
8.4.2 Increased constitutive activity in membranes expressing  
hH2R-C17Y-A271D-GsαS 
In membranes expressing hH2R-C17Y-A271D-GsαS high efficiency coupling was observed as 
GTPase activities were increased upon agonist stimulation similar to hH2R-GsαS and  
gpH2R-GsαS. Moreover, with this receptor mutant enhanced basal GTPase activities, 
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increased potencies of the agonists, as well as increased inverse agonist efficacies of 
antagonists were detected, representing the hallmarks of enhanced constitutive activity 
compared to the wild-type proteins (Lefkowitz et al., 1993). The determination of AC activity 
in Sf9 cell membranes has previously shown to be an alternative and sensitive system to 
quantify differences in the constitutive activities of GPCRs (Seifert et al., 1998a). In 
membranes expressing hH2R-C17Y-A271D-GsαS the high basal AC activities and the strong 
AC activity increases upon stimulation with GTP additionally reflect high constitutive activity 
compared to hH2R-GsαS, gpH2R-GsαS, and hH2R-C17Y-GsαS. 
The discovery of increased constitutive activity at hH2R-C17Y-A271D-GsαS further supports 
the concept of an H-bond between Tyr-17(1.31) in TM1 and Asp-271(7.36) in TM7 (Kelley et 
al., 2001) as basis for the distinct pharmacological properties of human and guinea pig H2Rs. 
Our data suggest that this interhelical interaction stabilizes an active receptor conformation 
not only when agonists are bound but also when ligands are absent. However, gpH2R-GsαS 
containing Tyr-17(1.31) and Asp-271(7.36) also was similarly constitutively active as hH2R-
GsαS which is presumably due to additional intramolecular interactions constraining the 
gpH2R in an inactive conformation and thereby compensating for the activating function of 
both residues. 
Of interest, the tertiary structure of the α1b-adrenergic receptor (α1b-AR) contains 
Lys-331(7.36) in TM7 corresponding to Ala-271(7.36) in hH2R. Strikingly, α1b-AR mutants 
with Lys-331(7.36) exchanged by alanine or glutamate were more constitutively active than 
wild-type α1b-AR (Porter et al., 1996), suggesting a general role of an amino acid at this 
position for the activation mechanism of related GPCRs. 
 
8.4.3 Species-selectivity of guanidines and NG-acylguanidines at wild-type and 
mutant H2R-GsαS 
The main intention of this study was to elucidate the impact of Cys-17(1.31)/Tyr-17(1.31) and 
Ala-271(7.36)/Asp-271(7.36) on the species-selectivity of N-[3-(1H-imidazol-4-
yl)propyl]guanidines and NG-acylated imidazolypropylguanidines between hH2R and gpH2R. 
In our GTPase activity experiments some of these agonists were more potent and more 
efficacious at hH2R-C17Y-A271D-GsαS than at hH2R-GsαS, and some compounds were not 
selective. Overall, the potencies and efficacies of the agonists were still higher at gpH2R-GsαS 
than at hH2R-C17Y-A271D-GsαS. The following conclusions can be drawn from these results.  
First, both Tyr-17(1.31) and Asp-271(7.36) contribute to the enhanced potencies and 
efficacies of guanidines and NG-acylguanidines at the gpH2R. This investigation adds to a 
previous study at an hH2R-A271D-GsαS mutant conferring high potency to guanidines without 
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affecting the efficacies (Kelley et al., 2001). However, the pharmacological differences 
between hH2R-C17Y-A271D-GsαS and gpH2R-GsαS indicate that more than these two amino 
acids determine the species-selectivity of agonists and will have to be identified in further 
mutagenesis studies (chapter 9). 
Second, the concept of ligand-specific conformations (Kenakin, 2003) in H2R species (Kelley 
et al., 2001; Xie et al., 2006a) is further supported. The variable side chains of the 
compounds distinctly interact with wild-type and mutant H2R-GsαS which is represented by 
compounds 8 and 9 containing a 2-thiazolyl group and being more potent  
at hH2R-C17Y-A271D-GsαS than at hH2R-GsαS in contrast to compound 10 with a cyclohexyl 
group being similarly potent at both proteins. The 5-methyl-1H-imidazol-4-yl group in IMP (5) 
presumably directly interacts with Asp-271(7.36) (Kelley et al., 2001) thus yielding the high 
potency increase of ~4-fold at hH2R-C17Y-A271D-GsαS vs. hH2R-GsαS.  
GPCRs with enhanced constitutive activity exhibit an increased affinity for agonists with the 
affinity increase being correlated with the efficacy of the ligand (Samama et al., 1993). 
Accordingly, the parameter of constitutive activity not only affects elevated potencies of small 
H2R agonists at hH2R-C17Y-A271D-GsαS but also potency increases of the guanidines and 
NG-acylguanidines. Different magnitudes of constitutive activity therefore add to the 
complexity of the system for the analysis of species-selective ligand/GPCR interactions. 
Moreover, inverse agonists are less potent at constitutively active than at quiescent GPCRs 
(Kenakin, 2001). Accordingly, 14-18 were expected to be less potent at the more 
constitutively active hH2R-C17Y-A271D-GsαS than at hH2R-GsαS. However, the potencies of 
inverse agonists were not decreased, and 16 and 18 were even more potent at the mutant 
receptor, assuming that not only guanidine-type agonists but also inverse agonists could 
stabilize ligand-specific conformations in H2R species isoforms. 
 
8.4.4 Conclusion 
In the present study we demonstrate that an hH2R-GsαS fusion protein with mutations of  
Cys-17(1.31)→Tyr-17(1.31) in TM1 and Ala-271(7.36)→Asp-271(7.36) in TM7 displayed 
enhanced constitutive activity compared to hH2R-GsαS and gpH2R-GsαS. We additionally 
showed that an interaction between Tyr-17(1.31) and Asp-271(7.36) in gpH2R contributes to 
the species-selective action of N-[3-(1H-imidazol-4-yl)propyl]guanidines and their NG-
acylated derivatives. Distinct potencies and efficacies of agonists and inverse agonists 
further support the concept of ligand-specific conformations in wild-type and mutant H2R-GsαS 
fusion proteins. A single point mutation of Cys-17(1.31)→Tyr-17(1.31) was devoid of efficient 
GPCR-G-protein coupling. By analogy, point mutations of Phe-153→Leu-153 or 
Ile-433→Val-433 in the hH1R (hH1R→gpH1R) resulted in functional inactivity, whereas a 
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Phe-153→Leu-153/Ile-433→Val-433 double mutant was functionally active (Seifert et al., 
2003). The reasons for the annihilating effects of the single point mutations at hH1R and 
hH2R are not known, but they illustrate the limitations of site-directed mutagenesis 
experiments. The characterization of closely related wild-type GPCR species isoforms is, 
therefore, an important alternative approach to relate distinct pharmacological properties to 
relatively few molecular determinants. 
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Point Mutations in the Second Extracellular 
Loops of Human and Guinea Pig Histamine H2 
Receptors 
 
 
9.1 Introduction 
The histamine H2 receptor (H2R) is a biogenic amine receptor that belongs to the class 1 
(rhodopsin-like) of G protein coupled receptors (GPCRs) (Foord et al., 2005). GPCRs 
represent the largest class of cell surface receptors and are predicted to share a common 
molecular structure consisting of seven α-helical transmembrane domains (TM1-TM7) 
connected by three intracellular and three extracellular loops (Kristiansen, 2004). Many 
aminergic class 1 GPCRs are predicted to bind endogenous small molecule ligands via a 
cavity formed by TM3 to TM7 (Shi and Javitch, 2002). The crystal structure of bovine 
rhodopsin (Palczewski et al., 2000) suggests that in addition to amino acids within the TM 
domains residues in the second extracellular loop (e2) contact the endogenous ligand retinal. 
Due to the considerable homology with rhodopsin, a participation of e2 residues to the 
binding pocket was proposed for members of class 1 GPCRs, too (Shi and Javitch, 2002). To 
date, experimental evidence for a contribution of e2 on ligand binding has been provided for 
the dopamine D2 receptor (Shi and Javitch, 2004), the adenosine A2a receptor (Kim et al., 
1996), and the M3 muscarinic acetylcholine receptor (Scarselli et al., 2007). 
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The endogenous H2R ligand histamine (1, HA; Figure  9.1) and related small agonists 
dimaprit (2, DIM) and amthamine (3, AMT) similarly interact with the binding site of the H2R. 
The amino group of HA forms an ionic interaction with Asp-98(3.32) in TM3 (Gantz et al., 
1992), and the imidazolyl ring presumably interacts with Tyr-182(5.38) and Asp-186(5.42) in 
TM5 (Nederkoorn et al., 1996). The guanidine-type H2R agonists impromidine (4, IMP), 
arpromidine (5, ARP), and the NG-acylated derivatives 6-9 share a common N-[3-(1H-
imidazol-4-yl)propyl]guanidine moiety that mimics binding of HA and thus is crucial for 
agonistic activity (Dove et al., 2004). The variable side chains of compounds 4-9 are 
supposed to interact with a pocket formed by multiple residues in TM2, TM3, TM6, and TM7 
(chapter 4.3.2.1). Strikingly, N-[3-(1H-imidazol-4-yl)propyl]guanidines and NG-acylguanidines 
but not the small H2R agonists are considerably more potent and efficacious at fusion 
proteins of the guinea pig H2R coupled to the short splice variant of Gsα, GsαS, (gpH2R-GsαS) 
than at the human isoforms (hH2R-GsαS). Tyr-17(1.31) in TM1 and Asp-271(7.36) in TM7 of 
gpH2R (Cys-17(1.31) and Ala-271(7.36) in hH2R) have been shown to contribute to this spe-
cies-selectivity (chapter 8). However, the results from this study also suggest participation of 
additional as yet unidentified residues as molecular basis for the selective agonist activities. 
Figure  9.1: Structures of H2R agonists. 1-3, small H2R agonists; 4-5, H2R agonistic N-[3-(1H-imidazol-
4-yl)propyl]guanidines; 6-9, H2R agonistic NG-acylated N-[3-(1H-imidazol-4-yl)propyl]guanidines. 
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The e2 sequences of hH2R and gpH2R comprise 23 amino acids varying at four positions, 
Gly-167/Asp-167, His-169/Asp-169, Thr-171/Ile-171, and Ser-172/Val-172 (hH2R/gpH2R) 
(Figure  9.2). The aim of this study was to elucidate the role of these differences for the 
species-selectivity of guanidines and NG-acylguanidines. We therefore generated a mutant 
hH2R-GsαS fusion protein with Gly-167→Asp-167, His-169→Asp-169, Thr-171→Ile-171, and 
Ser-172→Val-172 exchanges (hH2R-gpE2-GsαS) and a reverse mutant gpH2R-GsαS with the 
corresponding Asp-167→Gly-167, Asp-169→His-169, Ile-171→Thr-171, and Val-172→Ser-
172 mutations (gpH2R-hE2-GsαS). 
 
 
 
 
Similar to rhodopsin, a highly conserved disulfide bond between two cysteines in e2 and TM3 
was proposed to constrain the spatial orientation of the distal portion of e2 in close proximity 
to the putative binding site of class 1 GPCRs (Shi and Javitch, 2002). In a three-dimensional 
homology model of the hH2R, adjacent to Cys-174 (forming a disulfide bond with 
Cys-91(3.25) in TM3), Lys-173 and Lys-175 are predicted to face UR-PG136 (cpd. 6) (Figure 
 9.3). To elucidate the putative role of both residues for interactions with H2R agonists, we 
generated two hH2R-GsαS fusion proteins with single point mutations of Lys-173→Ala-173 
(hH2R-K173A-GsαS) and Lys-175→Ala-175 (hH2R-K175A-GsαS). Sf9 cell membranes 
expressing mutant and wild-type H2R-GsαS were used to measure steady-state GTPase 
activity as this system was previously shown to be reliable and very sensitive to analyze 
ligand potencies and efficacies independently of the expression levels (Seifert et al., 1999; 
Milligan, 2000). 
 
 
 
 
 
 
Figure  9.2: Comparison of the e2 sequences of hH2R and gpH2R. Amino acid sequences of hH2R 
(Gantz et al., 1991) and gpH2R (Traiffort et al., 1995) are given in the one-letter code. Dots in the 
sequence of gpH2R indicate identity with hH2R. Numbers below the sequences indicate residues that 
were mutated in the present study. 
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9.2 Materials and Methods 
9.2.1 Materials 
The generation of pGEM-3Z-SF-hH2R-GsαS, pGEM-3Z-SF-gpH2R-GsαS, and pVL1392-SF-
hH2R-GsαS was described previously (Kelley et al., 2001). The generation of the 
baculoviruses encoding hH2R-GsαS and gpH2R-GsαS was described previously (Kelley et al., 
2001; Houston et al., 2002). A description of all remaining materials is given in chapter 6.1. 
 
9.2.2 Construction of the cDNA for gpH2R-hE2-GsαS 
The point mutations in the sequence of the gpH2R were generated by sequential overlap-
Figure  9.3: Side-view of a 3D model of the hH2R in complex with UR-PG136. The model was 
generated as described in chapter 4.2. The putative agonist binding site and the extracellular 
components of the hH2R are shown. UR-PG136 is shown as space-filling representation. e2 is shown 
as a thick line. Residues differing in the e2 sequences of hH2R and gpH2R are shown in orange. 
Adjacent to the highly conserved Cys-174 (yellow) forming a disulfide bond to Cys-91(3.25), Lys-173 
and Lys-175 (both magenta) are predicted to face the binding pocket and were mutated into alanine 
within this study. Asp-98(3.32), Tyr-182(5.38), and Asp-186(5.42) designate the main interaction sites 
of agonists with the H2R. 
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extension PCRs. With pGEM-3Z-SF-gpH2R-GsαS as template, PCR 1A was used to amplify a 
DNA fragment consisting of the cleavable signal peptide from influenza hemagglutinin (S), 
the FLAG epitope (F) recognized by the M1 monoclonal antibody, and the N-terminal part of 
the gpH2R. The sense primer annealed with 18 bp of pGEM-3Z prior to the 5’-end of SF. The 
antisense primer encoded the sequence CTTACTAGTGGTATGATTGCCCT-
TGCTGGTCTCATTCC to generate the amino acid exchanges Asp-167→Gly-167, 
Asp-169→His-169, Ile-171→Thr-171, and Val-172→Ser-172, and a new Spe I site 
(ACTAGT). In PCR 1B, the DNA sequence for the C-terminal part of gpH2R, a hexahistidine 
tag, and the entire sequence of GsαS was amplified using pGEM-3Z-SF-gpH2R-GsαS as 
template. The hexahistidine tag was included to allow future purification and to provide 
additional protection against proteolysis (Seifert et al., 1998). The sense primer encoded the 
sequence GGCAATCATACCACTAGTAAGTGCAAAGTCCAGGTC to generate the amino 
acid exchanges Asp-167→Gly-167, Asp-169→His-169, Ile-171→Thr-171, and 
Val-172→Ser-172, and the new Spe I site. The antisense primer annealed with the cDNA 
encoding the 5 C-terminal amino acids of GsαS, the stop codon, and an Xba I site. In PCR 2, 
the products of PCR 1A and 1B annealed in the region of the newly created point mutations 
and the new Spe I site. Here, the sense primer of PCR 1A and the antisense primer of PCR 
1B were used. In that way, the complete cDNA for the gpH2R-hE2-GsαS fusion protein was 
amplified. The product of PCR 2 was digested with Nco I and Xba I and cloned into pGEM-
3Z-SF-hH2R-GsαS digested with Nco I and Xba I. pGEM-3Z-SF-gpH2R-hE2-GsαS was digested 
with Nco I and EcoR I and cloned into the baculovirus transfer vector pVL1392-SF-hH2R-GsαS 
digested with Nco I and EcoR I. PCR-generated DNA sequences were confirmed by 
extensive restriction enzyme analysis and enzymatic sequencing. 
 
9.2.3 Construction of the cDNA for hH2R-gpE2-GsαS 
The strategy for the generation of the cDNA for the epitope-tagged hH2R-gpE2-GsαS was 
analogous to the strategy for the generation of the cDNA for gpH2R-hE2-GsαS. With pGEM-
3Z-SF-hH2R-GsαS as template, PCR 1A was used to amplify a DNA fragment encoding SF 
and the N-terminal part of the hH2R. The sense primer annealed with 18 bp of pGEM-3Z prior 
to the 5’-end of SF. The antisense primer encoded the sequence 
CTTAACGATCGTATCATTATCCTTGCTGGTCTCGTTCC to generate the amino acid 
exchanges Gly-167→Asp-167, His-169→Asp-169, Thr-171→Ile-171, and Ser-172→Val-172, 
and a new Pvu I site (CGATCG). In PCR 1B, the DNA sequence for the C-terminal part of 
hH2R, the hexahistidine tag, and the entire sequence of GsαS was amplified using pGEM-3Z-
SF-hH2R-GsαS as template. The sense primer encoded the sequence 
GATAATGATACGATCGTTAAGTGCAAAGTCCAGGTC to generate the amino acid 
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exchanges Gly-167→Asp-167, His-169→Asp-169, Thr-171→Ile-171, and Ser-172→Val-172, 
and the new Pvu I site. The antisense primer annealed with the cDNA encoding the 5 C-
terminal amino acids of GsαS, the stop codon, and an Xba I site. In PCR 2, the products of 
PCR 1A and 1B annealed in the region of the newly created point mutations and the new 
Pvu I site. Here, the sense primer of PCR 1A and the antisense primer of PCR 1B were 
used. In that way, the complete cDNA for the hH2R-gpE2-GsαS was amplified. The product of 
PCR 2 was digested with Nco I and Xba I and cloned into pGEM-3Z-SF-hH2R-GsαS digested 
with Nco I and Xba I. pGEM-3Z-SF-hH2R-gpE2-GsαS was digested with Nco I and EcoR I and 
cloned into the baculovirus transfer vector pVL1392-SF-hH2R-GsαS digested with Nco I and 
EcoR I. 
 
9.2.4 Construction of the cDNA for hH2R-K173A-GsαS 
With pGEM-3Z-SF-hH2R-GsαS as template, PCR 1A was used to amplify a DNA fragment 
encoding SF and the N-terminal part of the hH2R. The sense primer annealed with 18 bp of 
pGEM-3Z prior to the 5’-end of SF. The antisense primer encoded the sequence 
CTTTGCACGCACTAGTGGTATGATTGCCCTTGC to generate the Lys-173→Ala-173 
exchange and a new Spe I site. In PCR 1B, the DNA sequence for the C-terminal part of 
hH2R, the hexahistidine tag, and the entire sequence of GsαS was amplified using pGEM-3Z-
SF-hH2R-GsαS as template. The sense primer encoded the sequence 
CATACCACTAGTGCGTGCAAAGTCCAGGTCAATG to generate the Lys-173→Ala-173 
exchange and the new Spe I site. The antisense primer annealed with the cDNA encoding 
the 5 C-terminal amino acids of GsαS, the stop codon, and an Xba I site. In PCR 2, the 
products of PCR 1A and 1B annealed in the region of the newly created Lys-173→Ala-173 
exchange and the new Spe I site. The product of PCR 2 was digested with Nco I and Xba I 
and cloned into pGEM-3Z-SF-hH2R-GsαS digested with Nco I and Xba I. pGEM-3Z-SF-hH2R-
K173A-GsαS was digested with Nco I and EcoR I and cloned into the baculovirus transfer 
vector pVL1392-SF-hH2R-GsαS digested with Nco I and EcoR I. 
 
9.2.5 Construction of the cDNA for hH2R-K175A-GsαS 
With pGEM-3Z-SF-hH2R-GsαS as template, PCR 1A was used to amplify a DNA fragment 
encoding SF and the N-terminal part of the hH2R. The sense primer annealed with 18 bp of 
pGEM-3Z prior to the 5’-end of SF. The antisense primer encoded the sequence 
CTTCGTTAACCTGGACTGCGCACTTAGAGGTGGTATG to generate the Lys-175→Ala-175 
exchange and a new Hpa I site (GTTAAC). In PCR 1B, the DNA sequence for the C-terminal 
part of hH2R, the hexahistidine tag, and the entire sequence of GsαS was amplified using 
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pGEM-3Z-SF-hH2R-GsαS as template. The sense primer encoded the sequence 
GTGCGCAGTCCAGGTTAACGAAGTGTACGGGCTGGTG to generate the Lys-175→ 
Ala-175 exchange and the new Hpa I site. The antisense primer annealed with the cDNA 
encoding the 5 C-terminal amino acids of GsαS, the stop codon, and an Xba I site. In PCR 2, 
the products of PCR 1A and 1B annealed in the region of the newly created Lys-175→ 
Ala-175 exchange and the new Hpa I site. The product of PCR 2 was digested with Nco I 
and Xba I and cloned into pGEM-3Z-SF-hH2R-GsαS digested with Nco I and Xba I. pGEM-3Z-
SF-hH2R-K175A-GsαS was digested with Nco I and EcoR I and cloned into the baculovirus 
transfer vector pVL1392-SF-hH2R-GsαS digested with Nco I and EcoR I. 
 
9.2.6 Generation of recombinant baculoviruses, cell culture, and membrane 
preparation 
A description is given in chapter 6.2. 
 
9.2.7 SDS-PAGE and immunoblot analysis 
A description is given in chapter 6.3. 
 
9.2.8 Steady-state GTPase activity assay 
A description is given in chapter 6.4. 
 
 
9.3 Results 
9.3.1 Immunological detection of recombinant proteins in Sf9 cell membranes 
In Sf9 cells, hH2R-GsαS, gpH2R-GsαS, gpH2R-hE2-GsαS, hH2R-gpE2-GsαS, hH2R-K173A-GsαS, 
and hH2R-K175A-GsαS were well expressed (Figure  9.4). In SDS-PAGE, monomeric H2Rs 
migrate as ~33 kDa (Fukushima et al., 1997) and GsαS as ~45 kDa bands (Graziano et al., 
1989). With all fusion proteins, strong bands were detected at ~80 kDa thus representing 
fusion protein monomers. The bands appeared somewhat diffuse presumably due to 
differently glycosylated forms of fusion proteins. Comparison with the peak intensities of 
calibrated Sf9 membranes expressing the β2AR at 7.5 pmol mg-1 (as determined by 
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[3H]dihydroalprenolol saturation binding) revealed expression levels of ~3 pmol mg-1 for 
hH2R-GsαS, ~4 pmol mg-1 for hH2R-K175-GsαS, and ~1 pmol mg-1 for gpH2R-GsαS, gpH2R-hE2-
GsαS, hH2R-K173-GsαS, and hH2R-gpE2-GsαS, respectively. 
 
 
 
 
 
9.3.2 GTPase activities in Sf9 membranes expressing wild-type and mutant 
H2R-GsαS 
The basal GTPase activities were approximately similar in Sf9 membranes expressing both 
wild-type and all mutant H2R-GsαS fusion proteins. At wild-type hH2R-GsαS, stimulation with 
100 µM HA yielded GTPase activities approximately 450% of the basal levels (Figure  9.5 A). 
The maximum HA-stimulated GTPase activities were slightly reduced at hH2R-gpE2-GsαS and 
strongly reduced at hH2R-K173A-GsαS and hH2R-K175A-GsαS. By contrast, HA stimulation 
was similar at gpH2R-GsαS and gpH2R-hE2-GsαS (Figure  9.5 B). Apparently, these values 
were independent of the different expression levels in Sf9 cells (chapter 9.3.1). 
 
Figure  9.4: Immunological detection of recombinant proteins in Sf9 cells. Sf9 membranes expressing 
various proteins were prepared, separated by SDS-PAGE on gels containing 12% (w/v) acrylamide, 
transferred onto Immobilon P membranes, and probed with the anti FLAG (M1) antibody. In each lane, 
10 µg of membrane protein was loaded onto the gel. Exceptionally, 40 µg of a membrane expressing 
gpH2R-GsαS was loaded onto the gel. Numbers on the left of membranes designate masses of marker 
proteins in kDa. 
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Efficacies and potencies of compounds 1-9 at wild-type hH2R-GsαS and at hH2R-gpE2-GsαS, 
hH2R-K173A-GsαS, and hH2R-K175A-GsαS are listed in Table  9.1. In Table  9.2, the 
corresponding values at gpH2R-GsαS and gpH2R-hE2-GsαS are shown. The small agonists HA 
(1), DIM (2), and AMT (3) were similarly efficacious and potent at hH2R-GsαS, hH2R-gpE2-
GsαS, and hH2R-K173A-GsαS. Whereas HA (1) and DIM (2) were less potent at hH2R-K175A-
GsαS than at hH2R-GsαS, the potencies of AMT (3) did not differ between both proteins. DIM 
(2) and AMT (3) were similarly efficacious at hH2R-K175A-GsαS and at hH2R-GsαS. The 
majority of guanidines (4, 5) and NG-acylguanidines (6-9) was similarly efficacious and potent 
at hH2R-gpE2-GsαS, hH2R-K173A-GsαS, and hH2R-K175A-GsαS, respectively, compared to the 
human wild-type receptor. However, IMP (4) was 2.5-fold (not significant) more and ARP (5) 
and compound 9 slightly less potent at hH2R-K175A-GsαS than at hH2R-GsαS. The potency of 
compound 7 was somewhat higher at hH2R-gpE2-GsαS vs. hH2R-GsαS. In agreement with 
previous studies, guanidines and NG-acylguanidines were more potent and more efficacious 
at gpH2R-GsαS than at hH2R-GsαS (Kelley et al., 2001; Xie et al., 2006a, b). Most of the 
agonists tended to be less potent at gpH2R-hE2-GsαS than at gpH2R-GsαS but these 
differences were only significant for ARP (5). All compounds studied were similarly 
efficacious at gpH2R-hE2-GsαS and gpH2R-GsαS. 
Figure  9.5: Concentration-dependent increase of GTPase activity by HA in membranes expressing
wild-type and mutant H2R-GsαS fusion proteins. A, hH2R-GsαS (■), hH2R-gpE2-GsαS (●), hH2R-K173A-
GsαS (◊), hH2R-K175-GsαS (□); B, gpH2R-GsαS (▼), gpH2R-hE2-GsαS (▲). GTPase activity in Sf9 
membranes was determined as described in chapter 6.4. Reaction mixtures contained membranes 
(10 µg of protein/tube) expressing fusion proteins and HA at concentrations indicated on the abscissa. 
Data shown are the means ± S.E.M. of three independent experiments performed in duplicates or 
triplicates.  
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 hH2R-GsαS hH2R-gpE2-GsαS hH2R-K173A-GsαS hH2R-K175A-GsαS 
Cpd. EMaxa EC50 (nM) EMaxa EC50 (nM) EMaxa EC50 (nM) EMaxa EC50 (nM) 
1 1.00 990 ± 92 1.00 700 ± 190 1.00 990 ± 430 1.00 2400 ± 
870* 
2 0.85 ± 
0.02 
910 ± 430 0.88 ± 
0.04 
1000 ± 230 0.86 ± 
0.04 
1200 ± 240 0.91 ± 
0.05 
2600 ± 
1500* 
3 0.91 ± 
0.02 
190 ± 50 0.94 ± 
0.05 
140 ± 30 0.89 ± 
0.01 
130 ± 14 0.94 ± 
0.04 
180 ± 36 
4 0.82 ± 
0.02 
160 ± 42 0.83 ± 
0.06 
140 ± 65 0.85 ± 
0.05 
130 ± 67 0.95 ± 
0.08 
63 ± 10 
5 0.84 ± 
0.03 
72 ± 9 0.88 ± 
0.08 
77 ± 4 0.85 ± 
0.03 
69 ± 7 0.84 ± 
0.04 
87 ± 8* 
6 0.82 ± 
0.05 
100 ± 8 0.76 ± 
0.08 
89 ± 7 0.82 ± 
0.02 
88 ± 25 0.91 ± 
0.09 
150 ± 81 
7 0.14 ± 
0.03 
250 ± 13 0.09 ± 
0.03 
110 ± 52* 0.14 ± 
0.02 
150 ± 68 0.22 ± 
0.06 
270 ± 41 
8 0.80 ± 
0.04 
120 ± 45 0.74 ± 
0.03 
96 ± 32 0.81 ± 
0.02 
120 ± 49 0.85 ± 
0.07 
150 ± 61 
9 0.86 ± 
0.05 
15 ± 4 0.76 ± 
0.13 
12 ± 3 0.85 ± 
0.07 
17 ± 8 0.98 ± 
0.10 
27 ± 6* 
 
 
 
 gpH2R-GsαS gpH2R-hE2-GsαS 
Cpd. EMaxa EC50 (nM) EMaxa EC50 (nM) 
1 1.00 850 ± 340 1.00 1400 ± 280 
2 0.94 ± 0.06 740 ± 360 0.96 ± 0.04 1500 ± 480 
3 1.04 ± 0.01 190 ± 42 0.94 ± 0.06 310 ± 110 
4 0.96 ± 0.06 18 ± 9 0.98 ± 0.02 41 ± 19 
5 0.94 ± 0.05 7 ± 1 0.97 ± 0.03 18 ± 3** 
6 1.02 ± 0.11 29 ± 10 1.02 ± 0.10 27 ± 2 
7 0.40 ± 0.02 220 ± 22 0.37 ± 0.07 250 ± 79 
8 0.94 ± 0.05 14 ± 4 1.00 ± 0.05 26 ± 10 
9 0.97 ± 0.18 14 ± 6 0.97 ± 0.08 15 ± 1 
 
Table  9.1: Agonist efficacies (EMax) and potencies at hH2R-GsαS, hH2R-gpE2-GsαS, hH2R-K173A -GsαS, 
and hH2R-K175A-GsαS in the GTPase assay. GTPase activity in Sf9 membranes was determined as 
described in chapter 6.4. Data shown are the means ± S.D. of three to five experiments performed in 
duplicates or triplicates. Efficacies and potencies, respectively, of ligands at hH2R-GsαS were compared 
with the corresponding parameters at hH2R-gpE2-GsαS, hH2R-K173A-GsαS, and hH2R-K175A-GsαS, 
respectively, using one-way ANOVA. 
Table  9.2: Agonist efficacies (EMax) and potencies at gpH2R-GsαS and gpH2R-hE2-GsαS in the GTPase  
a Efficacy relative to HA ( = 1.00) 
* comparison with the EC50 value at hH2R-GsαS; * p < 0.05
assay. Please consider the 
legend of Table  9.1 for 
experimental conditions. 
Efficacies and potencies, 
respectively, of ligands at
gpH2R-GsαS were compared 
with the corresponding 
parameters at gpH2R-hE2-
GsαS, using the t-test. 
a Efficacy relative to HA ( = 1.00) 
* comparison with the EC50 value at hH2R-GsαS; ** p < 0.01 
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9.4 Discussion 
Several reports showed that e2 contributes to the ligand-specificity in aminergic and 
nucleoside-binding GPCRs. For example, a single residue in e2 was sufficient to interconvert 
ketanserin specificity between canine and human 5-HT1D receptors (Wurch and Pauwels, 
2000). Additionally, three adjacent residues in e2 were identified to be responsible for α1-
adrenergic receptor subtype-selective antagonist binding (Zhao et al., 1996). Moreover, the 
distal eleven amino acids of the e2 determined the selectivity of agonist and antagonist 
binding to A1/A3 adenosine receptors (Olah et al., 1994). 
In the steady-state GTPase activity assay, efficacies and potencies of the small H2R agonists 
HA, DIM, AMT, and the more bulky N-[3-(1H-imidazol-4-yl)propyl]guanidines and NG-
acylated derivatives did neither significantly differ between hH2R-gpE2-GsαS and hH2R-GsαS, 
nor between gpH2R-hE2-GsαS and gpH2R-GsαS. From this follows that selective interactions of 
guanidine-type agonists with human and guinea pig H2R species isoforms are not 
determined by the specific e2 loop sequences differing in the four non-conservative 
exchange positions 167, 169, 171 and 172. Presumably, residues at these positions do not 
directly face the agonist binding pockets of hH2R and gpH2R. At the most, the slightly 
reduced potencies of the small agonists and the non-NG-acylated guanidines at  
gpH2R-hE2-GsαS vs. gpH2R-GsαS may be due to minor conformational modifications of the 
gpH2R binding pocket. 
The high-resolution structure of bovine rhodopsin revealed that e2 folds down into the 
transmembrane domain and forms part of the ligand binding surface for retinal (Palczewski et 
al., 2000). Characteristically, a disulfide bond in rhodopsin between Cys-187 in e2 and Cys-
110 in TM3 is highly conserved among class 1 GPCRs. The obvious suggestion that the 
structure of e2 in the region around the conserved cysteine is similar in rhodopsin and 
aminergic receptors was supported by SCAM (substituted-cysteine accessibility method) 
studies at the dopamine D2 receptor (Shi and Javitch, 2004). Additionally, the M3 muscarinic 
acetylcholine receptor (Scarselli et al., 2007), the adenosine A2a receptor (Kim et al., 1996), 
the α1A and α1B adrenoceptors (Zhao et al., 1996), and the 5-HT1D receptor (Wurch and 
Pauwels, 2000) contain residues in the corresponding regions of e2 that directly participate in 
the binding of ligands. Adjacent to Cys-174 in e2 forming a disulfide bond with Cys-91(3.25) 
in TM3, the hH2R contains Lys-173 and Lys-175. In hH2R-GsαS, substitution of Lys-173 by 
alanine did not affect the efficacies and potencies of small and bulky agonists in the GTPase 
assay. The role of Lys-175 in the hH2R-GsαS is ambiguous since alanine mutation significantly 
reduced the potencies of HA, DIM, ARP, and UR-AK57, but slightly increased the potency of 
IMP. These results clearly demonstrate the non-existence of electrostatic interactions 
between the amine group of Lys-173 and Lys-175, respectively, with the agonists. However, 
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the homology model of the hH2R proposes Lys-175 to be in close proximity to the small 
agonist binding pocket including TM3 and TM5 (see Figure  9.3). Corresponding weak 
interactions may occur that could be partly counterbalanced by entropic effects. Moreover, it 
cannot be ruled out that alanine by itself maintains some interaction potential.  
At hH2R-K173A-GsαS and hH2R-K175A-GsαS, the HA-stimulated increases in GTPase activity 
were strongly reduced compared to hH2R-GsαS. Thus, with both mutant receptors agonist-
bound active conformations are stabilized that activate GsαS less efficiently than the 
corresponding activated wild-type hH2R. Possibly, the two lysines in e2 undergo distinct ionic 
or H-bonding interactions in the active state whose disruption impairs the coupling to GsαS. 
 
Taken together, in the present study we show that the second extracellular loop does not 
contribute to the species-selective interactions of N-[3-(1H-imidazol-4-yl)propyl]guanidines 
and NG-acylated derivatives with human and guinea pig H2R species isoforms, thereby 
broadening our understanding of the molecular basis for this pharmacological phenomenon. 
The six mutated amino acids presumably do not directly face the H2R binding pocket of 
guanidine-type agonists, indicating that participation of residues in the distal part of e2 to the 
binding pocket may apply for many (Shi and Javitch, 2002) but possibly not for all class 1 
GPCRs. Despite the constraining function of the conserved disulfide bond between two 
cysteines in e2 and TM3, the loop regions are much more flexible than the backbone of the 
TM domains. It is therefore generally difficult to state precise predictions about backbone 
structures and side chain conformations of loop regions in 3D structural models which 
emphasizes the need for supplementing molecular pharmacological studies. 
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Summary 
 
 
The histamine H2 receptor (H2R) is a biogenic amine receptor that belongs to the class 1 of 
G protein coupled receptors. N-[3-(1H-imidazol-4-yl)propyl]guanidines such as arpromidine 
are the most potent H2R agonists known so far and might be useful as positive inotropic 
drugs. Recently, less basic NG-acylated derivatives with improved pharmacokinetic 
properties, i.e. oral bioavailability and the capability of penetrating across the blood-brain-
barrier, have been developed. Guanidines and NG-acylguanidines are more potent and 
efficacious agonists at the guinea pig (gp) than at the human (h) H2R species isoform. 
The aim of this thesis was to investigate molecular mechanisms underlying distinct functions 
of H2R species isoforms. Structural models of hH2R and gpH2R were expected to provide 
insight into the binding mode of guanidine-type agonists and to explore the molecular basis 
for the species-selectivity of these agonists. Predictions emerging from molecular modelling  
provided a basis for subsequent experimental molecular pharmacological studies. 
Three-dimensional homology models of hH2R and gpH2R were generated using the crystal 
structure of bovine rhodopsin as template. With these models, conserved intramolecular 
interactions were reproduced according to present concepts of GPCR structure and function. 
Analysis of the binding site predicted amino acids within the transmembrane (TM)-spanning 
domains TM2, TM3, TM5, TM6, and TM7, as well as Lys-173 and Lys-175 of the second 
extracellular loop for interactions with guanidine-type agonists. An interaction between the 
non-conserved Tyr-17 in TM1 and Asp-271 in TM7 was selectively formed in the gpH2R 
model and proposed to determine the species-selectivity of the compounds. A virtual 
screening approach with the program LUDI resulted in the development of alkyl-branched 
NG-(phenylalkanoyl)guanidines with enhanced potencies at the hH2R. 
The hH2R model was subjected to molecular dynamics simulations both in its ligand-free 
form and in complex with arpromidine. A hydrated 1-palmitoyl-2-oleoyl-sn-glycero-3-
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phosphatidylcholine bilayer was added to the model to realistically simulate the membrane 
environment of the receptor. The selective formation and deletion of interactions dependent 
on the presence or absence of arpromidine in the binding pocket was proposed to represent 
perturbations that are necessary for the transition from an inactive towards an active receptor 
state. The results from simulations help on further refining dynamic models of the binding 
mode of guanidine-type agonists. 
In the experimental part of this thesis H2R species isoforms of human, guinea pig, rat and 
canine were pharmacologically characterized. Recombinant proteins were expressed using a 
baculovirus/Sf9 insect cells expression system. In a steady-state GTPase activity assay at 
membranes expressing fusion proteins of the H2R and the short splice variant of Gsα (GsαS), 
only canine H2R exhibited an increased level of constitutive activity compared to hH2R. 
Moreover, in membranes expressing fused and non-fused receptors the highest basal and 
GTP-dependent increases in adenylyl cyclase activity were observed with canine H2R. From 
H2R modelling, the constitutive activities of H2R species isoforms were predicted to depend 
on the presence or absence of interactions requiring the non-conserved Arg-228. 
Characterization of a mutant hH2R-GsαS fusion protein with Cys-17 and Ala-271 mutated into 
the corresponding gpH2R residues, Tyr-17 and Asp-271, confirmed the selective formation of 
an interaction between both amino acids in the gpH2R and the critical role of this interaction 
in determining the species-selectivity of guanidine-type agonists. An hH2R-GsαS fusion protein 
with the four amino acids in the second extracellular loop differing in human and guinea pig 
mutated into the gpH2R sequence, and a gpH2R-GsαS protein with the corresponding point 
mutations into the hH2R sequence, were generated. Efficacies and potencies of agonists 
were similar in the GTPase assay at these mutants and the wild-type receptors indicating 
that the second extracellular loop does not contribute to the species-selectivity. With two 
additional mutant hH2R-GsαS proteins bearing single point mutations of Lys-173→Ala-173 and 
Lys-175→Ala-175, respectively, agonist activities remained unchanged, suggesting that both 
amino acids do not participate in direct ligand-receptor interactions. 
The complementary application of three-dimensional structural models and molecular 
pharmacological studies provided striking insight into molecular mechanisms and species-
selectivity of H2R functions and ligand-receptor interactions. An improved knowledge of the 
binding mode of guanidine-type agonists may facilitate the development of more potent and 
selective derivatives. Moreover, results from this thesis are not restricted to the H2R subclass 
but may also apply to other members of the G protein coupled receptor family. 
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Appendix 1: Principles of Molecular Mechanics and MD Simulations 
Empirical force field methods: molecular mechanics 
For modelling of proteins and protein-ligand interactions empirical force fields are commonly 
used to approximate reasonable low-energy structures. The core of any force field is a 
potential energy function which describes the relationship of a molecular structure to the 
energy (V) of the system of interest. For an exhaustive description of all nuclei and electrons 
in the system, high-level quantum mechanical methods would be required. With increasing 
complexity of the molecular system, these methods will become infeasible due to the large 
time-consumption of the calculations required. Force field methods ignore the electronic 
motions and calculate the energy of a system as a function of the nuclear positions only. This 
simplification is permitted by the Born-Oppenheimer approximation, separating the 
Schrödinger equation into the parts of electron motion and the motion of atomic nuclei. 
Typically, the potential energy function of the system contains additive contributions of 
bonded and non-bonded interactions (Figure  11.1). Bonded interactions can be subdivided 
into terms describing bond stretching (Vstretch), angle bending (Vbend), and bond rotation 
(Vtorsion). Non-bonded interactions are calculated between all pairs of atoms (i and j) that are 
in different molecules or in the same molecule but separated by at least three bonds. The 
non-bonded term is usually modelled using a Coulomb potential term for electrostatic 
interactions (Velec) and a Lennard-Jones potential for van der Waals interactions (VvdW). 
Depending on the force field, additional terms are included. 
Chapter 11: Appendix 168
 
 
 
 
 
The total potential energy in the system is given by: 
 
 ...vdWelectorsionbendstrech +++++= VVVVVV  (11.1) 
 
The potential due to variations in bond length between atoms i and j is usually modelled as a 
harmonic spring: 
 
 ( )20stretch 2)( ijij
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ij rr
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rV −=  (11.2) 
 
where kijb is the bond-stretching force constant and rij0 is the equilibrium bond length. In more 
refined force fields a cubic term (Allinger, 1977), a quartic function (Allinger et al., 1989; Lii 
and Allinger, 1989a, b), or a Morse function (Morse, 1929) have been included. In a similar 
way, angle stretching for the atoms i, j, k (where j is the central atom) can be described by 
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with θijk0 being the equilibrium bend angle and kijkθ the angle-bending force constant. The 
potential energy associated with the rotation of a bond is usually expressed as 
Figure  11.1: Bonded and non-bonded interactions between 
atoms calculated in a force field potential. 
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with the torsion angle φ defined by the atoms i, j, k, l (where atoms j and k form the bond). 
The multiplicity n determines the number of minima and barriers during a full rotation and φ0 
their positions. kjkφ is the force constant. 
To adjust the geometry of planar groups such as aromatic rings or ester functions, improper 
torsion and out-of-plane bending terms are usually added to the potential energy function. 
The Lennard-Jones potential describes the interaction of two non-bonded atoms using both 
an attractive dispersive (van der Waals interactions) and a strong repulsive contribution 
important on short distances: 
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with rij being the distance between the atoms i and j, σij the collision diameter, and εij the well 
depth. The electrostatic interaction between two charged particles can be calculated by 
Coulomb’s law: 
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qi and qj are the charges, separated by the distance rij, and ε0 and εr are the dielectric 
constant of free space and the relative permittivity, respectively. 
There are several force fields for protein modelling implemented in software programs. The 
most frequently used methods are AMBER (Weiner et al., 1984, 1986), CVFF (Dauber-
Osguthorpe et al., 1988), CHARMM (Brooks et al., 1983), and GROMOS (van Gunsteren 
and Berendsen, 1987). 
 
Energy minimization 
Energy minimization techniques are commonly used to optimize the geometry of molecular 
structures into a minimum state. Considering the entire energy hypersurface of a 
macromolecule comprising a very large number of local minima, energy minimization 
protocols approach the energy minimium that is closest to the starting structure rather than 
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the global energy minimum (Figure  11.2). Hence, energy minimizations are generally limited 
to explore only a small fraction of the energy hypersurface. Energy minimization methods 
can be divided into the classes of solely energy-based methods like simplex, first-derivative 
techniques like steepest-descent and conjugate gradient, and second-derivative methods like 
the Newton-Raphson and related algorithms. The simplex method is useful for initial 
geometry optimizations in systems with very high energy, whereas first derivative methods 
are most often used for subsequent minimizations of large biomolecules. 
 
 
 
 
 
 
 
Molecular dynamics (MD) simulations 
The aim of MD simulations is to reproduce the time-dependent motional behavior of a 
molecule containing N interacting atoms by integrating Newton’s equations of motion 
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where ri(t) is the position and vi(t) the velocitiy of the atom i . The momentary force Fi on each 
atom is calculated from the derivative of the potential energy function V in the force field, 
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Figure  11.2: Principles of energy minimization (Min.) and MD 
simulation (MD), illustrated as a walk on the total energy 
hypersurface (shown in only one dimension). 
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For most MD simulations the Verlet algorithm (Verlet, 1967) is used for integration. With this 
approach, velocities and accelerations of the atoms are assumed to be constant over the 
time step Δt of integration. Usually, a time step of 1 fs is applied corresponding to vibrational 
movements of bonds (fastest vibration: C-H stretch ~10 fs). The Verlet algorithm is based on 
the addition and subtraction of the Taylor expansions for the time dependence of the 
coordinates ri at the times t - Δt and t + Δt. A slightly modified algorithm of the Verlet 
algorithm is the Leap-Frog scheme (Hockney and Eastwood, 1981), 
 
 ( ) ( ) i
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ii Fm
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The velocities vi and coordinates ri are calculated at alternating half and whole time steps. 
In MD simulations, velocities are generated acting on all atoms depending on the adjusted 
temperature, thus kinetic energy is supplied to the system. Hence, with MD simulations local 
energy maxima in the energy hypersurface can be overcome enabling exploration of the 
conformational space of molecules rather than approaching the closest energy minimum 
(Figure  11.2). 
The reference temperature T0 in a system is controlled by rescaling the atom velocities every 
time step with a calculated factor λ: 
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with the temperature coupling constant τT. This weak coupling scheme (Berendsen et al., 
1984) produces an exponential relaxation to the reference temperature. Similarly, the 
pressure P in the system can be controlled through a coupling method scaling the 
coordinates of all atoms and the box size every time step with a factor μ: 
 
 ( )3 01 PPt
p
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where β is the isothermal compressibility of the system, τP the time constant for pressure 
coupling, and P0 the reference pressure. 
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Appendix 2: Parameters for MD simulations in GROMACS 
 
 
Parameter Value Description 
VARIOUS PREPROCESSING OPTIONS: 
title md2 Title of the MD simulation. 
cpp /lib/cpp Location of the preprocessor. 
include  Directories to include in the topology. 
define  Enables the option of including positional 
restraints on atom positions. 
RUN CONTROL PARAMETERS: 
integrator md Application of a leap-frog algorithm for 
integrating Newton’s equations of 
motions. 
tinit (ps) 0 Starting time of the MD run. 
dt (ps) 0.002 Time step for integration.  
nsteps 1250000 Number of steps to integrate. The 
simulation period results from the 
equation 0.002 ps · 1250000 steps = 
2500 ps. 
comm-mode Linear Remove center of mass translation. 
nstcomm (steps) 1 Frequency for center of mass removal. 
comm-grps  Groups for center of mass removal; 
default is the whole system. 
OUTPUT CONTROL OPTIONS: 
nstxout (steps) 500 Frequency to write coordinates to the 
output trajectory file. 
nstvout (steps) 500 Frequency to write velocities to the output 
trajectory file. 
nstlog (steps) 250 Frequency to write energies to the log 
file. 
nstenergy (steps) 250 Frequency to write energies to the energy 
file. 
nstxtcout (steps) 500 Frequency to write coordinates to an xtc 
file. 
xtc-precision 1000 Precision to write an xtc file. 
energygrps Protein  POP  SOL Groups to write to the energy file. 
NEIGHBORSEARCHING PARAMETERS: 
nstlist (steps) 10 Frequency to update the neighbor list. 
 
Table  11.1: Example of a GROMACS input file containing run parameters for MD simulations. 
Description of parameters was adapted from the GROMACS user manual version 3.2. 
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ns_type grid Make a grid in the box and only check 
atoms in neighboring grid cells when 
constructing a new neighbor list every 
nstlist steps. 
pbc xyz Use periodic boundary conditions in all 
directions. 
rlist (nm) 1.0 Cut-off distance for the short-range 
neighbor list. 
OPTIONS FOR ELECTROSTATICS AND VDW: 
coulombtype PME Use Particle-Mesh Ewald electrostatics to 
calculate long-range electrostatic 
interactions. 
rcoulomb (nm) 1.0 Distance for the Coulomb cut-off. 
vdwtype Cut-off Apply twin-range cut-off’s for van der 
Waals interactions. 
rvdw (nm) 1.4 Distance for the Lennard-Jones cut-off. 
fourierspacing (nm) 0.12 Maximum grid spacing for the Fast 
Fourier Transform grid when using PME. 
pme_order 4 Interpolation order for PME. 
ewald_rtol 1e-05 Relative strength of the Ewald-shifted 
direct potential. 
ewald_geometry 3d Geometry to use for Ewald summations. 
OPTIONS FOR WEAK COUPLING ALGORITHMS: 
tcoupl berendsen Temperature coupling with a Berendsen-
thermostat to a bath with temperature 
ref_t and the time constant tau_t. 
tc-grps Protein ARP POP 
SOL Cl 
Groups to couple separately to the 
temperature bath. 
tau_t (ps) 0.1 0.1 0.1 0.1 0.1 Time constants for coupling the 
temperature for each group separately. 
ref_t (K) 300 300 300 300 
300 
Reference temperatures for each group. 
pcoupl berendsen Exponential relaxation pressure coupling 
using a time constant tau_p. 
pcoupltype anisotropic Anisotropic pressure coupling. 
tau_p (ps) 5.0 5.0 5.0 0.0 0.0 
0.0 
Time constant for anisotropic pressure 
coupling for the xx, yy, zz, xy/yx, xz/zx, 
and yz/zy components. 
compressibility (bar-1) 4.5e-5 4.5e-5 4.5e-5 
0.0 0.0 0.0 
Compressibilities for anisotropic pressure 
coupling. A value of 4.5 e-5 bar-1 
corresponds to the compressibility of 
water at 1 atm and 300 K. 
ref_p (bar) 1.0 1.0 1.0 0.0 0.0 
0.0 
 
Reference pressure. 
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GENERATE VELOCITIES FOR STARTUP RUN: 
gen_vel no Do not generate velocities but use 
velocities from the previous run. 
gen-temp (K)  Temperature for Maxwell distribution. 
gen-seed  Used to initialize random generator for 
random velocities. 
OPTIONS FOR BONDS: 
constraints all-bonds Constrain all bonds for using the LINCS 
algorithm. 
constraint_algorithm lincs Apply the Linear Constraint Solver 
(LINCS) algorithm to allow for the usage 
of a time step for integration of 2 fs. 
NMR refinement stuff: 
disre simple Application of distance restraints of pairs 
of atoms. 
disre_weighting equal Divide the restraint force equally over all 
atom pairs in the restraint. 
disre_mixed no The violation used in the calculation of 
the restraint force is the time averaged 
violation. 
disre_fc (kJ mol-1 nm-2) 1000 Force constant for distance restraints. 
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